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Chemotherapeutic-induced peripheral neuropathy (CIPN) is associated with a unique stocking-
glove distribution of signs and symptoms. CIPN starts with numbness and tingling and proceeds 
to ongoing pain. The potential impact of target of innervation on CIPN has been largely ignored 
despite the tremendous heterogeneity among sensory neurons regarding their resting and injury-
induced properties. Moreover, there is compelling evidence from other neuropathy models 
indicating that dysregulation of intracellular Ca2+ in sensory neurons contributes to the signs and 
symptoms of the neuropathy. Therefore, the central hypothesis I pursued in this thesis was that 
both the positive and negative signs of CIPN are due to subpopulation-specific changes in Ca2+ 
regulation, which I tested in a paclitaxel-induced peripheral neuropathy model. Paclitaxel was 
associated with a persistent decrease in mechanical nociceptive threshold in response to stimuli 
applied to the glabrous hindpaw skin, but not the other areas that were tested. While paclitaxel 
had no detectable influence on either resting or depolarization-evoked Ca2+ transients in putative 
non-nociceptive neurons, there was a significant paclitaxel-induced decrease in the evoked Ca2+ 
transient duration in putative nociceptive glabrous neurons, which correlated with the paclitaxel-
induced nociceptive behavior. This paclitaxel-induced change in Ca2+ regulation was not due to 
increased activity of Na+-Ca2+-exchanger (NCX), which contributes to the regulation of evoked 
Ca2+ transient durations in this subpopulation of neurons. However, the paclitaxel-induced 
decrease in the duration of the evoked Ca2+ transient did appear to be due to both direct and 
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indirect influences of mitochondria. The direct influence reflected an increase in mitochondria 
volume, enabling an increase in total Ca2+ uptake, while the indirect influence reflected an 
increase in the activity of ATP-dependent Ca2+ regulatory mechanisms, such as the sarco-
endoplasmic-reticulum-ATPase (SERCA). The results generated in this dissertation expand the 
current view of CIPN mechanisms and constitute an important step towards understanding the 
roles of intracellular Ca2+ as well as mitochondrial changes to the pain associated with CIPN, 
paving the road for novel therapeutic strategies to limit the side effects of chemotherapy. 
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1.0  INTRODUCTION 
1.1 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY    
Cancer is the second leading cause of death in the United States following heart disease, 
claiming approximately 1620 lives per day (American Cancer Society, 2015). Thus early 
intervention and the use of aggressive treatments are often essential to save lives. 
Chemotherapeutics, drugs from a variety of different classes that share the essential ability to 
arrest cell division, are widely used for the treatment of a most cancers. In addition to the impact 
of chemotherapeutics on dividing cells, these drugs have effects on post-mitotic cells, including 
sensory neurons of the peripheral nervous system (Windebank and Grisold, 2008, Gornstein and 
Schwarz, 2014). This side effect of chemotherapy is associated with the development of 
chemotherapy-induced peripheral neuropathy (CIPN) in a significant fraction of cancer patients 
(Jaggi and Singh, 2012). Sensory disturbances associated with CIPN can range from mild 
tingling to severe ongoing pain in distal appendages. The severity of symptoms often increases 
with continued therapy, resulting in dose limitation or even therapy cessation (Dougherty et al., 
2004, Windebank and Grisold, 2008, Pachman et al., 2011, Jaggi and Singh, 2012, Schneider et 
al., 2015). Understanding the mechanisms underlying CIPN may enable the development 
adjuvant treatments that prevent or reverse CIPN so that it is possible to increase dosing and 
consequently, the efficacy for existing chemotherapeutics.  
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1.1.1 Clinical Presentation 
There is general agreement between studies that 30 - 40 % of chemotherapy patients develop 
CIPN (Xiao et al., 2008, Pachman et al., 2011, Jaggi and Singh, 2012, Gornstein and Schwarz, 
2014). This prevalence as well as the severity of CIPN is thought to be directly related to initial 
and cumulative doses of chemotherapeutics and duration of the therapy. Co-administration of 
other drugs, and the presence of other conditions, such as diabetes, may also increase the 
likelihood of developing painful symptoms (Chaudhry et al., 2003, Cata et al., 2008). CIPN is 
reported to be a predominantly sensory neuropathy that is manifest in a “stocking-glove” 
distribution, i.e. with signs and symptoms of the neuropathy that occur most frequently in distal 
appendages (Dougherty et al., 2004, Windebank and Grisold, 2008, Wolf et al., 2008, Jaggi and 
Singh, 2012).  
As with other forms for neuropathy, the sensory changes associated with CIPN are referred 
to as both gain of function and loss of function (Schneider et al., 2015). The most common gain-
of-function symptoms are paresthesias, tingling, and pain, whereas the most common loss-of 
function symptoms are numbness, reduced proprioception, and/or vibratory sense (Schneider et 
al., 2015). The gain-of-function symptoms appear to be due to increased spontaneous activity of 
sensory neurons as well as a decrease in the threshold for activation, whereas the loss-of-function 
symptoms are thought to reflect a dieback of large diameter sensory axons or loss of 
intraepidermal nerve fibers (IENFs).  
Since loss of the loss of IENFs has been associated with various neuropathic conditions such 
as complex regional pain syndrome and diabetic neuropathy (Shun et al., 2004, Albrecht et al., 
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2006) a series of studies were conducted to determine whether CIPN was likewise associated 
with loss of IENFs. Indeed, skin biopsies taken from chemotherapy patients receiving 
bortezomib, paclitaxel, and vincristine showed significant decreases Meissner’s corpuscles and 
IENFs compared to healthy control subjects (Boyette-Davis et al., 2011b, Boyette-Davis et al., 
2013). Animal models of oxaliplatin- and paclitaxel-induced peripheral neuropathy are also 
associated with loss of IENFs at the time of peak (maximal) mechanical hypersensitivity, which 
was reversed with minocycline treatment in both cases (Liu et al., 2010, Boyette-Davis and 
Dougherty, 2011, Boyette-Davis et al., 2011a). This suggested that loss of IENFs is downstream 
of an inflammatory response. Nevertheless, the observation of a decrease in the density of IENF 
in both painful areas as well as pain-free areas in patient studies (Boyette-Davis et al., 2013) 
suggests that loss of IENF and pain are not causally linked. 
Whereas, sensory disturbances of CIPN are a major concern, effects of chemotherapeutics on 
motor and autonomic systems are less likely to lead to dose limitation or therapy cessation. Signs 
and symptoms relating to motor system abnormalities are fairly uncommon and have been 
generally reported for cases treated with significantly high doses of chemotherapeutics 
(Windebank and Grisold, 2008, Jaggi and Singh, 2012, Gornstein and Schwarz, 2014). Thus, it is 
not clear whether occurrence of chemotherapy-induced motor neuropathy is simply a severe 
variant of the same processes leading to sensory neuropathy or whether it reflects completely 
different mechanisms (Schneider et al., 2015).  Similarly, while chemotherapy is associated with 
nausea, vomiting and other digestive tract symptoms (Windebank and Grisold, 2008) as well as 
orthostatic hypotension and arrhythmia (Windebank and Grisold, 2008), autonomic system 
problems are also not a primary reason for dose limitation or cessation. 
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1.1.2 Temporal Profile 
Treatment with certain chemotherapy agents, such as paclitaxel and oxaliplatin, leads to acute 
painful symptoms (Loprinzi et al., 2007, Hill et al., 2010). Even though chemotherapy-induce 
acute pain syndrome can resolve within days (Loprinzi et al., 2007), a significant fraction of 
patients develops a persistent form of CIPN (Jaggi and Singh, 2012). This persistent form of 
CIPN develops days to weeks after the initiation of chemotherapy, and most patients experience 
it for months even after the cessation of treatment (Boyette-Davis et al., 2013). Moreover, the 
time-courses of loss- and gain-of-function symptoms are also temporally dissociated and loss-of-
function symptoms, such as numbness, are reported generally earlier than painful symptoms 
(Schneider et al., 2015).   
1.2 MECHANISMS IMPLICATED IN CIPN 
Various mechanisms have been proposed to underlie CIPN. These include: primary 
antineoplastic mechanisms of chemotherapeutic drugs, inflammatory mechanisms, dying back of 
long axons and as well as mitotoxicity.  
1.2.1  Primary Antineoplastic Mechanisms 
Multiple classes of chemotherapeutic drugs with distinct primary mechanisms of action were 
designed to kill rapidly dividing cancer cells. These actions can be roughly grouped according to 
whether the target is transcription of nuclear DNA or the assembly of the mitotic spindle during 
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cell division. Commonly used classes of chemotherapeutics that target the nuclear DNA are 
platinum compounds, DNA alkylating agents, and antineoplastic antibiotics, such as actinomycin 
derivatives. Taxane compounds and vinca alkaloids are examples of mitotic spindle inhibitors. 
Since cancer cells have very high metabolic rates and inhibition of their metabolism leads them 
to commit apoptosis, metabolic inhibitors represent a third group of chemotherapeutics examples 
of which include the proteasome inhibitor bortezomib and the antimetabolites such as 
methotrexate, gemcitabine, and 5-fluorouracil. 
1.2.1.1  DNA Targeting  
 
Many heavy metals are of environmental concern due their high affinity to cellular structures, 
especially to cellular DNA. For more than three decades cancer biology has been taking 
advantage of one heavy metal, platinum, which has strong covalent binding properties to N7 on 
purines (Bonetti et al., 2009). Commonly used platinum compounds are cisplatin, oxaliplatin, 
and carboplatin, all of which lead to irreparable DNA damage, which in turn initiates apoptosis 
(Windebank and Grisold, 2008, Bonetti et al., 2009). Use of each of these platinum compounds 
has been linked to a sensory neuropathy; 60-80% of patients on an oxaliplatin regimen develop 
stereotypical acute sensory symptoms (Windebank and Grisold, 2008, Jaggi and Singh, 2012) 
and patients receiving either of the three drugs develop a persistent neuropathy, which starts with 
paresthesias in distal limbs and progresses even after the last dose of chemotherapy (Grunberg et 
al., 1989). In advanced stages, sensory ataxia and severe neuropathic pain are reported (Jaggi and 
Singh, 2012).  
Antineoplastic antibiotics, such as actinomycin derivatives and doxorubicin, block 
transcription by intercalating into the DNA. Since these compounds are generally used in 
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combination with other chemotherapeutic agents, there is not enough data to conclude that their 
use leads to CIPN. Experimental evidence suggests doxorubicin can damage dorsal root ganglia 
(DRG) neurons in animal models however it does not seem to be associated with neurotoxicity in 
humans (Windebank and Grisold, 2008).  
As for DNA alkylating agents, neuropathy is not a prominent effect. For example, little to no 
peripheral neuropathy symptoms are reported in association with cyclophosphamide (Windebank 
and Grisold, 2008) and signs of neuropathy are reported in less than 10 percent of the patients 
treated with high-dose ifosfamide (Patel et al., 1997). Therefore among DNA-targeting 
chemotherapeutic agents, the platinum compounds are the only ones clearly linked to CIPN, 
suggesting that targeting DNA in general is unlikely to be the underlying mechanism of CIPN.  
1.2.1.2 Inhibition of the Mitotic Spindle 
 
The mitotic spindle is the machinery that binds and segregates chromosomes during cell division 
(Walczak and Heald, 2008) and is composed of microtubule polymers with a bipolar 
organization. The intrinsic polarity and dynamic properties of microtubules are essential for 
mitotic spindle function (Walczak and Heald, 2008). Microtubules are therefore targeted by 
drugs that either stabilize or inhibit the assembly of microtubules or such as taxanes or vinca 
alkaloids (Windebank and Grisold, 2008, Boyette-Davis et al., 2013). Disruption of the mitotic 
spindle arrests mitosis and ultimately activates apoptotic mechanisms (Windebank and Grisold, 
2008, Gornstein and Schwarz, 2014). Vinca alkaloids, such as vincristine, vinblastine, and 
vinorelbine inhibit assembly and promote disassembly of microtubules (Windebank and Grisold, 
2008, Boyette-Davis et al., 2013). On the other hand, taxanes, such as paclitaxel and docetaxel, 
stabilize microtubules (Windebank and Grisold, 2008, Boyette-Davis et al., 2013). More 
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specifically, taxanes bind along the microtubule lumen to β-tubulin that has been incorporated 
into the microtubules (Nogales et al., 1995), strengthening lateral contacts between subunits, 
hence suppressing microtubule depolarization (Prota et al., 2013). At higher concentrations, 
paclitaxel even enhances the polymerization of microtubules (Gornstein and Schwarz, 2014).  
The clinical features with each of these microtubule-targeting agents are similar; a dose 
dependent, predominantly-sensory neuropathy in a stocking-glove distribution (Dougherty et al., 
2004, Windebank and Grisold, 2008, Wolf et al., 2008, Jaggi and Singh, 2012, Boyette-Davis et 
al., 2013, Gornstein and Schwarz, 2014, Schneider et al., 2015). It has been suggested that 
microtubule-targeting drugs cause CIPN via disrupting axonal transport, which in turn may 
disrupt axonal structure and function resulting in axon degeneration (Windebank and Grisold, 
2008, Jaggi and Singh, 2012, Gornstein and Schwarz, 2014). However, other microtubule-
disrupting drugs such as colchicine and TZT-1027 do not induce neuropathic pain (Raffa et al., 
2012), suggesting that even if microtubule-disruption contributes to CIPN, there is another 
mechanism underlying CIPN at large.  
1.2.1.3  Metabolic Inhibitors  
 
Rapidly dividing cancer cells have high metabolic activity, and interfering with their metabolism 
leads to apoptosis. Bortezomib, a boronic acid derivative, interferes with cellular metabolism by 
inhibiting the mammalian 26S proteasome complex of the ubiquitin degradation pathway 
(Windebank and Grisold, 2008). Bortezomib-induced neuropathy, similar to CIPN observed with 
taxanes, vinca alkaloids, and platinum compounds, is predominantly sensory and distal (Wolf et 
al., 2008, Jaggi and Singh, 2012, Zheng et al., 2012). The sensory neuropathy caused by 
bortezomib often involves significant neuropathic pain and is thought to involve a small fiber 
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neuropathy (Windebank and Grisold, 2008). On the other hand, there is another class of 
metabolic inhibitors known as antimetabolites, which are biologically inactive folic acid, 
pyrimidine or purine analogues. Antimetabolites induce apoptosis after getting incorporated into 
nucleic acids or inhibit crucial metabolic enzymes. However these drugs rarely cause neuropathy 
and if any, are associated with central rather than peripheral neuropathy (Windebank and 
Grisold, 2008). These differences between bortezomib and antimetabolies argue against 
metabolic interference as a primary mechanism of CIPN. 
In conclusion, sensory disruption leading to painful paresthesias is associated with members 
of all major classes of chemotherapeutic agents. Although some of these primary mechanisms 
can contribute to the signs and symptoms of CIPN, none of these primary mechanisms alone 
appear sufficient to cause CIPN both because of the common phenotype of the neuropathy 
independent of the primary mechanism and because not all members of each class are associated 
with neuropathy. This led many groups to search for a common mechanism of CIPN that might 
be employed by different classes of chemotherapeutic agents. 
1.2.2 Inflammatory Pathways 
Inflammation is generally associated with tissue injury or infection. One of the five cardinal 
signs of inflammation is pain and/or hypersensitivity. While changes in tissue have been 
implicated in inflammatory pain, the bulk of evidence indicates that the pain presented at the site 
of injury is due to the actions of inflammatory mediators on nociceptive afferents. Many 
mediators, such as protons, TNFα, or TRPV1 ligands, are able to directly activate nociceptive 
afferents, others, such as bradykinin, PGI2, and ATP are able to activate and sensitize 
nociceptive afferents, while others still, as such as PGE2, NGF, and IL-1β are only able to 
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sensitize nociceptive afferents (Kidd and Urban, 2001, Koltzenburg et al., 2013). Resident and 
recruited immune cells are an important source of inflammatory mediators, but nonimmune cells 
also have been shown to release inflammatory mediators in response to injury. These cells 
include keratinocytes in the skin, endothelial cells, as well as glial cells and Schwann cells in the 
nervous system (Koltzenburg et al., 2013).  
While the focus on neuropathic pain, as least in the context of underlying mechanisms, has 
historically been on the changes in the injured nerves, it is now clear that inflammatory processes 
also contribute to pain associated with nerve injury. In the context of traumatic nerve injury, 
mediators are released from Schwann cells and resident immune cells, such as mast cells and 
macrophages (Scholz and Woolf, 2007, Ellis and Bennett, 2013) which are initially activated as 
part of the process of wallerian degeneration of damaged fibers (Scholz and Woolf, 2007).  
Macrophages, as well as lymphocytes and satellite cells also drive an immune response within 
the DRG (Scholz and Woolf, 2007, Koltzenburg et al., 2013). Moreover, peripheral nerve injury 
leads to activation of spinal microglia and subsequently activation and proliferation of astrocytes, 
which are responsible for the release of inflammatory mediators within the spinal cord (Scholz 
and Woolf, 2007). In addition, proinflammatory cytokines and chemokines have been shown to 
be crucial for the development and maintenance of painful peripheral neuropathy (Watkins and 
Maier, 2002) and induction of proinflammatory mediators was proposed as an underlying 
mechanism for CIPN as well (Wang et al., 2012). 
Both neuronal and non-neuronal cells are involved in the immunomodulation due to 
chemotherapy and the release of cytokines and chemokines is one of the primary mechanisms 
facilitating these changes. There is evidence that paclitaxel treatment in rats is associated with 
infiltration of activated macrophages into the DRG, sciatic nerve, and the spinal cord (Peters et 
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al., 2007, Nishida et al., 2008, Zhang et al., 2016).  This macrophage infiltration as a response to 
chemotherapy initiates production and secretion of various cytokines, chemokines, growth 
factors, inflammatory mediators, prostaglandins, and serotonin (Wang et al., 2012). Moreover, 
Schwann cells start undergoing phenotype modulation and releasing TNF-α, IL-1β, IL-6, PGE2, 
ATP, leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 (MCP-1) (Wang 
et al., 2012). In addition, primary afferents themselves have also been implicated in the 
immunomodulation; paclitaxel was shown to induce MCP-1 in small diameter neurons whereas 
its receptor CCR2 was shown to be expressed in large myelinated neurons (Zhang et al., 2013), 
suggesting a potential paracrine MCP-1/CCR2 signaling in DRG. 
Inflammatory mediators have been implicated in the pain associated with CIPN, although 
there appears to be differences between traumatic nerve injury and CIPN, with respect to the 
mechanisms responsible for the “inflammatory” component of these neuropathic pains. 
Chemotherapeutic agents with distinct primary antineoplastic mechanisms have been shown to 
induce upregulation of genes associated with inflammatory and immune responses in DRG 
(Wang et al., 2012). Remarkably, in a rat model of paclitaxel-induced peripheral neuropathy, 
nearly half of upregulated genes from the DRG were associated with inflammatory and immune 
responses (Nishida et al., 2008). Expression of the proinflammatory cytokine IL-6 was found to 
be increased in a bortezomib-induced peripheral neuropathy model (Mangiacavalli et al., 2010). 
Similarly, TNFα and IL-1β mRNA levels were shown to be elevated in the DRG in a rat model 
of paclitaxel-induced neuropathy (Ledeboer et al., 2007). Importantly, intrathecal administration 
of IL1 receptor antagonist reversed paclitaxel-induced allodynia (Ledeboer et al., 2007). 
Immunomodulatory agents such as thalidomide and minocycline that have been shown to 
attenuate mechanical allodynia in a sciatic nerve inflammation model (Ledeboer et al., 2005), 
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effectively reduced paclitaxel-induced mechanical allodynia and hyperalgesia (Cata et al., 2008, 
Liu et al., 2010). Similarly, another such inhibitor, propentophylline, attenuated vincristine-
induced pain symptoms (Sweitzer et al., 2006). Recently paclitaxel-induced neuropathy was also 
shown to involve activation of cellular immune responses via the toll-like receptor 4 (TLR4) 
pathway (Li et al., 2015a, Li et al., 2015b). Thus, in contrast to traumatic nerve injury, where 
immune activation appears to be a consequence of the tissue injury, at least some of the immune 
activation associated with CIPN appears to be due to direct actions of the chemotherapeutics.  
While the evidence for the role of inflammatory mediators in CIPN is compelling, there are 
several lines of evidence against a primary role for inflammatory mediators, alone, in either the 
positive or the negative signs of CIPN. First, anti-inflammatory medications fail to relieve pain 
associated with CIPN (Wang et al., 2012). Moreover, a general activation of inflammatory 
pathways is not sufficient to explain the stocking-glove manifestation of the CIPN symptoms. 
1.2.3 Axonal Length and Loss of Intraepidermal Nerve Fibers 
An intuitive explanation for the stocking-glove distribution of CIPN, is that longer axons will be 
more susceptible to disruption of axonal transport, and therefore more likely to be deleteriously 
impacted by the accumulation of drug effects over longer distances. The result would be a die-
back of the nerve endings (Windebank and Grisold, 2008). Early evidence indicating that 
mechanisms involved in axonal degeneration may underlie symptoms caused by paclitaxel 
treatment came from slow wallerian degeneration (Wlds) mice that possess a unique resistance to 
axonal degeneration. These mice have also been shown to be resistant to paclitaxel-induced 
peripheral neuropathy (Wang et al., 2002). Thus, the long nerve hypothesis can account for the 
loss of IENF in CIPN, where there is no loss of fibers for short axons and toxicity is peripherally 
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manifest. Loss of IENF density, which is proposed to account for the negative signs, could also 
contribute to pain, if there is a decrease in the low-threshold input based on the gate theory. 
However, the link between CIPN and damage to long axons falls short of providing a 
generalizable mechanism for CIPN. First, even in paclitaxel-induced pain models, there is no 
evidence of microtubule anomalies along the sensory and motor axons (Polomano et al., 2001, 
Flatters and Bennett, 2006, Xiao et al., 2011). Second, motor axons with comparable lengths 
appear to be spared from the effects of chemotherapy. Last, acute pain symptoms and rapid 
prognosis with some chemotherapeutics cannot be explained with a slow-scale die-back 
hypothesis of long axons. Therefore, even though damage to long axons might be responsible for 
some symptoms of CIPN, another mechanism is necessary to account for the full spectrum of 
signs and symptoms.  
1.2.4 Mitotoxicity 
Mitochondria are versatile organelles responsible for vital and interdependent functions 
including adenosine triphosphate (ATP) production, intracellular Ca2+ regulation, the generation 
of reactive oxygen species, and the regulation of apoptotic signaling pathways. Therefore a 
change in mitochondrial homeostasis may have a tremendous impact on the health and function 
of a cell.  
Mitochondria were the focus of some of the earliest mechanistic studies of CIPN. 
Mitochondrial damage is associated with the release of the electron transfer chain protein, 
cytochrome c, into the cytosol (Kulikov et al., 2012). Indeed, incubating mitochondria isolated 
from human neuroblastoma cells with taxanes resulted in release of cytochrome c (Andre et al., 
2000), as well as activation of the apoptotic protease caspase-8 (Goncalves et al., 2000).  It has 
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been proposed that association of β-tubulin with the mitochondrial permeability transition pore 
(mPTP) provides paclitaxel a mitochondrial binding site (Flatters and Bennett, 2006). Consistent 
with the suggestion that chemotherapeutics were directly responsible for mitotoxicity, in vitro 
data linked paclitaxel to mitochondrial calcium release in cancer cells and pancreatic acinar cells 
via the mPTP (Evtodienko et al., 1996, Kidd et al., 2002).  
That mitotoxicity may also be a mechanism of CIPN in vivo, was suggested by data from 
animal models of paclitaxel- oxaliplatin-, and bortezomib-induced CIPN, in which there was 
evidence of mitotoxicity along sensory axons. Toxicity was manifest in the form of 
mitochondrial swelling, increase in the percentage of vacuolated mitochondria, reduced rate of 
ATP production and respiration, as well as an increase in the production of reactive oxygen 
species (ROS) (Flatters and Bennett, 2006, Xiao et al., 2011, Zheng et al., 2011, 2012). This 
chemotherapeutic-induced mitotoxicity was observed in both small diameter slow-conducting 
fibers and large diameter myelinated sensory fibers, but was absent in motor fibers (Xiao et al., 
2011). The authors suggested that the sensory fiber specific changes in mitochondria in CIPN 
models stems from high levels of paclitaxel accumulation in DRG, where the sensory neuron cell 
bodies are located (Xiao et al., 2011). In addition, an increase in the number of atypical 
mitochondria was detectable within days after the initiation of chemotherapy and returned back 
to normal levels when the pain behavior had resolved (Flatters and Bennett, 2006), providing 
correlational evidence of a link between toxicity and the hypersensitivity associated with CIPN.  
According to the mitotoxicity model, it is the increase in ROS combined with the chronic 
energy deficit that are responsible for both spontaneous discharges (thus, tingling and pain) and 
degeneration in primary afferents (Bennett et al., 2014). Superoxide is the major ROS made in 
mitochondria, produced during oxidative phosphorylation. In support of this model are data from 
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studies in which it was demonstrated that manipulations that increase mitochondrial health or 
reduce ROS levels were effective at preventing painful symptoms of CIPN in animal models.  
For example, inhibition of superoxide production by systemic injection of complex I inhibitor 
rotenone or complex III inhibitor Antimycin A (Griffiths and Flatters, 2015) attenuated the 
established paclitaxel-induced mechanical hypersensitivity. Antimycin A also attenuated the 
development of paclitaxel-induced hypersensitivity (Griffiths and Flatters, 2015).  However, in a 
study using a general ROS scavenger and a superoxide-selective scavenger, the general ROS 
scavenger, phenyl N-tert-butylnitrone (PBN), has been shown to attenuate the development of 
paclitaxel-induced mechanical hypersensitivity, however the superoxide selective scavenger, 4-
hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL) inhibited mechanical hypersensitivity 
only when administered at high doses but to a lesser degree than PBN, and daily systemic 
administration of TEMPOL failed to prevent the development of paclitaxel-induced mechanical 
hypersensitivity (Fidanboylu et al., 2011), suggesting a role for ROS but not necessarily for 
superoxide.  
Acetyl-L-carnitine received a fair amount of attention in the context of CIPN and ROS 
production. This compound is naturally produced inside the mitochondria from L-carnitine and 
acetyl-CoA during periods of high energy demand and transported to the cytoplasm, where it 
converts back to its original constituents. Subsequently, L-carnitine enters mitochondria 
transporting fatty acids and facilitating fat metabolism, while acetyl-CoA stays in the cytoplasm. 
Enhancing this L-carnitine cycle is believed to improve mitochondrial function (Jin et al., 2008). 
Indeed, treatment with acetyl-L-carnitine was shown to block pain behavior and neurotoxicity in 
animal models of paclitaxel-, cisplatin-, oxaliplatin-, bortezomib-, and vincristine-induced 
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peripheral neuropathy (Ghirardi et al., 2005a, Ghirardi et al., 2005b, Jin et al., 2008, Xiao et al., 
2012, Zheng et al., 2012), suggesting reduced mitochondrial health in CIPN. 
While there is compelling evidence both for the presence of mitotoxicity in response to 
chemotherapeutic administration, as well as the contribution of mitotoxicity to both the positive 
and negative signs of CIPN, there are several important limitations of this model. First, it is 
unclear how a global change in mitochondria in sensory axons would result in stocking-glove 
manifestation of the CIPN that affects predominantly the glabrous skin. It has been suggested 
that the effects of mitotoxicity will be more detrimental in regions of high metabolic demand 
(Xiao and Bennett, 2008). These authors argued that the nerve endings of relatively longer 
primary afferent fibers have high levels of metabolic activity due to greater energy demands for 
maintenance and signal transmission over longer distance (Xiao and Bennett, 2008), however, 
there is no reason to suggest that the demands of the terminals in the glabrous skin, are any 
different than the demands to terminals throughout the body. Furthermore, there are afferents, 
such as muscle spindles, that have even higher metabolic demands than cutaneous afferents, yet 
there are no reports of paclitaxel-induced ill effects on muscle function. The mitotoxicity model 
does not account for relative restriction of CIPN symptoms to the glabrous but not to the dorsal 
surfaces of extremities (Dougherty et al., 2004) even though both surfaces are innervated by 
axons of comparable length. Furthermore, if there was a length-dependent influence of 
mitotoxicity, one would predict that there should be an increase in atypical mitochondria further 
along the axons. However, the percentage of atypical mitochondria were actually higher in dorsal 
roots than along the peripheral nerves from both control and paclitaxel treated rats (Xiao et al., 
2011). Moreover, while rotenone and Antimycin A were used to block complex I and complex 
III of electron transport chain in order to reduce superoxide production (Griffiths and Flatters, 
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2015), these substances are actually thought to increase superoxide levels (Li et al., 2003, Drose 
and Brandt, 2008). Furthermore, even though CIPN models are associated with mitotoxicity in 
both small diameter and myelinated larger diameter axons, ameliorating effect of acetyl-L-
carnitine was limited to only mitochondria along small diameter fibers (Jin et al., 2008). And 
despite the success of acetyl-L-carnitine to alleviate CIPN symptoms in preclinical models, and 
promising findings from pilot studies (Maestri et al., 2005), there was no detectable benefit to 
acetyl-L-carnitine treatment in a randomized double-blind trial (Hershman et al., 2013). In fact, 
acetyl-L-carnitine significantly worsened the symptoms of CIPN in participating patients 
(Hershman et al., 2013). As a result, the American Society of Clinical Oncology advises against 
the use of acetyl-L-carnitine for the management of CIPN (Hershman et al., 2014). In 
conclusion, even though there is accumulating evidence that certain symptoms of preclinical 
chemotherapy models are associated with mitotoxicity along sensory axons, crucial pieces of the 
puzzle are still missing.  
 
1.3 HETEROGENEITY OF PRIMARY AFFERENTS 
The main function of the peripheral nervous system (PNS) is to serve as a communication relay 
between the central nervous system (CNS) and the rest of the body. The PNS includes both a 
sensory component, the somatosensory nervous system (SNS) that carries information from the 
periphery to the CNS, and a motor component that carries information from the CNS to the 
effector areas. (Patestas and Gartner, 2016). Anatomically, cell bodies of sensory neurons, called 
primary afferents, are located in eight of the 12 cranial ganglia and all of the 31 pairs of dorsal 
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root ganglia (DRG) that lie in the intervertebral foramina on both sides of the spinal cord 
(Patestas and Gartner, 2016). There are no synapses within the ganglia and neurons leave their 
respective ganglion with a single bifurcating axon (Woolf and Ma, 2007, Mai and Paxinos, 2011, 
Patestas and Gartner, 2016). The peripheral branch of the axon terminates in the target somatic 
tissue whereas the central branch projects to the superficial dorsal horn of the spinal cord (Mai 
and Paxinos, 2011). Despite the uniformity of their general anatomical organization, primary 
afferents relay a variety of information, such as information relevant to the maintenance of 
homeostasis and the internal state of the organism including the temperature of the body, 
cardiovascular state, proprioception; information about the external environment including the 
modality, intensity, location of stimuli, as well as the features of the stimuli that appear to have 
affective valence such as pleasant, painful, itchy or tickling (Greger and Windhorst, 2013).  
1.3.1 Classification of Primary Afferent Subpopulations 
Currently multiple criteria are used to classify primary afferents into specific subpopulations 
based on their anatomical, physiological, and biochemical characteristics (Koerber et al., 1988, 
Lawson, 2002). Primary afferent cell soma can be classified roughly in three subpopulations 
based on cell body size. The ranges generally used to define small, medium and large diameter 
rat sensory neurons are less than 30 μm, 30 - 40 μm, and greater than 40 μm, respectively 
(Caffrey et al., 1992). Evidence suggests that the cell body diameter and axon conduction 
velocity of a primary afferent are at least roughly correlated (Harper and Lawson, 1985). 
Neurons with a small cell body diameter tend to give rise to non-myelinated, slow-conducting 
(C-fibers) axons, while those with a large cell body diameter tend to give rise to large diameter, 
myelinated fast-conducting (Aβ fibers) axons (Harper and Lawson, 1985, Lawson, 2002). 
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Furthermore, given that nociceptors tend of have slowly conducting axons and neurons with 
rapidly conducting axons generally convey non-nociceptive information, neurons with small cell 
body diameter are likely to relay nociceptive information whereas those with a large cell body 
diameter are likely to be non-nociceptive (Lawson, 2002). Medium diameter neurons are thought 
to relay both nociceptive and non-nociceptive information (Lawson, 2002). 
A way to further classify primary afferents takes advantage of their biochemical profiles. 
Primary afferents can be roughly divided into as peptidergic and non-peptidergic. These two 
classes of afferents express different repertoires of receptors and ion channels as well as project 
to distinct target areas in the dorsal horn (Woolf and Ma, 2007). During early development, all 
afferent neurons express the receptor for the nerve growth factor (NGF) trkA, however at later 
stages approximately half of these neurons switch off TrkA and instead begin to express the 
transmembrane signaling component of the receptor for glial cell-derived growth factor (GDNF) 
in addition to other associated factors (Molliver et al., 1997, Woolf and Ma, 2007). The cells that 
continue to express TrkA also express the neuropeptides calcitonin related gene peptide (CGRP) 
and substance P, hence become the peptidergic primary afferents, whereas the cell expressing 
GDNF that do not express CGRP or substance P become non-peptidergic primary afferents 
(Woolf and Ma, 2007).  
Primary afferents can also be categorized by the modality of stimuli they are responsive to 
(i.e., mechanical, thermal or chemical). They are often referred to by their response profile as 
chemoreceptors, mechanoreceptors, baroreceptors, thermoreceptors, among others. These 
response properties are usually not mutually exclusive nor anatomically homogenous (Caterina 
and Julius, 1999). Some afferents are activated by multiple types of stimuli and thus are referred 
to as polymodal, while others are activated only by a single stimulus modality. Even within a 
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single modality, neurons are likely to be responsive to a narrow range of stimuli. For example, 
thermoreceptors that are activated by noxious heat are not necessarily activated by cold or even 
ambient temperatures.  
Although sensory neurons can be classified into different subpopulations using various 
criteria, one should not rely on a single criterion for classification. For example, as discussed 
earlier, small dimeter neurons are likely to be nociceptive and large diameter neurons non-
nociceptive. However, neurons with similar sizes often have different biochemical profiles and 
distinct modalities, thus not all small diameter neurons are nociceptive and large diameter fibers 
are non-nociceptive, thus classification of neurons into nociceptive/non-nociceptive 
subpopulations should not be done by using the cell body diameter alone. In summary, 
heterogeneity of primary afferents makes it hard to classify subpopulations based on a single 
criterion. 
1.3.2 Multi-criterion Approach for Subpopulation Classification 
Studying differences between neurons using isolated neurons provides precise control over 
extracellular environment and facilitates identification of intrinsic changes in neurons that are not 
dependent on the influence of other cell types. However, isolated neuron preparations lack axons 
and terminals hence neither conduction velocity nor functional analysis of response properties of 
peripheral terminals can be utilized to further identify subpopulations. As discussed earlier, 
categorization of primary afferent neurons using single criteria has limitations, therefore in this 
dissertation I used a multi-criterion approach to categorize subpopulations of primary afferents 
using target of innervation, cell body diameter (Caffrey et al., 1992, Lawson, 2002), Isolectin B4 
(IB4) binding (Fang et al., 2006), and sensitivity to capsaicin (Holzer, 1991).  
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An important factor that contributes to differences in subpopulations of primary afferents is 
the targets of innervation. Our laboratory as well as others have identified electrophysiological 
and biochemical differences between afferents identified based on target of innervation 
(Yoshimura et al., 2003, Beyak et al., 2004, Gold and Traub, 2004, Harriott et al., 2006, Harriott 
and Gold, 2009, Vaughn and Gold, 2010, Malin et al., 2011).  For example, cutaneous and 
colonic afferents differ in their passive and active electrophysiological characteristics in both the 
absence and the presence of prostaglandin stimulation (Gold and Traub, 2004). Of note, these 
differences that are based on target of innervation appear to be most pronounced under 
pathological conditions, such as the presence of inflammatory mediators (Gold and Traub, 2004, 
Vaughn and Gold, 2010) or persistent inflammation (Harriott et al., 2006, Zhang et al., 2012b). I 
hypothesized that differences between neurons based on target of innervation contribute to the 
unique pattern in which CIPN is manifest, target of innervation was therefore used as a primary 
criteria with which to define subpopulations of neurons.  
IB4 preferentially binds to the outer plasma membrane of the non-peptidergic afferents (Fang 
et al., 2006). IB4-binding, referred to as IB4+, and those that do not bind IB4, referred to as IB4- 
populations have been associated with distinct but somewhat overlapping innervation patterns, 
even though both populations are thought to be activated by all noxious stimulus modalities in 
the rat (Silverman and Kruger, 1990). Moreover, it has been shown that IB4+ afferents had 
longer duration action potentials (APs) and a higher density of voltage-gated tetrodotoxin (TTX)-
resistant sodium channels while IB4- afferents had larger heat-evoked currents (Stucky and 
Lewin, 1999). Due to these differences between IB4+ and IB4- populations, IB4 binding was 
included in the multi-criterion approach in this dissertation.  
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Application of capsaicin to the skin causes a burning pain sensation (Martin et al., 1987). The 
receptor for capsaicin, transient receptor potential vanilloid 1 (TRPV1) is implicated in 
inflammatory thermal sensitivity and capsaicin application is widely used to identify nociceptors. 
The advantage of using capsaicin is that it is easily applied to dissociated neurons and produce a 
Ca2+ influx, thus using capsaicin is a valuable criterion since dissociated neurons lack axons that 
would enable functional characterization.  
1.4  REGULATION OF INTRACELLULAR CALCIUM SIGNALING 
Calcium is the Swiss army knife of a cell, versatile and useful as a secondary messenger capable 
of helping a cell do, just about everything a cell needs to do (Berridge et al., 2000, Berridge et 
al., 2003). Ca2+ can influence transcriptional and translational regulation, differentiation, 
apoptosis, contraction, excitability, and neurotransmitter release (Berridge et al., 2000). The 
versatility of Ca2+ dictates that its levels be tightly regulated. To achieve this level of regulation, 
cells possess a variety of Ca2+ regulatory mechanisms, generically referred to as the Ca2+ 
signaling toolkit. The specific features of the tool-kit depend in part on the function of the cell, 
enabling Ca2+ signaling with different spatial and temporal properties (Berridge et al., 2003).  
Ca2+ signals are initiated via influx across the cell membrane or release from internal stores. 
There are a variety of influx pathways, which are most often ion channels activated by 
membrane depolarization, mechanical, thermal and chemical stimuli, as well as depletion of 
intracellular stores (Berridge et al., 2003). One of the most common stores from which Ca2+ is 
released is the endoplasmic reticulum (ER), where release is triggered via activation of inositol-
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1,4,5-trisphosphate receptor (IP3R) or ryanodine receptor (RyR) (Berridge et al., 2003, 
Verkhratsky and Toescu, 2003).  
Once cytosolic Ca2+ levels start increasing, regulatory mechanisms are engaged that attenuate 
or amplify the increase. These regulatory mechanisms often include, cytosolic buffers, uptake 
into the mitochondria (via the mitochondrial calcium uniporter (MCU)) or the ER via the sarco-
endoplasmic reticulum ATPase (SERCA), or extrusion via the Na+-Ca2+ exchanger (NCX) or the 
plasma membrane calcium ATPase (PMCA).  
All of these mechanisms act over different ranges of Ca2+ levels, reflecting their density, 
distribution, and biophysical and pharmacological properties. For example PMCA and SERCA 
pumps have lower transport rates but high affinities allowing them to respond to modest 
elevations in Ca2+ concentration and set resting Ca2+ levels inside the cell. On the other hand, 
NCX and the MCU have higher rates of Ca2+ transport, enabling them to limit the duration and 
the magnitude of Ca2+ increases (Berridge et al., 2003). Similarly, the differential distribution of 
these regulatory mechanisms contributes to the spatial and temporal regulation of Ca2+ resulting 
in yet another layer of versatility to this important second messenger (Berridge et al., 2000, 
Berridge et al., 2003). Often Ca2+ regulatory proteins are organized into microdomains, which 
can function as autonomous units to create diverse signaling networks within the same cell 
(Berridge et al., 2000). For example, individual spines on neurons have been shown to operate as 
autonomous Ca2+-signaling units with diverse responses (Berridge et al., 2003). 
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1.4.1 Regulation of Ca2+ in primary afferents 
Given the heterogeneity among the primary afferents with respect to every other property 
assessed, it should not be surprising that there is also heterogeneity in the regulation of 
intracellular Ca2+. Consistent with this expectation it was demonstrated in an early study, that 
caffeine-induced Ca2+ release from the ER was only observed in 2/3 of the DRG neurons 
(Shmigol et al., 1995). Another study has shown that NCX contributed to the regulation of 
resting Ca2+ in some neurons, but the duration of the evoked Ca2+ transient in others (Verdru et 
al., 1997). Others have reported that components of mitochondrial Ca2+ buffering differed 
depending on the size of the DRG neuron (Kostyuk et al., 1999). Although these studies 
provided evidence about differential regulation of Ca2+ in sensory neuron subpopulations, a 
comprehensive characterization of Ca2+ regulatory components in healthy primary afferents was 
not completed until later (Lu et al., 2006). Clear differences among DRG neuron subpopulations 
with respect to both the magnitude and the duration of the depolarization-evoked Ca2+ transients 
were documented (Lu et al., 2006). More specifically, small diameter, IB4-binding, and 
capsaicin responsive “putative nociceptor” neurons had longer lasting Ca2+ transients with large 
amplitudes, whereas the large diameter IB4-negative and capsaicin unresponsive neurons had 
fast decaying transients with small amplitudes (Lu et al., 2006). These differences were not 
attributable to differences in voltage gated Ca2+ currents, instead revealed a differential 
contribution of Ca2+ regulatory mechanisms among subpopulations of afferents (Lu et al., 2006). 
For example, RyR-mediated Ca2+ release, removal of Ca2+ via SERCA and PMCA, and 
mitochondrial Ca2+ buffering were found to play prominent roles in large diameter IB4-negative 
and capsaicin unresponsive afferents, however store operated Ca2+ entry and NCX were shown 
to play a major role in putative nociceptor subpopulation of DRG neurons (Lu et al., 2006). 
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1.4.2 Regulation of Ca2+ and pain models 
In addition to the heterogeneity in Ca2+ regulation in subpopulations of afferents, there is 
growing evidence of changes in the regulation of Ca2+ in disease states. For example, 
inflammation increases the magnitude and the duration of the evoked Ca2+ transients in putative 
nociceptors (Lu and Gold, 2008). The increase in the duration of evoked Ca2+ transients in this 
inflammatory model was due to loss of NCX3 in the soma of putative nociceptors that innervated 
the site of inflammation due to an increase in unidirectional NCX3 trafficking to the periphery 
(Scheff and Gold, 2015). A distinct pattern of changes in Ca2+ have been described in response to 
nerve injury as well. For example, in models of traumatic nerve injury, the duration of evoked 
Ca2+ transients were shorter in injured but longer in adjacent putative nociceptive neurons (Fuchs 
et al., 2007). There was also a decrease in resting Ca2+ concentration in injured non-nociceptors, 
while adjacent putative nociceptive neurons did not manifest such changes (Fuchs et al., 2005). 
However, a diabetic neuropathy model was associated with an increase in both resting Ca2+ 
levels and the duration of the evoked Ca2+ transient in nociceptive afferents (Kostyuk et al., 
2001). Taken together, these studies emphasize the impact of the nature of the injury on the 
specific changes in Ca2+ regulation.  
Dysregulation of Ca2+ has been implicated to be critical in peripheral neuropathy models. In 
a diabetic neuropathy model, Fernyhough and Calcutt characterized dysregulation of both 
depolarization and  caffeine-evoked Ca2+ transients in the axons (Fernyhough and Calcutt, 2010). 
These authors found evidence of axonal damage without any signs of oxidative stress or 
degeneration in the cell bodies of the same neurons (Fernyhough and Calcutt, 2010). Therefore, 
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it is likely that loss of function symptoms associated with the diabetic neuropathy model may be 
mediated by changes in Ca 2+ regulation. In another study, drugs reducing intra- and extra-
cellular Ca2+ inhibited mechanical hypersensitivity and allodynia in rat models of paclitaxel- and 
vincristine-induced neuropathy (Siau and Bennett, 2006), providing evidence that regulation of 
Ca2+ is critical for pain-related behaviors of at least some peripheral neuropathy models. Taken 
together, dysregulation of Ca2+ can underlie both the loss of function and gain of function 
symptoms associated with peripheral neuropathy.  
1.5  A NEW HYPOTHESIS FOR CIPN 
 
In this chapter, I have laid out the major lines of evidence that served as the basis for the central 
hypothesis pursued in this thesis. These included 1) the unique features of CIPN, which includes 
both positive and negative signs that are largely restricted to the glabrous skin and appear to 
reflect changes in both nociceptive and non-nociceptive afferent; 2) evidence of the tremendous 
heterogeneity among sensory neurons that includes resting properties, as well as the response to 
injury. In this regard, it was important to highlight the impact of target of innervation as well as 
the regulation of intracellular Ca2+. 3) I also summarized evidence indicating that Ca2+ is not 
only dysregulated in the presence of injury, but that dysregulation contributes to the 
manifestation of both positive and negative signs of neuropathic pain. Based on these lines of 
evidence in combination with the limitation associated with the current models of CIPN, I 
hypothesize that both the positive and negative signs of CIPN are due to subpopulation and 
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target-of-innervation specific changes in Ca2+ regulation. The experiments described in the 
following chapters constitute the work completed so far towards the test of this hypothesis. 
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2.0  SENSORY NEURON SUBPOPULATION-SPECIFIC DYSREGULATION OF 
INTRACELLULAR CALCIUM IN A RAT MODEL OF CHEMOTHERAPY-INDUCED 
PERIPHERAL NEUROPATHY 
2.1 INTRODUCTION 
The impact of peripheral nerve injury on the regulation of the intracellular Ca2+ concentration 
([Ca2+]i) in sensory neurons has received considerable attention because of the importance of 
neural [Ca2+]i to transmitter release (Parnas and Parnas, 2010), gene expression (Fields et al., 
2005), excitability (Hogan, 2007), and neurotoxicity (Berridge et al., 2000). These are all neural 
processes that are not only changed by nerve injury (Lekan et al., 1997, Costigan et al., 2002, 
Yaksh, 2006, Wilson et al., 2012, Ratte et al., 2014) but appear to contribute to the signs and 
symptoms of peripheral neuropathy (Siau and Bennett, 2006). For example, in models of 
traumatic nerve injury, which is often associated with paresthesias, dysesthesias, and ongoing 
pain, there are changes in the regulation of [Ca2+]i in both putative nociceptive and non-
nociceptive neurons in a pattern that appears to depend on whether or not the neurons were 
injured or were adjacent to those that were injured. That is, the duration of evoked Ca2+ 
transients were shorter in injured, but longer in adjacent putative nociceptive neurons (Fuchs et 
al., 2007). Similarly there was a decrease in resting [Ca2+]i in injured putative non-nociceptive 
neurons with no change in resting [Ca2+]i in putative nociceptive neurons (Fuchs et al., 2007). In 
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contrast, in a model of diabetic neuropathy, while there is an increase in the duration of the 
evoked Ca2+ transient in putative nociceptive neurons, there is also an increase in resting [Ca2+]i 
(Kostyuk et al., 2001). In both models of peripheral neuropathy, there is evidence to suggest that 
the mechanisms contributing to the changes in the regulation of [Ca2+]i contribute to changes in 
excitability (Tang et al., 2012). While there may be marked differences between peripheral nerve 
injury models with respect to the pattern of changes in the regulation of [Ca2+]i, there are only 
relatively subtle differences in the pain behavior associated with each model, highlighting the 
fact that the nervous system is able to achieve the same phenotype via multiple mechanisms. 
One potential explanation for the differences between models with respect to the pattern 
of changes in the regulation of [Ca2+]i, is that each model impacts a different subpopulation of 
sensory neurons and as a result different subpopulations of neurons contribute to the observed 
pain behavior. For example, spontaneous activity in muscle afferents appears to play a 
particularly important role in pain behavior associated with traumatic nerve injury (Michaelis et 
al., 2000), while neurons innervating more superficial targets appear to play a more prominent 
role on diabetic neuropathy (Johnson et al., 2008). Furthermore, there are differences between 
subpopulations of sensory neurons with respect to the regulation of [Ca2+]i (Lu et al., 2006). 
Consequently, the specific pattern of changes in the regulation of [Ca2+]i may be a reflection of 
an interaction between the unique properties of specific subpopulations of sensory neurons and 
the relative impact of the nerve injury.  
We reasoned that a chemotherapy model of peripheral neuropathy might enable us to 
begin to test this suggestion. Chemotherapeutic-induced peripheral neuropathy (CIPN) is 
associated with a unique distribution, in what is referred to as a “stocking-glove” pattern, with 
signs and symptoms of neuropathy largely restricted to the hands and feet. More interestingly, 
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CIPN also presents with what appears to be a differential impact on subpopulations of sensory 
neurons. Numbness and tingling appear to be associated with a loss of intra-epidermal nerve 
fiber density thought to reflect a selective dye-back of low threshold fibers, while the pain and 
hypersensitivity is thought to reflect the sensitization of nociceptive afferents (Tanner et al., 
1998, Dougherty et al., 2004). Thus, we predicted, that this unique manifestation of CIPN would 
be reflected in a specific pattern of changes in the regulation of [Ca2+]i in subpopulations of 
cutaneous neurons. To test this prediction, employed a combination of behavioral analysis and 
fura-2 based microfluorimetry to study the impact of paclitaxel-induced CIPN on different 
subpopulations of sensory neurons. An electronic von Frey device was used to assess the pattern 
of changes in mechanical sensitivity in the hindlimb. Retrograde tracers were used to identify 
subpopulations of cutaneous neurons innervating the glabrous and hairy skin of the hindpaw and 
skin of the thigh. Acutely dissociated DRG neurons were used to assess the impact of paclitaxel-
induced CIPN on the regulation of [Ca2+]i in subpopulations of neurons defined by target of 
innervation. Our results support the suggestion that the unique manifestation of CIPN is reflected 
in a specific pattern of changes in the regulation of [Ca2+]i in subpopulations of cutaneous 
neurons and argue against a prevailing hypothesis that nerve length can account for the 
manifestation of CIPN. 
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2.2 METHODS 
2.2.1 Animals 
Adult (250-320g) male Sprague-Dawley rats (Harlan, Indianapolis, IN)) were used for all 
experiments. Rats were housed two per cage in a temperature and humidity controlled, 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC) accredited animal housing facility on a 12h:12h light:dark schedule with food and 
water available ad libitum. All procedures were approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee and performed in accordance with National 
Institutes of Health guidelines for the use of laboratory animals in research. 
2.2.2 Tissue Labeling 
1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbo-cyanine perchlorate (DiI) was injected 
intradermally at three different locations, one per animal, so as to label subpopulations of 
cutaneous afferents identified based on the target of innervation. These sites included the 
glabrous skin of the hind paw, the hairy skin on the dorsal side of the hind paw, and the hairy 
skin of the upper inner thigh. DiI was injected with a 30 g needle under isoflurane (Abbott 
Laboratories, North Chicago, IL) anesthesia at 3-5 sites per target for a total volume of 10 μL in 
the dorsal and ventral hindpaw and 20 μL in the thigh. 
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2.2.3 Paclitaxel Treatment 
One week following the DiI injection, rats were anesthetized with isofluorane and injected into 
the tail vein with 2 mg/kg paclitaxel or its vehicle (1:1:23, cremophor EL:ethanol:0.9% saline). 
The tail vein injection was repeated three more times every other day for a total of four 
injections.  
2.2.4 Behavioral Assessment of Mechanical Hypersensitivity 
All behavioral data were collected in the Rodent Behavior Analysis Core of the University of 
Pittsburgh Schools of Health Sciences. Rats were habituated to the testing procedure, equipment, 
and the experimenter for two to three days before the collection of baseline data. An electronic 
von Frey (IITC Plantar Test Analgesia Meter 2390; IITC Life Sciences Inc., Woodland Hills, 
CA) fitted with a rigid tip (1.0-mm tip diameter) was used to assess changes in mechanical 
threshold. For assessment of changes in mechanical threshold in the glabrous skin, rats were 
placed in acrylic clear boxes on an aluminum mesh, which were separated by opaque dividers 
and, the tip was applied to the center of the middle of the hind paw from below with steady 
vertical pressure until the paw was lifted off the mesh floor. For assessment of mechanical 
threshold on the dorsal side of the hindpaw, rats were gently restrained in cotton socks cut so that 
their hind legs and tail protruded from the back. This enabled application of the mechanical 
probe in a manner comparable to that used for the glabrous skin of the hindpaw, perpendicular to 
the plane of the skin. Mechanical threshold was assessed in a similar manner at mid-thigh 
following removal of the hair covering the thigh, and placement of a spot on the target for 
mechanical probing with a permanent marker. Mechanical sensitivity was assessed at each site 
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three times each day with an inter-stimulus interval of 5 minutes, and the average of the three 
measures for each paw or thigh was considered the withdrawal threshold. While the investigator 
collecting behavioral data was blinded to treatment group, the weight loss in the paclitaxel 
treated animals made blinding difficult through the entire testing period. 
2.2.5 Sensory Neuron Isolation 
Rats were deeply anesthetized with an intraperitoneal injection (1 ml/kg) of an anesthethic 
cocktail containing ketamine (55 mg/kg), xylazine (5.5 mg/kg) and acepromazine (1.1 mg/kg). 
L4 and L5 DRGs were removed bilaterally, enzymatically treated, and mechanically dissociated. 
DRG neurons were plated on laminin (Invitrogen, 1mg/ml) and poly-L-ornithine (Sigma-
Aldrich, 1 mg/ml) coated glass cover slips as previously described (Lu et al., 2006).  All 
subsequent experiments were performed within 8 h of tissue harvest. Only neurons containing 
the retrograde label DiI were included for further analysis.  
2.2.6 Ca2+ Imaging 
Prior to fluoremetric analysis, neurons were incubated with 2.5 μM Ca2+ indicator fura-2 AM 
ester with 0.025 % Pluronic F-127 for 20 min at room temperature. Neurons were then incubated 
with FITC-conjugated IB4 (10 μg/ml) for 10 min at room temperature, placed in a recording 
chamber and continuously superfused with a HEPES-buffered bath solution consistent of (in 
mM): 130 NaCl, 3 KCl, 2.5 CaCl2, 0.6 MgCl2, 10 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), 10 
glucose, pH 7.4, osmolality 325 mOsm. Fluorescence data were acquired on a PC running 
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Metafluor software (Molecular Devices, Sunnyvale, CA) via an EMCCD camera (Photometrics, 
Tucson, AZ; model QuantEM 512SC). The ratio (R) of fluorescence emission (510 nm) in 
response to 340/380nm excitation (controlled by a DG-4 (Sutter Instrument, Novato, CA)) was 
acquired at 1 Hz during application of KCl or capsaicin, which were applied through a computer-
controlled, piezo-driven perfusion system (switching time <20 ms; Warner Instruments, 
Hamden, CT, USA, Fast-Step Model SF-77B). [Ca2+]i was determined from fura-2 ratio 
according to the  equation [Ca2+ ]i (nM) = Kd (Sf2/Sb2) ((R-Rmin)/(Rmax-R))  following in situ 
calibration as described previously (Scheff et al., 2013), where Kd is the dissociation constant for 
fura-2 for Ca2+ at room temperature; Sf2/Sb2 is the fluorescence ratio of the emission intensity 
excited by 380 nm signal in the absence of Ca2+; Rmin and Rmax are the minimal and maximal 
fluorescence ratios respectively. 
2.2.7 Chemicals  
Paclitaxel (Sigma-Aldrich, St Louis, MO, USA), was dissolved at 25 mg/mL in 1:1 Cremophor 
EL: ethanol and freshly diluted 1:12.5 in 0.9% sterile saline prior to injections. The retrograde 
tracer, DiI (Invitrogen, Carlsbad, CA, USA), was dissolved at 170 mg/mL in dimethylsufoxide 
(DMSO, Sigma-Aldrich) and diluted 1:10 in 0.9% sterile saline. FITC-conjugated Isolectin B4 
(IB4, Sigma-Aldrich) was dissolved in dH20 as a stock solution of 1 mg/ml, and then diluted to a 
final concentration of 5 μg/ml in HEPES bath solution the day of use. Fura-2 acetoxymethyl 
(AM) ester (TEF Laboratories, Austin, TX, USA) was dissolved in DMSO as a 2.5 mM stock 
solution and diluted to a final concentration of 2.5 μM in HEPES bath solution.  Pluronic F-127 
(TEF Laboratories) was dissolved in DMSO as a 25% stock solution and diluted to 0.025% in 
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HEPES bath solution. Capsaicin (Sigma-Aldrich) was dissolved in ethanol as a 10 mM stock 
solution and diluted to 500 nM in HEPES bath solution.  
2.2.8 Data Analysis 
Neurons from a single field were studied on each coverslip. Resting Ca2+ was determined prior to 
stimulation and was taken as the average of measurements taken over the 30 second prior to 
evoking a Ca2+ transient with high K+ (30 mM, 4 seconds). The magnitude of the evoked Ca2+ 
transient was determined as the difference between resting and the peak of the evoked Ca2+ 
transient. The duration of the evoked Ca2+ transient was determined as the time for the transient 
to decay to 50% of the peak (T50). For experiments involving the application of test compounds, 
a vehicle control group was always included. Data are expressed as mean ± s.e.m. One and two-
way ANOVA were used for analysis of more than two groups with the Holm-Sidak test used for 
post-hoc analysis. Statistical significance was assessed at p < 0.05. Group sizes were determined 
by a power analysis which was based on the variability in T50 observed in putative nociceptive 
glabrous skin neurons from three naïve rats. With a power of 0.8, alpha of 0.05, and the standard 
six groups included in most experiments, with groups defined by target of innervation and 
paclitaxel treatment, we estimated the need for a group size of 47 neurons to enable us to detect a 
difference between groups of 50%. 
 
 
 
 35 
2.3 RESULTS 
2.3.1 Paclitaxel-Induced Mechanical Hypersensitivity 
The rat model of CIPN used in the present study has been well described (Polomano et al., 2001, 
Flatters and Bennett, 2006, Xiao et al., 2008, Boyette-Davis et al., 2011a). However, despite the 
fact that clinical manifestation of CIPN is largely restricted to the feet and hands (Dougherty et 
al., 2004, Boyette-Davis et al., 2013), and in particular, the glabrous skin of the feet and hands 
(Dougherty et al., 2004, Pachman et al., 2011), assessment of mechanical and thermal sensitivity 
has largely be restricted to the hindpaw (Flatters and Bennett, 2006, Xiao et al., 2008, Boyette-
Davis et al., 2011a). We therefore sought to determine the extent to which the pattern of 
hypersensitivity in the rat model parallels that observed clinically. Consistent with previous 
results (Polomano et al., 2001, Flatters and Bennett, 2006), mechanical hypersensitivity was 
readily detectable on the glabrous skin of the hindpaw with a significant decrease in threshold 
observed by the second paclitaxel injection (Figure 1A). In contrast, however, no detectable 
change in threshold was observed on the hairy skin of the hindpaw (Figure 1B) or the inner thigh 
(Figure 1C). 
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Figure 1. Paclitaxel-Induced Mechanical Hypersensitivity. Paclitaxel (2mg/kg per treatment, black circles) 
induced mechanical hypersensitivity in the glabrous skin of the hindpaw (A) but not in the hairy skin of the dorsal 
hindpaw (B) or inner thigh (C), as assessed with an electronic Von Frey device. No changes in mechanical threshold 
were observed in vehicle treated (grey circles) animals. Paclitaxel/vehicle were administered at the points indicated 
with gray arrows n = 7 per group. 
 
2.3.2 The impact of target of innervation on resting and evoked intracellular calcium 
concentration [Ca2+]i in putative nociceptive cutaneous neurons 
Given evidence that dysregulation of [Ca2+]i in subpopulations of nociceptive neurons may 
contribute to the manifestation of mechanical hypersensitivity (Kawano et al., 2009), we first 
sought to determine whether differences among subpopulations of nociceptive neurons defined 
by target of innervation may contribute to the selective manifestation of paclitaxel-induced 
hypersensitivity. Putative nociceptive neurons were identified based on cell body size (Lawson, 
2002), IB4 binding (Fang et al., 2006) binding, and sensitivity to the algogenic compound, 
capsaicin (Holzer, 1991). Resting and evoked Ca2+ transients (magnitude and decay) were 
assessed as illustrated in Figure 2A. In putative nociceptive cutaneous neurons from naïve rats, 
there was a significant (p < 0.01, One-way ANOVA) difference between subpopulations defined 
by target of innervation in the resting [Ca2+]i, due to the level of Ca2+ in neurons innervating the 
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thigh, which was significantly lower than that in neurons innervating the hairy (p < 0.01) or 
glabrous (p < 0.01) skin of the hindpaw (Figure 2B). However, magnitude (Figure 2C) and 
duration (Figure 2D) of the high K+ evoked transient were comparable between subpopulations 
(p > 0.05). 
While there was no detectable influence of the paclitaxel vehicle on nociceptive 
threshold, even relatively simple solvents, such as DMSO can influence a variety of cellular 
processes. More importantly, there is evidence suggesting that the paclitaxel vehicle may be 
responsible for some of the side effects of the chemotherapy treatment (Gelderblom et al., 2001, 
Ahn et al., 2014). We therefore assessed the impact of vehicle on resting [Ca2+]i and evoked 
transients in subpopulations of putative nociceptive neurons defined by target of innervation. 
Neurons from vehicle treated animals were harvested 14 days after the first IV administration. 
Data were analyzed with a two-way ANOVA. While there was a main effect associated with 
target of innervation (p < 0.01, Figure 2B) on resting [Ca2+]i, there was no detectable influence of 
vehicle on the resting [Ca2+]i or the magnitude (Figure 2C) and duration (Figure 2D) of the 
evoked Ca2+ transient among subpopulations of cutaneous neurons. Data from naïve and vehicle 
treated animals was therefore pooled for subsequent analyses and are referred to as control 
neurons. 
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Figure 2. The impact of target of innervation on resting and evoked intracellular calcium concentration 
[Ca2+]i in putative nociceptive cutaneous neurons. Resting and evoked Ca2+ transients from putative nociceptive 
DRG neurons defined by target of innervation from naive rats or rats treated with the paclitaxel vehicle (cremophor 
EL: ethanol 1:1, diluted 1/12.5 with saline). A) Typical Ca2+ transient evoked with 30 mM K+ in a putative 
nociceptive neuron labeled from the glabrous skin. Features of the Ca2+ transient subsequently analyzed are 
indicated. Pooled data from naïve and vehicle treated rats were analyzed with a two-way ANOVA. B) While there 
was no detectable influence of vehicle on resting [Ca2+]i in subpopulations of putative nociceptive neurons defined 
by target of innervation, there was a main effect of target of innervation on this parameter. There was no detectable 
influence of either vehicle treatment of target of innervation on either the magnitude (C) or decay (D) of the evoked 
Ca2+ transient. Glab (glabrous skin of the hindpaw), Dorsal (dorsal skin of the hindpaw) and Thigh (thigh skin of the 
hindleg) refer to targets of innervation. Numbers of neurons in each group are naïve glabrous = 38, vehicle glabrous 
= 53, naïve dorsal = 27, vehicle dorsal = 23, naïve thigh = 30, vehicle thigh = 32).  
 
2.3.3 Paclitaxel attenuates the duration of the evoked Ca2+ transient in putative 
nociceptors 
We next sought to determine whether changes in resting [Ca2+]i or evoked Ca2+ transients in 
putative nociceptive cutaneous neurons could account for the pattern of changes in mechanical 
sensitivity. Data were again analyzed with a two-way ANOVA, in which the impact of target of 
innervation and paclitaxel treatment were compared. While the main effect (p < 0.01) associated 
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with target of innervation persisted on resting Ca2+, there was no significant influence of 
paclitaxel treatment, or a significant interaction between paclitaxel treatment and target of 
innervation on this parameter (Figure 3A and B). There was no detectable influence of either 
paclitaxel or target of innervation, or an interaction between the two, on the magnitude of the 
evoked Ca2+ transient (Figure 3A and C). However, there was a significant interaction between 
target of innervation and paclitaxel treatment on the duration of the evoked Ca2+ transient (Figure 
3A and D). Post-hoc analysis indicated that the duration was significantly shorter in neurons 
innervating the glabrous (p < 0.01) and hairy skin of the hindpaw (p < 0.05) obtained from 
paclitaxel compared to control rats (Figure 3D). To determine whether there were differences 
between groups of putative nociceptive cutaneous neurons defined by target of innervation with 
respect to the paclitaxel-induced decrease in the duration of the evoked Ca2+ transient, T50 data 
from paclitaxel treated rats were analyzed as a percent of that in control neurons. Pooled data 
(Figure 3E) were analyzed with a one-way ANOVA that indicated there was a significant 
difference between groups (p < 0.01). Post-hoc analysis showed that while there was no 
difference between hairy hindpaw and thigh skin neurons with respect to the paclitaxel-induced 
decrease in T50, the decrease in the duration of the evoked transient in putative nociceptive 
glabrous skin neurons was significantly greater than that in hairy hindpaw or thigh skin neurons 
(Figure 3E). 
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Figure 3. Paclitaxel attenuates the duration of the evoked Ca2+ transient in putative nociceptors. Resting and 
evoked Ca2+ transients from putative nociceptive DRG neurons defined by target of innervation from control (naïve 
and vehicle treated) rats or rats treated with paclitaxel. A) Typical high K+ (30 mM) evoked Ca2+ transients from 
putative nociceptive DRG neurons innervating glabrous skin of the hindpaw from rats treated with either vehicle or 
paclitaxel. Pooled data were analyzed as in Figure 2. B) While the main effect of target of innervation on resting 
[Ca2+]i, persisted, there was no detectable influence of paclitaxel on this parameter. C) There was also no detectable 
influence of paclitaxel on the magnitude of the evoked Ca2+ transient. D) However, there was a significant 
interaction between target of innervation and paclitaxel treatment on the duration of the evoked Ca2+ transient.  Post-
hoc analysis confirmed that the decrease in the duration of the evoked Ca2+ transient in both glabrous and hindpaw 
hairy skin (Dorsal) neurons were significant. To determine whether there was a difference between groups defined 
by target of innervation with respect to the size of the paclitaxel-induced decrease in duration, data from paclitaxel 
treated neurons were analyzed as a percent change from control. These data (E), were analyzed with a one-way 
ANOVA, which confirmed that the difference between groups was significant (p < 0.01). Post-hoc analysis 
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confirmed the decrease in the glabrous neurons was significantly greater than that in neurons from either the dorsal 
hindpaw or thigh. Numbers of neurons in each group are control glabrous = 91, paclitaxel glabrous = 44, control 
dorsal = 50, paclitaxel dorsal = 33, control thigh = 62, paclitaxel thigh = 47; * p<0.05).  
 
2.3.4 Paclitaxel does not affect the resting or evoked Ca2+ transient properties in putative 
non-nociceptive sensory neurons. 
While we were focused on mechanisms that may contribute to the paclitaxel-induced decrease in 
mechanical threshold, the first sign of CIPN is numbness and tingling, thought to reflect changes 
in non-nociceptive afferents (Dougherty et al., 2004). We therefore assessed the impact of 
paclitaxel on resting [Ca2+]i and evoked Ca2+ transients in putative non-nociceptive cutaneous 
neurons defined by a relatively large cell body diameter, the absence of IB4 binding and 
insensitivity to capsaicin. Consistent with results from unlabeled DRG neurons (Lu et al., 2006), 
evoked Ca2+ transients in putative non-nociceptive cutaneous neurons were smaller and decayed 
more rapidly than those in putative nociceptive neurons (Figure 4A). Nevertheless, two-way 
ANOVA analysis of pooled data from control and paclitaxel-treated rats indicated that there 
were no significant interactions between target of innervation and paclitaxel treatment on resting 
Ca2+ (Figure 4B), the magnitude (Figure 4C), or the duration (Figure 4D) of the evoked transient. 
There was, however, a main effect of target of innervation on both the resting Ca2+ (Figure 4B) 
and the magnitude of the evoked Ca2+ transient (Figure 4C), which were significantly lower in 
thigh neurons than neurons innervating hindpaw hairy or glabrous skin.  
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Figure 4. Paclitaxel does not affect the resting or evoked Ca2+ transient properties in putative non-nociceptive 
sensory neurons.  Resting and evoked Ca2+ transients from putative non-nociceptive DRG neurons defined by target 
of innervation from control rats or rats treated with paclitaxel. A) Typical evoked Ca2+ transients from putative non-
nociceptive DRG neurons innervating glabrous skin of the hindpaw from rats treated with either vehicle or 
paclitaxel. Pooled data were analyzed as described in Figure 2. B) While there was no detectable influence of 
paclitaxel treatment on resting [Ca2+]i, there was a significant effect of target of innervation on this parameter. C) 
There was also a significant main effect of target of innervation on the magnitude of the high K+ evoked Ca2+ 
transient in putative non-nociceptive neurons. D) However, there was no detectable influence of either treatment or 
target of innervation on the duration of the high K+ evoked Ca2+ transient in these neurons. Numbers of neurons in 
each group are control glabrous = 14, paclitaxel glabrous = 10, control dorsal = 15, paclitaxel dorsal = 8, control 
thigh = 9, paclitaxel thigh = 8). 
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2.4 DISCUSSION 
The purpose of the present study was to begin to test the hypothesis that the unique manifestation 
of CIPN is due to unique properties of afferents defined by target of innervation, in particular, 
those involved in the regulation of [Ca2+]i. Towards this end, we provided further support for the 
validity of the rat paclitaxel model of CIPN, which was associated with mechanical 
hypersensitivity in the glabrous skin of the hindpaw, but not the hairy skin of the hindpaw or 
mid-thigh. Differences among subpopulations of sensory neurons from naïve animals defined by 
target of innervation were relatively small and included a lower resting [Ca2+]i in both putative 
nociceptive and non-nociceptive neurons innervating the thigh, as well as a smaller magnitude of 
depolarization-evoked Ca2+ transient in putative non-nociceptive thigh skin afferents. And while 
paclitaxel had no detectable influence on resting [Ca2+]i, or the magnitude or duration of the 
depolarization-evoked Ca2+ transient in subpopulations of non-nociceptive afferents defined by 
target of innervation, it was associated with a significant decrease in the duration of the evoked 
transient in putative nociceptive afferents. This change was significantly larger in neurons 
innervating glabrous skin than those innervating hairy skin of the hindpaw or thigh. These results 
suggest that subpopulation and target of innervation are important factors determining the 
susceptibility and degree of dysregulation of [Ca2+]i, by paclitaxel treatment. 
Our behavioral results indicate that the paclitaxel-induced mechanical hypersensitivity is 
associated with the type of target tissue (glabrous vs. hairy skin) rather than the axonal length. 
Previously, axonal length was thought to determine the presence of pain symptoms of paclitaxel-
induced neuropathy due to the microtubule stabilizing action of paclitaxel presumably disrupting 
axonal transport and eventually leading to peripheral axon damage (Gornstein and Schwarz, 
2014). Arguing against this proposal, however, is the observation that there are relatively minor 
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differences among chemotherapeutics with respect to the resulting CIPN phenotype despite the 
fact that the antineoplastic efficacy of different chemotherapeutics is due to completely different 
mechanisms such as proteasome inhibition, DNA alkylation, topoisomerase inhibition (Jaggi and 
Singh, 2012). Furthermore, our results are consistent with data obtained from chemotherapy 
patients, where painful symptoms of CIPN are confined in the glabrous surfaces and rarely occur 
in the hairy surfaces of hands and feet of most patients (Dougherty et al., 2004, Pachman et al., 
2011). If target of innervation plays a more dominant role in the manifestation of CIPN than 
axon length, it will be necessary to re-evaluate several of the leading hypotheses concerning the 
mechanisms of CIPN. 
While the differences between subpopulations of neurons defined by target of innervation 
were relatively small, the presence of differences among subpopulations of cutaneous neurons 
underscores the impact of target of innervation of afferent properties. Differences based on target 
of innervation are consistent with our own previous results (Gold and Traub, 2004, Harriott et 
al., 2006, Harriott and Gold, 2009, Vaughn and Gold, 2010) as well as the results of others 
(Yoshimura et al., 2003, Beyak et al., 2004, Malin et al., 2011), although differences appear to be 
most pronounced under pathological conditions, such as the presence of inflammatory mediators 
(Gold and Traub, 2004, Vaughn and Gold, 2010) or persistent inflammation (Harriott et al., 
2006, Zhang et al., 2012b). Minimally, these data suggest that target of innervation must be taken 
into consideration when analyzing the properties of putative nociceptive and non-nociceptive 
afferents.  
A paclitaxel-induced decrease in the duration of the evoked Ca2+ transient was surprising 
given the evidence for an increase in the duration of the evoked Ca2+ transient in putative 
nociceptive neurons from rats with diabetic neuropathy (Kostyuk et al., 2001), a neuropathic pain 
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syndrome that is also manifest in a stocking-glove distribution, as well as changes obtained with 
models of inflammatory pain, characterized by an increase in magnitude and duration of evoked 
Ca2+ transient (Lu and Gold, 2008, Scheff et al., 2013, Scheff and Gold, 2014).We predicted 
changes comparable to those observed in the persistent inflammation model based on previous 
results indicating that paclitaxel-induced neuropathic pain is associated with upregulation of 
proinflammatory cytokines and induction of TLR4-mediated signaling cascades (Ledeboer et al., 
2007, Li et al., 2014). The difference between our results and the changes described in these 
other models could be due to the differences between models with respect to the site of release 
and/or the actions of specific combination of inflammatory mediators released (Ledeboer et al., 
2007, Zhang et al., 2012a). More generally, however, the differences between models indicate 
that the pattern of changes in the regulation of [Ca2+]i in sensory neurons are relatively specific to 
the site and nature of the nerve injury.   
It is possible that the paclitaxel-induced changes in the regulation of [Ca2+]i in putative 
nociceptive afferents are not directly responsible for the mechanical hypersensitivity observed. 
For example, the decrease in the duration of the evoked Ca2+ transient could be a compensatory 
response to the mitotoxic effects of paclitaxel. In this case, facilitating the decrease in the 
duration of the evoked Ca2+ transient may be beneficial for increasing the health and survival of 
these neurons. Alternatively, it is reasonable to speculate that a decrease in the evoked Ca2+ 
transient will increase the excitability of putative nociceptive cutaneous neurons given the 
importance of Ca2+-dependent K+ (BK) channels in the regulation of excitability of this 
population of afferents (Chen et al., 2009, Zhang et al., 2010). However, the observation that 
there was a significant decrease in the duration of the evoked Ca2+ transient in putative 
nociceptive neurons innervating the hairy skin of the hindpaw, a tissue in which we detected no 
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decrease in mechanical threshold, suggests that if there is a relationship between the decrease in 
the duration of the evoked Ca2+ transient and nociceptive threshold, it is not so simple. There are 
at least two potentially complicating factors in this relationship: 1) it is possible that because of 
the biophysical properties of the BK channel and/or the spatial distribution of the channel 
relative to Ca2+ sources in the terminal, the decrease in the evoked Ca2+ transient must reach a 
threshold before a decrease in BK activity is manifest, and 2) there is a differential distribution of 
Ca2+-dependent channels in glabrous and hairy skin.  
While it will be important to determine the mechanism(s) responsible for the paclitaxel-
induced decrease in the duration of the evoked Ca2+, available evidence suggests that this change 
is likely to be orchestrated by several different Ca2+-regulatory mechanisms rather than a simple 
change in influx, release, extrusion, or re-uptake. For example, the persistent inflammation-
induced increase in the magnitude and duration of the evoked Ca2+ transient (Lu and Gold, 
2008), is associated with a decrease in voltage-gated Ca2+ current (Lu et al., 2010), a decrease in 
sodium/calcium exchanger (NCX) activity, secondary to selective trafficking of NCX to 
peripheral terminals (Scheff and Gold, 2014), and at least one more mechanism accounting for 
the increase in the magnitude of the evoked Ca2+ transient. With evidence that Ca2+ influx, re-
uptake, release and extrusion mechanisms may all be functionally isolated, even in an isolated 
cell body (Scheff et al., 2013), a simple shift in the coupling of Ca2+ regulatory mechanisms 
could account for the paclitaxel-induced decrease in the duration of the evoked Ca2+ transient. 
Ongoing investigations are focused on teasing apart the relative contribution of the various Ca2+ 
regulatory mechanisms to the paclitaxel effects observed. 
In conclusion, our results suggest that axon length alone does not account for the 
stocking-glove distribution of CIPN. Rather, our results are consistent with our central 
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hypothesis and suggest that the unique distribution of symptoms associated with CIPN are due to 
an interaction between the toxic effects of paclitaxel and unique properties of subpopulations of 
afferents defined by target of innervation. Identification of mechanisms responsible for the 
apparent vulnerability of glabrous skin neurons and/or the resistance of hairy skin neurons to the 
toxic effects of paclitaxel may suggest novel therapeutic approaches for the treatment, if not 
prevention of CIPN.  
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3.0  PACLITAXEL-INDUCED INCREASE IN NCX ACTIVITY IN 
SUBPOPULATIONS OF NOCICEPTIVE AFFERENTS: A PROTECTIVE 
MECHANISM AGAINST CHEMOTHERAPY-INDUCED PERIPHERAL 
NEUROPATHY? 
3.1 INTRODUCTION 
Chemotherapeutic-induced peripheral neuropathy (CIPN) is a painful condition mainly restricted 
to the hands and feet (Dougherty et al., 2004). We have recently shown that a rat model of CIPN 
is associated with a significant decrease in the duration of the depolarization-evoked Ca2+ 
transients in isolated cell bodies of putative nociceptive afferents, but no changes in the 
magnitude of the transient, or in resting levels of Ca2+ (Yilmaz and Gold, 2015). Moreover, the 
degree of this change in duration was significantly larger in neurons innervating the glabrous 
skin of the hindpaw, than those targeting the hindpaw hairy skin or the inner thigh where no 
change in transient duration was detected. Interestingly, paclitaxel-induced mechanical 
hypersensitivity was only detected in the glabrous skin (Yilmaz and Gold, 2015). These data 
indicate the presence of a subpopulation-specific dysregulation of Ca2+ caused by paclitaxel 
treatment in this model.   
The purpose of the present study was to test the hypothesis that increased activity of the 
Na+-Ca2+ exchanger (NCX) is the underlying mechanism for the paclitaxel-induced changes in 
 49 
the evoked Ca2+ duration. This hypothesis was based on several observations: 1) NCX is a major 
Ca2+ extrusion mechanism, but with a low affinity for Ca2+, it is only activated with relatively 
high [Ca2+]i such as during depolarization-induced Ca2+ transients (Blaustein and Lederer, 1999, 
DiPolo and Beauge, 2006). In the sensory neuron cell soma, NCX plays a major role in the 
regulation of the duration of the evoked Ca2+ with no influence on transient magnitude (Lu et al., 
2006, Scheff et al., 2014). Consequently, NCX has the biophysical properties in DRG neurons to 
account for the selective paclitaxel-induced changes in the evoked Ca2+ transient. 2) Among 
sensory neurons, NCX is active only in putative nociceptive neurons (Lu et al., 2006, Scheff et 
al., 2014), the same subpopulation in which we observed the paclitaxel-induced decrease in the 
evoked Ca2+ transient duration (Yilmaz and Gold, 2015). 3) There is evidence that a change in 
NCX activity is associated with inflammatory hypersensitivity, albeit, a decrease in NCX activity 
(Scheff et al., 2014). Thus, given the often opposing cellular response to inflammation and nerve 
injury (Gold and Gebhart, 2010), it is possible that paclitaxel-induced neuropathy is associated 
with an increase in NCX activity.  
To test this hypothesis, retrograde tracer-labeled, small-diameter, IB4+, capsaicin responsive 
DRG neurons from naïve, vehicle-treated, and paclitaxel-treated rats were studied with 
ratiometric Ca2+ imaging in combination with a variety of pharmacological manipulations. Our 
results suggest that the paclitaxel-induced decrease in the duration of the evoked Ca2+ transient is 
not due to an increase in NCX activity. However, both vehicle and paclitaxel treatments were 
associated with NCX sensitization. A compensatory Ca2+ regulatory mechanism was also present 
in afferents innervating target areas where there was no detectable evidence of a chemotherapy-
induced change in mechanical sensitivity. Furthermore, paclitaxel treatment affects NCX 
subtypes differentially based on target of innervation. 
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3.2 METHODS 
3.2.1 Animals 
Adult (250-320g) male Sprague-Dawley rats (Harlan, Indianapolis, IN)) were used for all 
experiments. Rats were housed two per cage in a temperature and humidity controlled, 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC) accredited animal housing facility on a 12h:12h light:dark schedule with food and 
water available ad libitum. All procedures were approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee and performed in accordance with National 
Institutes of Health guidelines for the use of laboratory animals in research. 
3.2.2 Tissue labeling 
1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbo-cyanine perchlorate (DiI) was injected 
intradermally at three different sites, one location per animal, so as to label subpopulations of 
cutaneous afferents identified based on the target of innervation. These sites included the 
glabrous skin of the hind paw, the hairy skin on the dorsal side of the hind paw, and the hairy 
skin of the upper inner thigh. The hair covering the thigh was removed with an electrical shaver 
before retrograde labeling. DiI was injected with a 30 g needle under isoflurane (Abbott 
Laboratories, North Chicago, IL) anesthesia at 3-5 sites per target for a total volume of 10 μL in 
the dorsal and ventral hindpaw and 20 μL in the thigh. 
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3.2.3 Paclitaxel treatment 
One week following the DiI injection, rats were anesthetized with isofluorane and received 2 
mg/kg paclitaxel or its vehicle (1:1:23, cremophor EL:ethanol:0.9% saline) via the tail vein. The 
tail vein injection was repeated three more times every other day for a total of four injections.  
3.2.4 Sensory Neuron Isolation 
Rats were deeply anesthetized with an intraperitoneal injection (1 ml/kg) of an anesthetic 
cocktail containing ketamine (55 mg/kg), xylazine (5.5 mg/kg) and acepromazine (1.1 mg/kg). 
L4 and L5 DRGs were removed bilaterally, enzymatically treated, and mechanically dissociated. 
DRG neurons were plated on laminin (Invitrogen, 1mg/ml) and poly-L-ornithine (Sigma-
Aldrich, 1 mg/ml) coated glass cover slips as previously described (Lu et al., 2006).  All 
subsequent experiments were performed within 8 h of tissue harvest. Only neurons containing 
the retrograde label DiI were included for further analysis.  
3.2.5 Ca2+ Imaging 
Neurons were first incubated with 2.5 μM Ca2+ indicator fura-2 AM ester with 0.01 % Pluronic 
F-127 for 20 min at room temperature. Neurons were then incubated with FITC-conjugated IB4 
(5 μg/ml) for 10 min at room temperature. Following labeling, neurons were placed in a 
recording chamber and continuously superfused with a HEPES-buffered bath solution (HBS) 
consisting of (in mM): 130 NaCl, 3 KCl, 2.5 CaCl2, 0.6 MgCl2, 10 HEPES, 10 glucose, pH 7.4, 
osmolality 325 mOsm. Fluorescence data were acquired on a PC running Metafluor software 
 52 
(Molecular Devices, Sunnyvale, CA) via an EMCCD camera (Photometrics, Tucson, AZ; model 
QuantEM 512SC). The ratio (R) of fluorescence emission (510 nm) in response to 340/380nm 
excitation (controlled by a DG-4 (Sutter Instrument, Novato, CA)) was acquired at 1 Hz during 
application of KCl or capsaicin, which were applied through a computer-controlled, piezo-driven 
perfusion system (switching time <20 ms; Warner Instruments, Hamden, CT, USA, Fast-Step 
Model SF-77B). The concentration of intracellular Ca2+ ([Ca2+]i) was determined from fura-2 
ratio according to the equation [Ca2+ ]i (nM) = Kd (Sf2/Sb2) ((R-Rmin)/(Rmax-R)) following in situ 
calibration as described previously (Scheff et al., 2013), where Kd is the dissociation constant for 
fura-2 for Ca2+ at room temperature (224 nM); Sf2/Sb2 is the fluorescence ratio of the emission 
intensity excited with the 380 nm wavelength in the absence of Ca2+ to that in the presence of 
saturating Ca2+; Rmin and Rmax are the minimal and maximal fluorescence ratios, respectively. 
Sf2/Sb2, Rmin and Rmax were determined empirically with calibration runs as described 
previously (Kao, 1994), run periodically throughout the data collection period. 
3.2.6 Chemicals 
The retrograde tracer, DiI (Invitrogen, Carlsbad, CA, USA), was dissolved at 170 mg/mL in 
dimethylsufoxide (DMSO, Sigma-Aldrich, St Louis, MO, USA) and diluted 1:10 in 0.9% sterile 
saline. Paclitaxel (Sigma-Aldrich), was dissolved at 25 mg/mL in 1:1 Cremophor EL (Sigma-
Aldrich): ethanol and freshly diluted 1:12.5 in 0.9% sterile saline prior to injections. FITC-
conjugated Isolectin B4 (IB4, Sigma-Aldrich) was dissolved in dH20 as a stock solution of 1 
mg/ml, and then diluted to a final concentration of 10 μg/ml in HBS the day of use. Fura-2 
acetoxymethyl (AM) ester (TEF Laboratories, Austin, TX, USA) was dissolved in DMSO as a 
2.5 mM stock solution and diluted to a final concentration of 2.5 μM in HBS.  Pluronic F-127 
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(TEF Laboratories) was dissolved in DMSO as a 20% stock solution and diluted to 0.01% in 
HBS. Capsaicin (Sigma-Aldrich) was dissolved in ethanol as a 10 mM stock solution and diluted 
to 500 nM in HBS. LiCl (Sigma-Aldrich) was used to replace NaCl in HBS. KB-R7943 mesylate 
(Tocris, Bristol, UK) was dissolved in DMSO as a 100 mM stock solution and diluted to 100 nM 
in HBS. SEA0400 (ChemScene, Monmouth Junction, NJ, USA) was dissolved in DMSO as a 
100 mM stock solution and diluted to 1 μM in HBS. 
3.2.7 Data Analysis 
Neurons from a single field were studied on each coverslip. Resting Ca2+ was determined prior to 
stimulation as the average of measurements taken over the 30 second prior to evoking a Ca2+ 
transient with high K+ (30 mM, 4 seconds). The magnitude of the evoked Ca2+ transient was 
determined as the difference between resting and the peak of the evoked Ca2+ transient. The 
duration of the evoked Ca2+ transient was determined as the time for the transient to decay to 
50% of the peak (T50). For experiments involving the application of test compounds, a vehicle 
control group was always included. Neurons with a small cell body diameter (<30 μm) (Lawson, 
2002), responsive the capsaicin (500 nM) (Holzer, 1991), and labeled with the lectin IB4 (Fang 
et al., 2006), were studied and are referred to as putative nociceptors. While there are other 
subpopulations of putative nociceptors, IB4-negative nociceptors were not included in this study 
both because we previously failed to detect an influence of paclitaxel on the evoked Ca2+ 
transient in this subpopulation of neurons (Yilmaz and Gold, 2015), and because NCX is 
restricted to the subpopulation of small diameter, capsaicin responsive, IB4+ neurons (Scheff et 
al., 2014). Cell body diameter was determined with a calibrated eye-piece reticle. Capsaicin 
sensitivity was assessed at the end of every experiment and neurons were considered capsaicin 
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sensitive if application of capsaicin (500 nM, 1 second) resulted in an increase in [Ca2+]i greater 
than 20% above baseline. IB4 binding was determined under epifluorescence illumination prior 
to the start of each experiment. Neurons in which the plasma membrane was clearly defined by 
epifluorescence were considered IB4+.  Data are expressed as mean ± s.e.m. One and two-way 
ANOVA were used for analysis of more than two groups with the Holm-Sidak test used for post-
hoc analysis. Statistical significance was assessed at p < 0.05. The Chi-Square or Fisher exact 
tests were used to assess the presence of significant differences between groups with respect to 
the proportion or percentage of neurons with any evidence of NCX activity, or evidence of KB-
R7943-sensitive or SEA0400-sensitive NCX activity. Group sizes were determined by power 
analysis which was based on the variability in the percent increase in T50 observed in putative 
nociceptive glabrous skin neurons from three naïve rats following block of NCX with Li+. This 
analysis was performed for both a three group experiment, with groups defined only be treatment 
(naïve, vehicle and paclitaxel) as well as a six group experiment with groups defined by 
treatment and target of innervation. With a power of 0.8 and alpha = 0.05, we estimated the need 
for 20 neurons in the first set and 27 in the second. 
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3.3 RESULTS 
3.3.1 NCX does not mediate the paclitaxel-induced attenuation of the depolarization-
evokedCa2+ transient duration in putative glabrous nociceptors. 
To determine whether paclitaxel-induced attenuation of the evoked Ca2+ transients was due to 
increased NCX activity, we assessed NCX activity in glabrous skin neurons from naïve, vehicle- 
and paclitaxel-treated rats. We focused on IB4-binding, capsaicin-responsive, small diameter 
(<30 µm) lumbar DRG neurons that project to the glabrous skin of the hindpaw, because of our 
previous results indicating that the paclitaxel-induced attenuation of the depolarization-evoked 
Ca2+ transient was manifest in this subpopulation (Yilmaz and Gold, 2015). We blocked NCX 
activity by replacing Na+ in HBS with Li+ taking advantage of the fact that NCX activity requires 
presence of Na+ ions in the extracellular environment (Yu and Choi, 1997), and minimal impact 
that replacing Na+ with Li+ has on the functioning of voltage-gated Na+ channels (Gold and Thut, 
2001). The relative increase in the duration of depolarization-evoked Ca2+ transient in the 
presence of Li+ was assumed to reflect the loss NCX activity, and was therefore used as an 
indirect measure of NCX activity. Consequently, in neurons from paclitaxel-treated rats, an 
increase in NCX activity should be associated with a relatively larger increase in the duration of 
the evoked Ca2+ transient following NCX block. Consistent with our previous results (Yilmaz 
and Gold, 2015), the duration of the high K+ (30 mM, 4 sec)-evoked Ca2+ transient in neurons 
from paclitaxel-treated rats was shorter than that neurons from vehicle treated rats (Figure 5A 
and 5B). Further, as expected, in the presence of Li+, the duration of the evoked Ca2+ transient 
was increased in neurons from both vehicle- and paclitaxel-treated rats (Figure 5A, solid lines). 
However, the relative increase in the duration of evoked Ca2+ transients was comparable (p > 
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0.05) in neurons from both groups of rats as illustrated when these data were analyzed as a 
percent change in duration (Figure 5C).  
 
 
Figure 5. NCX does not mediate the paclitaxel-induced attenuation of the depolarization evoked Ca2+ 
transient duration in putative glabrous nociceptors. Paclitaxel-induced attenuation of the duration of the 
depolarization-evoked Ca2+ transient in putative glabrous nociceptors is not mediated by NCX. A) Ca2+ transients 
evoked with 4s application of 30 mM K+ in putative nociceptive neurons labeled from the glabrous skin from naïve 
(left) vehicle-treated (middle) and paclitaxel-treated (right) rats before (dotted traces) and after (solid traces) block 
of NCX by exchanging Na+ for Li+ in the bath solution. The duration of the evoked Ca2+ transient was quantified as 
the time to decay to 50 percent of the magnitude of the evoked Ca2+ transient (T50). B) Pooled T50 data from naïve 
(n = 8), vehicle-treated (n = 17 neurons) and paclitaxel-treated (n = 16 neurons) glabrous skin neurons in Na+ bath. 
C) Relative increase in the duration of evoked Ca2+ transients from the same group of neurons in (B) analyzed as a 
percent increase in T50 following block of NCX with Li+. * is p < 0.05. 
 
3.3.2 NCX is sensitized by the vehicle of paclitaxel. 
NCX activity not only depends on the extracellular Na+ concentration but also on [Ca2+]i.  
Because NCX has a low affinity for Ca2+ (Blaustein and Lederer, 1999), the magnitude and the 
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duration of the evoked Ca2+ transient required to reach the threshold for engaging NCX activity 
are relatively large (Scheff et al., 2014). However, the duration of the evoked Ca2+ transient in 
putative nociceptors from paclitaxel-treated rats was shorter than that previously demonstrated to 
be required for NCX activation in glabrous skin neurons (Scheff et al., 2014). This raised the 
possibility that NCX was sensitized in glabrous skin neurons from paclitaxel treated rats. An 
increase in NCX activity in response to smaller and shorter duration increases in [Ca2+]i could 
contribute to an overall decrease in the duration of the evoked transient, even if there was no 
difference in peak NCX activity in neurons from paclitaxel- and vehicle-treated rats. We tested 
this possibility with a stimulation-duration analysis of the activation of NCX, by application of 
30 mM KCl for durations ranging between 0.1 to 2 s in the presence and absence of Li+ to 
neurons from vehicle- and paclitaxel-treated rats. Consistent with our previous findings (Scheff 
et al., 2014), both the amplitude (Figure 6A) and duration (Figure 6B) of the depolarization 
evoked transient depends on the duration of KCl application. The amplitude saturates with a KCl 
application of ~2 seconds while the duration of the evoked transient appears to be bi-phasic, and 
has not fully saturated with even a 4 second application of KCl. A neuron was considered Li+-
responsive, if the duration of the evoked Ca2+ transient increased ≥ 20% in the presence of Li+. 
There was no difference in the proportion of Li+-responsive neurons from paclitaxel- (12/15 and 
13/14 for 1 and 2 sec applications of 30 mM KCl, respectively) and vehicle- (12/12 and 10/10 for 
1 and 2 sec applications of 30 mM KCl, respectively) treated rats. Similarly, in neurons 
stimulated with 4 sec of high K+ (i.e., in figure 1), 1 out of 17 and 4 out of 21 neurons from 
paclitaxel and vehicle-treated rats, respectively, were unresponsive to Li+. Furthermore, there 
were no detectable differences between the Li+-responsive and non-responsive neurons from 
paclitaxel-treated rats with respect to the properties of the evoked Ca2+ transient. However, in 
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contrast to our previous results with glabrous neurons from naïve rats, where [Ca2+]i above 325 
nM for at least 12 seconds was required for NCX activation (Scheff et al., 2014), in the presence 
of Li+ there was a ~2-fold increase in the duration of the evoked Ca2+ transient in response to any 
stimulus duration that was sufficient to drive an increase in [Ca2+]i (Figure 6C,  6D, and 6E). 
This apparent sensitization of NCX was observed in neurons from both vehicle- and paclitaxel-
treated rats.  
Evidence of NCX activity induced with relatively small and brief Ca2+ transients in 
putatively nociceptive glabrous skin neurons suggested the possibility that the paclitaxel vehicle 
(Cremaphor EL and ethanol) was responsible for the sensitization of NCX. To test this 
possibility, we repeated the stimulation-duration experiment in glabrous neurons from naïve rats. 
The results of this experiment were comparable to our previous findings (Scheff et al., 2014), 
where an increase in NCX activity was only detected in neurons that had an increase in [Ca2+]i 
above 325 nM that lasted longer than 11 seconds. 
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Figure 6. NCX is sensitized by the vehicle of paclitaxel. Paclitaxel vehicle sensitizes NCX. A) Peak evoked Ca2+ 
transients from naïve, vehicle-, and paclitaxel-treated rat putative nociceptor neurons as a function of 30 mM K+ 
application duration (n for each 30 mM K+ duration: 0.1s n = 4, 4, and 5; 0.2s n = 6, 7, and 10; 0.5s n = 6, 7, and 10; 
1s n = 7, 12, and 15; 2s n = 7, 10, and 14; 4s n = 9, 17, and 21 neurons for naïve, vehicle, and paclitaxel, 
respectively). B) The T50 duration of the evoked Ca2+ transients of the same neurons plotted in (A). C) Ca2+ 
transients evoked with 0.1s application of 30 mM K+ in putative nociceptive neurons labeled from the glabrous skin 
from naïve (left), vehicle-treated (middle), and paclitaxel-treated (right) rats in the before (dotted traces) and after 
(solid traces) block of NCX with Li+ bath solution. D)  Ca2+ transients evoked in the same neurons as in A, with 1 
and 2 s applications of 30 mM K+, before and after block of NCX with Li+ bath. E) Pooled data from neurons 
stimulated with 30 mM K+ as illustrated in A and B, analyzed as a percent increase in T50 following NCX block 
with Li+ (Percent Δ T50), are plotted as a function of 30 mM K+ application duration.  
 
3.3.3 The impact of paclitaxel on NCX activity is dependent on target of innervation. 
The observation that NCX was sensitized in neurons from vehicle-treated rats, in the absence of 
any detectable influence of the paclitaxel vehicle on the duration of the depolarization-evoked 
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Ca2+ transient in these neurons (as compared to neurons from naïve rats (Figure 1 and (Yilmaz 
and Gold, 2015)) suggests that there are at least two Ca2+ regulatory mechanisms that are altered 
in neurons from vehicle treated rats: 1) the apparent increase in NCX activity and 2) another 
mechanism that compensates for the increase in NCX activity. Because we also previously failed 
to detect an influence of paclitaxel or its vehicle on depolarization-evoked Ca2+ transients in 
putative nociceptive neurons innervating the inner thigh (Yilmaz and Gold, 2015), the presence 
of compensatory changes in glabrous skin neurons that were undetected with a depolarizing 
stimulus alone raised the possibility that compensatory mechanisms contributed to the negative 
results in thigh neurons as well. To test this possibility, we repeated the Li+ application 
experiments with neurons labeled from the hairy skin of the hindpaw and the inner thigh.  
The fraction of Li+-responsive neurons was significantly (p < 0.05, Chi-square test) lower 
in thigh skin neurons (7/15 neurons from vehicle-treated rats and 13/20 neurons from paclitaxel-
treated rats) than that in glabrous skin neurons. However, the fraction of Li+-responders in hairy 
hindpaw neurons (16/22 neurons from vehicle-treated rats and 15/18 neurons from paclitaxel-
treated rats) was not significantly (p > 0.05, Chi-square test) different from that in either thigh or 
glabrous skin neurons (Figure 7A). Moreover, of the Li+-responders, there was a significant 
interaction (p < 0.05) between treatment (paclitaxel vs vehicle) and target of innervation (thigh, 
hairy hindpaw and glabrous skin), where post-hoc analysis confirmed that the paclitaxel-induced 
increase in NCX activity in thigh neurons was significantly greater than that in neurons 
innervating either the hairy hindpaw (p < 0.05) or glabrous skin (p < 0.01). To determine 
whether the relative increase in evoked transient duration observed in thigh neurons was 
different than that in the hairy hindpaw or glabrous skin neurons, duration data for the paclitaxel 
groups from each target of innervation were analyzed as a percent increase over the mean change 
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in duration in the respective vehicle groups.  Statistical analysis of these data confirmed that this 
difference based on target of innervation was significant (p < 0.01, one-way ANOVA), where 
post-hoc analysis confirmed that the increase in duration in thigh neurons was significantly 
greater than that in either hairy hindpaw (p<0.05) or glabrous skin neurons (p<0.01) (Figure 7B). 
This indicated that in contrast to glabrous skin neurons, paclitaxel was associated with an 
increase in NCX activity in thigh neurons.  
 
Figure 7. The impact of paclitaxel on NCX activity is dependent on target of innervation. Effect of paclitaxel 
on NCX depends of target of innervation. A) Putative nociceptive neurons from vehicle (V) and paclitaxel (P) 
treated rats retrogradely labeled from the glabrous skin (Glabrous), the dorsal skin of the hindpaw (Dorsal), and the 
inner thigh skin (Thigh), were analyzed as a function of whether or not Li+ was associated with an increase in the 
duration of the evoked Ca2+. The proportion of Li+ responsive neurons in each group is plotted. The total number of 
neurons studied in each group is indicated in parenthesis. B) Li+-induced increase in the duration of the Ca2+ 
transient evoked with a 4 s application of 30 mM K+ was analyzed as a percent increase T50. Pooled data are from 
the Li+-responsive neurons plotted in A. Data from the glabrous skin neurons from Figure 1C have been replotted 
here to facilitate comparisons between groups. * is p < 0.05 
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3.3.4 Paclitaxel-induced increase in NCX activity in thigh neurons is not due to NCX3 
activity. 
We sought to confirm our Li+ results with another NCX blocker both because Li+ influences a 
number of cellular processes in addition to blocking NCX and because of previous evidence that 
all three NCX isoforms are expressed in sensory neurons (Scheff et al., 2014). Based on previous 
evidence that NCX3 accounts for the majority of depolarization-evoked NCX activity in 
glabrous skin neurons, we used the NCX3 preferring blocker, KB-R7943 (Iwamoto and 
Shigekawa, 1998, Scheff et al., 2014). In this set of experiments, we focused on glabrous skin 
neurons and thigh neurons, in which there was no effect of paclitaxel on the Li+-induced increase 
in the evoked Ca2+ transient duration and the largest paclitaxel-induced change in the response to 
Li+ was observed, respectively. As with Li+, neurons were again subgrouped based on the impact 
of KB-R7943 on the duration of the depolarization (4 seconds of 30 mM K+) evoked Ca2+ 
transient, where those in which the duration of the evoked Ca2+ transient was ≥20% were 
considered KB-R7943 responders (Figure 8A).  Of the 10 glabrous skin neurons from naïve rats 
tested, 8 were KB-R7943 responders. A similar proportion of glabrous skin neurons from 
paclitaxel-treated rats (15/16) were KB-R7943 responders. However, the proportion of KB-
R7943 responders from vehicle-treated rats (9/18) was significantly (p < 0.01) lower than that in 
the paclitaxel group (Figure 8B). In thigh neurons, paclitaxel treatment was associated with a 
significant (p < 0.01, Chi Square test) increase in the proportion of KB-R7943 responders 
(21/23) relative to that observed in neurons from either naïve (4/8) or vehicle-treated (10/19) rats 
(Figure 8B). This suggested at least some of the paclitaxel-induced increase in NCX activity in 
thigh neurons was due to an increase in a KB-R7943 sensitive NCX isoform (i.e., NCX3). 
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To further assess the contribution of a KB-R7943-sensitive NCX isoform to the paclitaxel-
induced increase in NCX activity in thigh neurons, we analyzed the KB-R7943-induced increase 
in the Ca2+ transient duration of responders.  Strikingly, the KB-R7943-induced increase in 
transient duration was comparable (p > 0.05) in glabrous and thigh skin neurons from naïve, 
vehicle-, and paclitaxel-treated rats (Figure 8A and 8C) suggesting that the majority of NCX 
activity in these neurons was KB-R7943-insensitive. To confirm this impression, KB-R7943 data 
were analyzed as a percentage of the mean response (increase in transient duration) to Li+. 
Analysis of these data revealed a significant interaction between target of innervation and 
treatment, where post-hoc analysis confirmed that there was a significant reduction in the KB-
R7943 sensitive fraction of the Li+-induced increase in the duration of the evoked Ca2+ transient 
(Figure 8D). Finally, the NCX1 preferring blocker, SEA0400 was used to determine whether the 
apparent paclitaxel-induced increase in KB-R7943 insensitive NCX activity in thigh neurons was 
due to an increase in NCX1 activity. Thigh neurons from vehicle- and paclitaxel-treated rats 
were studied before and after application of SEA0400 (1 μM) (Figure 8E). Nine out of 10 thigh 
neurons tested from paclitaxel-treated rats were SEA0400 responders, however only two out of 
10 thigh neurons from vehicle-treated rats were SEA0400 responders (Figure 8F, p < 0.01, 
Fisher Exact test). Analysis of the pooled transient duration data of the responders indicated that 
the paclitaxel-induced increase in KB-R7943-insensitive NCX activity in thigh neurons is 
associated, at least partially, with an increase in SEA0400-sensitive NCX activity, which 
accounted for 42 ± 24 percent of the Li+-induced increase in the duration of the evoked transient.  
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Figure 8. Paclitaxel-induced increase in NCX activity in thigh neurons is not due to NCX3 activity. The 
paclitaxel-induced increase in NCX activity in thigh neurons is KB-R7943 resistant and SEA0400 sensitive. A) Ca2+ 
transients evoked with 4s application of 30 mM K+ in putative nociceptive neurons labeled from the thigh skin from 
vehicle-treated (left) and paclitaxel-treated (right) rats before (dotted traces) and after (solid traces) block of NCX 
with KB-R7943 (100 nM). B) Putative nociceptive neurons from vehicle (V) and paclitaxel (P) treated rats 
retrogradely labeled from the glabrous skin (Glabrous) and the inner thigh skin (Thigh), were analyzed as a function 
of whether or not KB-R7943 was associated with an increase in the duration of the evoked Ca2+. The proportion of 
KB-R7943-responsive neurons in each group is plotted. The total number of neurons studied in each group is 
indicated in parenthesis. C) KB-R7943-induced increase in the duration of the Ca2+ transient evoked with a 4 s 
application of 30 mM K+ was analyzed as a percent increase T50. Pooled data are from the KB-R7943-responsive 
neurons plotted in B. D) To estimate the fraction of total NCX activity sensitive to KB-R7943, increase in T50 
associated with KB-R7943 was analyzed as a percentage of the average increase in T50 in response to Li+ (%Li+-
induced ΔT50). Pooled data from C analyzed in this way are plotted in D). E) Ca2+ transients evoked with 4s 
application of 30 mM K+ in putative nociceptive neurons labeled from the thigh skin from vehicle-treated (left), and 
paclitaxel-treated (right) rats before (dotted traces) and after (solid traces) application of the putative NCX1 
preferring blocker SEA0400. F) The proportion of SEA0400-responsive thigh neurons from paclitaxel (P) treated 
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rats was significantly greater than that in neurons from vehicle (V) treated rats. The number in parentheses is the 
total number of neurons studied from each group.* is p < 0.05, ** is p < 0.01. 
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3.4 DISCUSSION 
 
The purpose of this study was to test the hypothesis that the paclitaxel-induced decrease in the 
duration of the evoked Ca2+ transient in putative nociceptive glabrous skin neurons is due to an 
increase in activity of NCX. Because we observed the paclitaxel-induced decrease in the duration 
of the Ca2+ transient evoked with a four second application of high K+, this stimulus duration was 
used to estimate the total NCX activity. With this stimulus duration, we failed to detect a 
difference in the relative levels of NCX activity between neurons from paclitaxel or vehicle-
treated animals. Furthermore, there was no evidence of a paclitaxel-selective sensitization of 
NCX that was assessed with shorter duration applications of high K+. In contrast to glabrous skin 
neurons from naïve rats in which a relatively large and long lasting increase in [Ca2+]i was 
needed to evoke NCX activity, there was evidence of NCX activity in neurons from both vehicle 
and paclitaxel-treated rats in response to evoked transients that were significantly smaller and of 
shorter duration.  There were also differences between thigh, hairy hindpaw and glabrous skin 
with respect to the proportion of neurons with detectable NCX activity. Interestingly, there was a 
paclitaxel-induced increase in the proportion of thigh neurons with evidence of NCX activity. 
Even more interestingly, there was also a paclitaxel-induced increase in the impact of Li+ on 
thigh neurons that was associated with no change in the actions of KB-R7943, but an increase in 
the impact of the NCX1-preferring blocker, SEA0400. Taken together, while these observations 
argue against our initial hypothesis, they highlight the potential confounding influence of the 
chemotherapeutic vehicle on cellular properties that may not only contribute to the manifestation 
of CIPN, but also potentially mask the underlying mechanism(s). They also suggest the 
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emergence of potential compensatory mechanisms in subpopulations of neurons that serve to 
protect them from the deleterious consequences of chemotherapeutics. 
 Our results argue against an increase in NCX activity as the mechanism of the paclitaxel-
induced decrease in the duration of the evoked Ca2+ transient in glabrous skin neurons. 
Nevertheless, this conclusion is made with caution because of limitations associated with 
assumptions implicit in the indirect assessment of NCX activity. These include the specificity of 
the reagents used to block NCX activity, that a block of NCX will necessarily increase the 
duration of the evoked Ca2+ transient, and that it is possible to manipulate a Ca2+ regulatory 
mechanism, such as NCX, without affecting other mechanisms. While it is clear that these 
assumptions reflect an over-simplification of a very complex system, we suggest that the 
limitations associated with these assumptions are unlikely to significantly influence the 
interpretation of our results. For example, consistent results were obtained with Li+ and the 
NCX3-prefering blocker KB-R7943, arguing against a contribution of NCX-independent 
mechanisms contributing to the effects of Li+. Similarly, that it was possible to detect a relative 
increase in NCX activity in thigh neurons suggests that the failure to detect a change in NCX 
activity in glabrous skin neurons was not due to a limitation in the sensitivity of this indirect 
assay. The changes detected in thigh neurons also argue against the possibility that the vehicle 
effects occluded our ability to detect a change in NCX activity in glabrous skin neurons.  
If a change in NCX activity is not the underlying reason for paclitaxel-induced decrease in the 
Ca2+ transient duration, it is worth considering other Ca2+ regulatory mechanisms that may 
contribute to this change. It is possible to rule out several regulatory mechanisms, however, 
because of evidence that they influence resting [Ca2+]i and/or the magnitude of the evoked Ca2+ 
transient. For example, the high affinity/low efficacy plasma membrane calcium ATPase 
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(PMCA) is the major regulator of resting Ca2+ level in many cells types (Carafoli, 1991) 
including putative nociceptive DRG neurons (Gemes et al., 2012), and therefore is unlikely to 
mediate the selective paclitaxel-induced change in the duration of the evoked transient. 
Similarly, because voltage-gated Ca2+ channels (VGCCs) and Ca2+-induced Ca2+ release (CICR) 
machinery contribute to the magnitude of the evoked Ca2+ transient, neither is likely to underlie 
the paclitaxel-induced decrease of the Ca2+ transient duration. This leaves mitochondria and 
sarco-endoplasmic reticulum calcium ATPase (SERCA), which have both been shown to 
contribute to the regulation of the evoked Ca2+ transient duration in sensory neurons (Lu et al., 
2006, Scheff et al., 2013). However, because previous results in unlabeled DRG neurons indicate 
that mitochondria can affect the magnitude of the evoked Ca2+ transients as well as the duration 
(Lu et al., 2006), future experiments should consider SERCA as a priority. Alternatively, because 
of the inter-dependence of Ca2+ regulatory mechanisms (Thibault et al., 2007, Garcia-Sancho, 
2014, Moccia et al., 2015), a more likely explanation for the paclitaxel-induced decrease in the 
evoked transient duration is that it reflects changes in a combination of regulatory mechanisms. 
For example, reduced coupling of VGCCs to CICR machinery, thus reduced release of 
endoplasmic reticulum (ER) Ca2+ after influx through VGCCs, may result in transients that are 
shorter in duration without an impact on the magnitude. 
Evidence of NCX activity in association with small amplitude brief duration Ca2+ 
transients in both vehicle- and paclitaxel-treated neurons indicates that the paclitaxel vehicle 
drives the sensitization of NCX. The presence of sensitized NCX in vehicle-treated neurons 
should have resulted in shorter duration-evoked transients in neurons from both vehicle and 
paclitaxel-treated rats, relative to that in neurons from naïve rats. However, the observation that 
evoked transient duration was comparable in neurons from vehicle-treated and naïve rats 
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(Yilmaz and Gold, 2015) indicates the presence of a second change in neurons from vehicle-
treated rats, needed to compensate for the vehicle-induced increase in NCX activity. This would 
not be the first evidence of a vehicle effect, as it has been previously reported that cremophor EL 
is associated with anaphylactoid hypersensitivity reactions, ganglionopathy, axonopathy, and 
demyelination (Gelderblom et al., 2001, Mielke et al., 2006). Whether an increase in NCX 
activity contributes to any of these changes has yet to be determined. Furthermore, it is possible 
that one or both of these changes in Ca2+ regulation, contribute to the side effects associated with 
at least a taxol-based chemotherapy. In particular, while we failed to detect an influence of 
vehicle on nociceptive threshold, it is possible that the changes associated with vehicle treatment 
contribute to the manifestation of hypersensitivity in paclitaxel-treated animals. However, 
because a variety of chemotherapeutics administered in different vehicles produce a neuropathy 
with comparable symptoms and manifestation pattern, we suggest that changes associated with 
the paclitaxel vehicle are unlikely to be an important determinant of CIPN. 
While the heterogeneity among subpopulations of sensory neurons has been well 
described, our results point to yet another manifestation of this phenomenon among 
subpopulations of sensory neurons based on target of innervation. First, there are differences 
between glabrous skin and inner thigh skin putative nociceptive neurons with respect to both the 
presence of NCX activity, and the NCX isoforms underlying this activity. Second, there is also a 
difference between these subpopulations with respect to the impact of paclitaxel on NCX 
activity.  More importantly, however, are the implications of the apparently selective increase in 
NCX activity in thigh neurons. This observation suggests that in addition to the multiple vehicle-
associated changes in glabrous skin neurons, there also needs to be (at least) two opposing 
changes in Ca2+ regulatory processes in putative nociceptors innervating the inner thigh skin to 
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account for the apparent absence of a paclitaxel-induced change in transient duration in these 
neurons (Yilmaz and Gold, 2015). Furthermore, given the absence of a detectable paclitaxel-
induced change in the withdrawal threshold to noxious mechanical stimulation of the inner thigh, 
one, if not both of the changes in Ca2+ regulation may protect these neurons from the toxic 
effects of paclitaxel. This suggests an alternative explanation for the stocking glove distribution 
of CIPN, which is due to the failure of glabrous skin neurons to compensate for the toxic effects 
of chemotherapeutics, rather than the presence of a unique property of these neurons (such as 
their axon length), that confers a selective vulnerability. Identification of the protective 
mechanism(s) in thigh neurons may suggest novel approaches for the treatment, if not prevention 
of CIPN. 
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4.0  ROLE OF PACLITAXEL-INDUCED INCREASE IN 
MITOCHONDRIALVOLUME ON CALCIUM DYSREGULATION IN 
SUBPOPULATIONS OF NOCICEPTIVE AFFERENTS: DIRECT AND INDIRECT 
MECHANISMS  
4.1 INTRODUCTION 
Chemotherapy-induced peripheral neuropathy (CIPN) is not only of the leading dose-limiting 
side effects of chemotherapy but the primary reason for therapy cessation (Wolf et al., 2008, 
Jaggi and Singh, 2012). CIPN generally starts with tingling and numbness in the distal 
appendages and progresses to a painful neuropathy, severity of which escalates with cumulative 
dosage (Quasthoff and Hartung, 2002, Jaggi and Singh, 2012).  
We have recently demonstrated in a rat model of paclitaxel-induced CIPN, that the 
presence of mechanical hypersensitivity is associated with a dysregulation of intracellular Ca2+ in 
a subpopulation of putative nociceptive neurons. Specifically, we observed a significant decrease 
in the duration of the depolarization-evoked Ca2+ transient, with no changes in either the 
transient peak, or in resting Ca2+ (Yilmaz and Gold, 2015). Having recently described an 
inflammation-induced decrease in the activity of the Na+-Ca2+-exchanger (NCX) that was 
responsible for the inflammation-induced increase in the duration of the evoked Ca2+ transient 
(Scheff et al., 2014) in the same population of neurons in which paclitaxel produced a decrease 
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in the evoked transient duration, our initial hypothesis was that an increase in NCX activity was 
responsible for the paclitaxel-induced changes. However, while paclitaxel does drive changes in 
NCX activity in a different subpopulation of neurons, we were able to rule out an increase in 
NCX activity as the mechanism underlying the paclitaxel-induced decrease in transient duration 
(Yilmaz and Gold, 2016). Thus, in the present study, we have pursued an alternative hypothesis 
regarding the mechanism(s) underlying the paclitaxel-induced decrease in the duration of the 
depolarization evoked Ca2+ transient. 
Given the weight of evidence in support of mitotoxicity as a mechanism responsible for 
the numbness, tingling, and pain associated with CIPN (Bennett et al., 2014), in combination 
with the both a direct and indirect role for mitochondria in the regulation of intracellular Ca2+, a 
role for mitochondria in the paclitaxel-induced dysregulation of intracellular Ca2+ would seem to 
be an even more compelling hypothesis than that in support of a role for NCX. Based on several 
different lines of evidence, Bennett and colleagues proposed that an increase in reactive oxygen 
species (ROS) combined with the chronic energy deficit associated with chemotherapeutic-
induced mitotoxicity are responsible for both spontaneous discharges in afferents with 
myelinated (tingling) and unmyelinated (pain) axons, and degeneration of peripheral afferent 
terminals (numbness) (Bennett et al., 2014). Mitotoxicity has been documented in several 
different animal models of CIPN, which is characterized by mitochondrial swelling, an increase 
in the percentage of vacuolated mitochondria, and reduced rates of ATP production and 
respiration along sensory axons (Flatters and Bennett, 2006, Xiao et al., 2011, Zheng et al., 2011, 
2012). The morphological changes in mitochondria were observed in both small and large 
diameter sensory but not in motor fibers (Xiao et al., 2011). In addition, the highest level of 
paclitaxel accumulation was detected in dorsal root ganglia (DRG) (Xiao et al., 2011), raising the 
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possibility that mitochondria damage is initiated at the sensory neuron cell body. Because longer 
nerves would be particularly vulnerable to the deleterious impact of mitochondria damage, 
mitotoxicity has also been suggested to account for the “stocking glove” distribution of CIPN 
(Gornstein and Schwarz, 2014). 
Mitochondria are able to attenuate increases in intracellular Ca2+ directly via the 
mitochondrial uniporter (MCU) and indirectly via the regulation of primary active transporters 
including the plasma membrane Ca2+ ATPase (PMCA) and sarco-endoplasmic reticulum Ca2+ 
ATPase (SERCA), as well as secondary active transporters such as NCX. Thus, an increase in 
mitochondria and/or mitochondrial activity could account for the paclitaxel-induced decrease in 
the evoked Ca2+ transient. The problem with this suggestion, however, is that if mitochondria are 
damaged, there should be an attenuation of mitochondria-dependent Ca2+ uptake which should 
result in an evoked Ca2+ transient with a longer, not a shorter duration.   
We suggest, however, that it is possible for chemotherapeutics to contribute to both gain- 
and loss-off mitochondrial function, if the changes in mitochondria occur in different 
subpopulations of neurons. Consistent with this suggestion is the observation that despite being 
referred to as a “stocking-glove” distribution, more detailed analysis indicates that CIPN 
symptoms are preferentially localized in the glabrous skin of the hands and feet (Dougherty et 
al., 2004). We have recently demonstrated this far more restricted manifestation of CIPN in a rat 
model of paclitaxel-induced CIPN, where mechanical hypersensitivity was detected in the 
glabrous skin of the hindpaw but not in the dorsal skin of the hindpaw or the inner thigh (Yilmaz 
and Gold, 2015). Minimally, this observation argues against the axon length-dependence of the 
manifestation of CIPN, but also supports the suggestion that there is a sensory neuron 
subpopulation specific vulnerability to the actions of chemotherapeutics.  
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Furthermore, we and others have not only documented differences among sensory neuron 
subpopulations with respect to both the magnitude and the duration of the depolarization-evoked 
Ca2+ transients and the underlying Ca2+ regulatory pathways (Lu et al., 2006) but there are now a 
number of lines of evidence supporting the presence of a sensory neuron subpopulation specific 
response to injury (Gold and Traub, 2004, Harriott et al., 2006, Vaughn and Gold, 2010). Most 
relevant in this regard, the paclitaxel-induced reduction in the duration of the depolarization-
evoked Ca2+ transient in putative nociceptive afferents was significantly larger in neurons 
innervating the glabrous skin of the hindpaw in comparison to innervating the hairy skin of the 
hind paw or the inner thigh (Yilmaz and Gold, 2015). Similarly, while target of innervation was 
not determined, morphological evidence of mitotoxicity was only observed in 25 to 40% of 
axons (Flatters and Bennett, 2006, Xiao et al., 2011). Thus, we hypothesize that CIPN is due to 
both increases and decreases in mitochondria function, with changes manifest in distinct 
subpopulations of afferents. 
To begin to test this hypothesis, we used behavioral approaches, fluorescent 
immunohistochemistry, live confocal microscopy, and Ca2+ imaging in combination with 
pharmacological manipulations to study paclitaxel-induced changes in retrograde tracer-labeled, 
small-diameter, IB4+, capsaicin-responsive DRG neurons from naïve, vehicle-treated, and 
paclitaxel-treated rats. Our results suggest that the paclitaxel-induced decrease in the duration of 
the evoked Ca2+ transient in putative nociceptive glabrous skin neurons is indeed mediated by an 
increase in mitochondria function, facilitating an increase in the clearance of Ca2+ from the 
cytosol via direct and indirect mechanisms.  
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4.2 METHODS 
4.2.1 Animals 
Adult (250-320g) male Sprague-Dawley rats (Envigo, Indianapolis, IN)) were used for all 
experiments. Because preliminary results suggest that there is a sex different in the development 
of chemotherapy-induced mechanical sensitivity in rats, female rats were not included in this 
study. Rats were housed two per cage in a temperature and humidity controlled, Association for 
Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited 
animal housing facility on a 12h:12h light:dark schedule. Food and water were available ad 
libitum. All procedures were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee and performed in accordance with National Institutes of Health guidelines 
for the use of laboratory animals in research. 
4.2.2 Retrograde labeling 
1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbo-cyanine perchlorate (DiI) or 3,3'-
Dioctadecyloxacarbocyanine Perchlorate (DiO) was injected intradermally at one of three 
different locations so as to identify subpopulations of cutaneous afferents based on the target of 
innervation. These sites included the glabrous skin of the hind paw, the hairy skin on the dorsal 
side of the hind paw, and the hairy skin of the upper inner thigh. The hair covering the thigh was 
removed with an electrical shaver before retrograde labeling with DiI or DiO. The retrograde 
tracer was injected bilaterally under isoflurane (Abbott Laboratories, North Chicago, IL) 
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anesthesia with a 30 g needle at 3-5 sites per target for a total volume of 10 μL in the dorsal and 
glabrous hindpaw and 20 μL in the thigh. Only one tracer was injected into each animal. 
4.2.3 Paclitaxel treatment 
One week following the DiI or DiO injection, rats were anesthetized with isofluorane and 
injected into the tail vein with 2 mg/kg paclitaxel or its vehicle (1:1:23, cremophor 
EL:ethanol:0.9% saline). The tail vein injection was repeated three more times every other day 
for a total of four injections.  
4.2.4 Behavioral Assessment  
All behavioral data were collected in the Rodent Behavior Analysis Core of the University of 
Pittsburgh, School of Health Sciences by an experimenter blinded to the test group. Rats were 
habituated to the testing procedure, equipment, and the experimenter for two to three days before 
the collection of baseline data. For the cold hypersensitivity test, rats were placed individually in 
acrylic clear boxes (10 cm x 20 cm), separated by opaque dividers. The boxes were set on a 1/8 
inch-thick glass platform. The barrel of a 3 mL syringe filled with powdered dry ice, was placed 
on the surface of the glass platform precisely beneath the footpad of the hindpaw. Paw 
withdrawal latency was recorded three times per paw, with an interval of at least five minutes for 
each paw. The cold hypersensitivity test was conducted three times per week. 
For assessment of changes in mechanical sensitivity in the glabrous skin, the same clear 
acrylic boxes were used, except for this test, the boxes were placed on an aluminum mesh. Four 
g and 15 g von Frey filaments were applied to the center foot pad of the hind paw at a right angle 
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from below the mesh as previously described (Flatters and Bennett, 2006). Each filament was 
applied five times per paw (10 times total per rat), at a frequency of 3-5 min. Paw withdrawal 
response probability was calculated as, P = number of withdrawal responses / 10 trials. 
Mechanical assessments were conducted once per week on a day that the rats were not tested for 
cold sensitivity. 
4.2.5 Sensory Neuron Isolation 
Rats were deeply anesthetized with an intraperitoneal injection (1 ml/kg) of an anesthetic 
cocktail containing ketamine (55 mg/kg), xylazine (5.5 mg/kg) and acepromazine (1.1 mg/kg). 
L4 and L5 DRGs were removed bilaterally, enzymatically treated, and mechanically dissociated. 
DRG neurons were plated on laminin (Thermo-Fisher, 1mg/ml) and poly-L-ornithine (Sigma-
Aldrich, 1 mg/ml) coated glass coverslips as previously described (Lu et al., 2006). For 
immunocytochemistry experiments, chamber slides (EMD Millipore, Billerica, MA, USA) were 
used instead of glass coverslips.  All subsequent experiments were performed within 8 h of tissue 
harvest.  
4.2.6 Fura-2 and Rhod-2 Ca2+ Imaging 
Fura-2 was used to monitor changes in free cytosolic Ca2+, and Rhod-2 was used to monitor 
relative changes in mitochondrial Ca2+ (Davidson and Duchen, 2012). Cells were loaded with 
Fura-2 AM ester (2.5 μM) with 0.025 % Pluronic F-127 for 20 min at room temperature. They 
were loaded with Rhod-2 AM ester (500 nM) in combination with Fura-2 AM ester + Pluronic 
F-127 for 20 min at room temperature. Following loading with Ca2+ indicators, neurons from 
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DiI-labeled rats were then incubated with FITC-conjugated IB4 (10 μg/ml) for 10 min at room 
temperature. They were then placed in a recording chamber and continuously superfused with a 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2-Hydroxyethyl) piperazine-N′-(2-
ethanesulfonic acid) (HEPES)-buffered bath solution (HBS) consisting of (in mM): 130 NaCl, 3 
KCl, 2.5 CaCl2, 0.6 MgCl2, 10 HEPES, 10 glucose, pH 7.4, osmolality 325 mOsm. Fluorescence 
data were acquired on a PC running Metafluor software (Molecular Devices, Sunnyvale, CA) via 
an EMCCD camera (Photometrics, Tucson, AZ; model QuantEM 512SC). For Fura-2 imaging, 
the ratio (R) of fluorescence emission (510 nm) in response to 340/380nm excitation (controlled 
by a DG-4 (Sutter Instrument, Novato, CA)) was acquired at 1 Hz during application of KCl or 
capsaicin, which were applied through a computer-controlled, piezo-driven perfusion system 
(switching time <20 ms; Warner Instruments, Hamden, CT, USA, Fast-Step Model SF-77B). 
[Ca2+]i was determined from Fura-2 ratio according to the equation [Ca2+ ]i (nM) = Kd (Sf2/Sb2) 
((R-Rmin)/(Rmax-R)) following in situ calibration as described previously (Scheff et al., 2013), 
where Kd is the dissociation constant for Fura-2 for Ca2+ at room temperature; Sf2/Sb2 is the 
fluorescence ratio of the emission intensity excited with the 380 nm wavelength in the absence of 
Ca2+ to that in the presence of saturating Ca2+; Rmin and Rmax are the minimal and maximal 
fluorescence ratios, respectively. Sf2/Sb2, Rmin and Rmax were determined empirically with 
calibration runs as described previously (Kao, 1994), run every ~six weeks throughout the data 
collection period. The signal intensity of Rhod-2 at 580 nm in response to excitation at 555 nm 
was acquired simultaneously with Fura-2 acquisition with a custom dichroic and band pass 
emission filter. Rhod-2 intensity values were plotted as a change in fluorescence over baseline 
(ΔF/F). 
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Neurons from a single field were studied on each coverslip. Resting Ca2+ or Rhod-2 
intensity were determined prior to stimulation, where the average of the 30 seconds just prior to 
stimulation (with high K+ (30 mM)) was used for this value. The magnitude of the evoked Ca2+ 
transient was determined as the difference between resting and the peak of the evoked Ca2+ 
transient. The duration of the evoked Ca2+ transient was determined as the time for the transient 
to decay to 25%, 50%, 75%, and 90% of the peak (T25, T50, T75, and T90, respectively). For 
experiments involving the application of test compounds, a vehicle control group was always 
included. Neurons with a small cell body diameter (< 30 μm), responsive the capsaicin (500 nM), 
and labeled with the lectin IB4, determined under epifluorescence illumination, were referred to 
as putative nociceptors. Cell body diameter was determined with a calibrated eye-piece reticle. 
Capsaicin sensitivity was assessed at the end of every experiment and neurons were considered 
capsaicin sensitive if application of capsaicin resulted in an increase in [Ca2+]i greater than 20% 
above baseline. Neurons in which the plasma membrane was clearly defined by epifluorescence 
were considered IB4+. 
4.2.7 Live cell confocal microscopy  
All live cell confocal imaging experiments were carried using a Nikon A1R upright confocal 
microscope system, controlled with the Nikon (NIS) Elements software. Dissociated neurons 
were loaded with one or when appropriate in various combinations with Mitotracker Green (200 
nM in HBS), Mitotracker Deep Red (200 nM in HBS), TMRM (50 nM in HBS), and/or Mitosox 
(250 nM in HBS) in the dark for 30 min at room temperature. At the same time, they were 
labeled with IB4-AF647 (1 μg/mL in HBS). Neurons were then washed 10 min in HBS and 
placed in a live cell chamber on the microscope stage containing HBS. All experiments were 
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carried out at room temperature. For Mitotracker green density studies, images were collected 
with a 60x water immersion objective in a series of 3 μm-thick z-planes extending through the 
entire neuron at a 512 x 512 pixel resolution and a ½ frame/sec rate. For all other experiments, 
images were collected with a 60x water immersion objective as a single 3 μm z-plane at the 
center of the retrograde tracer-labeled neuron at a 2048 x 2048 pixel resolution and a 1/8 
frame/sec rate. Excitation/detection settings were determined with preliminary experiments using 
neurons from naïve rats with each fluorophore to yield an image that was not saturated. The 
same settings were applied for all conditions (naïve, vehicle, paclitaxel). For all experiments 
neurons from paclitaxel-, and vehicle-treated rats, as well a naïve rats were tested the same day. 
The quantitative measurement of the fluorescence signal was performed using Nikon (NIS) 
Elements and ImageJ software.  
4.2.8 Fluorescent Immunocytochemistry  
Neurons plated on chamber slides were fixed with 4% paraformaldehyde (PFA) in PBS for 30 
min at room temperature and then washed three times in PBS. Slides were blocked with the 
blocking buffer (0.2% Triton X-100, 3% normal donkey serum in PBS) for one hour at room 
temperature and incubated with anti-Tom20 primary antibody (Amoscato et al., 2014, Khare et 
al., 2016) at a 1:2000 dilution in the blocking buffer overnight at 4°C. Slides were washed three 
times for 10 min each in Tris-buffered saline with Tween 20 (TBST) at room temperature and 
then incubated with an AF488-conjugated donkey anti-rabbit secondary antibody at 1:200 
dilution in the blocking buffer for one hour at room temperature. Slides were washed two times 
10 min each in TBST and incubated in TBST containing 1μg/mL AF647-conjugated IB4 and 
1:1000 DAPI. Slides were washed one last time in TBST for 10 min and subsequently mounted 
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with coverslips using Fluoromount. The Tom20 images were collected with a 100x oil 
immersion objective in a series of 0.125 μm-thick z-planes extending through the entire neuron 
at a 2048 x 2048 pixel resolution and a 1/8 frame/sec rate using Nikon (NIS) Elements software. 
The same settings were applied for all neurons. The images in the stacks were deconvolved using 
the blind configuration for 20 iterations with Nikon (NIS) Elements software. Following 
deconvolution, the same 3D threshold setting was applied to all neurons. Data responding to 
volume and number of the mitochondria were transferred to a spreadsheet and used for further 
analyses.  
4.2.9 Chemicals  
Paclitaxel (Sigma-Aldrich, St Louis, MO, USA), was dissolved at 25 mg/mL in 1:1 Cremophor 
EL: ethanol and freshly diluted 1:12.5 in 0.9% sterile saline prior to injections. DiI (Thermo-
Fisher, Waltham, MA, USA), was dissolved at 170 mg/mL in anhydrous dimethyl sulfoxide 
(DMSO, Sigma-Aldrich) and diluted 1:10 in 0.9% sterile saline for a final concentration of 17 
mg/mL. DiO (Thermo-Fisher), was dissolved at a concentration of 10% (wt/vol) in anhydrous 
DMSO and diluted 1:10 in 0.9% sterile saline for a final concentration of 1%. Both DiI and DiO 
were freshly prepared before injections. As DiO is more susceptible to precipitation after the 
addition of saline, a small amount of fresh DiO stock was diluted in saline immediately before 
injection for each paw. FITC-conjugated Isolectin B4 (IB4, Sigma-Aldrich) was dissolved in 
dH20 as a stock solution of 1 mg/ml, and then diluted to a final concentration of 5 μg/mL in 
HEPES bath solution (HBS) the day of use. Alexa Fluor 647-conjugated IB4 (Thermo-Fisher) 
was dissolved in dH20 0.5 mm stock solution and diluted to a final concentration of 1μg/mL in 
HBS.  Fura-2 AM ester (TEF Laboratories, Austin, TX, USA) was dissolved in DMSO as a 2.5 
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mM stock solution and diluted to a final concentration of 2.5 μM in HBS. Pluronic F-127 (TEF 
Laboratories) was dissolved in DMSO as a 25% stock solution and diluted to 0.025% in HBS. 
Rhod-2 AM ester (Thermo-Fisher) was dissolved in DMSO as a 5 mM stock solution and diluted 
to a final concentration of 500 nM in HBS. Capsaicin (Sigma-Aldrich) was dissolved in ethanol 
as a 10 mM stock solution and diluted to 500 nM in HBS. Carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) and Cyclopiazonic acid (CPA) (both from Sigma-Aldrich) were 
dissolved in DMSO as 100 mM stocks and diluted to 10 μM in HBS. Oligomycin A (Tocris, 
Bristol, UK) was dissolved in DMSO as a 10 mM stock and diluted to 10 μM in HBS. 
Mitotracker Green FM and Mitotracker Deep Red FM (both from Thermo-Fisher) were 
dissolved in DMSO as 1 mM stocks and diluted to 200 nM in HBS. Mitosox (Thermo-Fisher) 
was dissolved in DMSO as a 1 mM stock and diluted to 250 nM. Tetramethylrhodamine Methyl 
Ester Perchlorate (TMRM, Thermo-Fisher) was dissolved in DMSO as a 10 mM stock and 
diluted to 50 nM. Rabbit polyclonal anti-Tom20 antibody (Santa Cruz, Dallas, TX, USA) was 
diluted in blocking buffer (0.2% Triton X-100, 3% normal donkey serum in phosphate buffer 
solution (PBS)) to 1:2000. Alexa Fluor 488-conjugated donkey anti-rabbit antibody (Jackson 
Immuno Research, West Grove, PA, USA) was diluted 1:200 in blocking buffer. 2-(4-
Amidinophenyl)-6-indolecarbamidine dihydrochloride, 4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI, Thermo-Fisher) was diluted in TBST to 1:1000. 
4.2.10 Statistical Analysis 
Data are expressed as mean ± s.e.m. Potential differences between two groups were assessed 
with T-tests, while experiments with more than two groups were analyzed with one and two-way 
ANOVAs with the Holm-Sidak test used for post-hoc comparisons. Statistical significance was 
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assessed at p < 0.05. Group sizes for the behavioral endpoints were determined by power 
analysis, which was based on the variability in responses to the mechanical and cold stimulations 
from three control animals. This analysis was performed for groups defined by treatment (vehicle 
and paclitaxel) over time. With a power of 0.8, alpha of 0.05, we estimated the need for a group 
size of 5 rats for the cold test and 6 rats for the mechanical test.  Group sizes for all other 
experiments were determined by power analyses that were based on the variability of the 
respective endpoint (such as ΔT50 or staining intensity) observed in putative nociceptive 
glabrous skin neurons from three naïve rats. These analyses were performed for two groups 
defined by treatment (vehicle and paclitaxel) for Rhod-2, Tom20, and SERCA experiments. 
With a power of 0.8 and alpha of 0.05, we estimated the need for nine, 13, and 24 neurons, 
respectively. Analyses for TMRM and Mitosox experiments were performed for three groups 
defined by treatment (naïve, vehicle, and paclitaxel). With a power of 0.8 and alpha of 0.05, we 
estimated the need for 16 and 14 neurons, respectively. Analyses for CCCP and Mitotracker 
were performed for experiments with eight and nine groups, defined by target of innervation and 
treatment. With a power of 0.8 and alpha of 0.05, we estimated the need for 12 and 31 neurons, 
respectively. 
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4.3 RESULTS 
4.3.1 The recovery of the paclitaxel-induced decrease in the duration of the 
depolarization evoked Ca2+ transient correlates with the resolution of paclitaxel-induced 
hypersensitivity. 
We previously described the paclitaxel-induced decrease in the duration of the depolarization 
evoked Ca2+ transient in putative nociceptive neurons that were isolated during a period of peak 
mechanical hypersensitivity (i.e., one week after the last paclitaxel injection) (Yilmaz and Gold, 
2015). To further assess the association between the paclitaxel-induced decrease in the transient 
duration and pain behavior, we assessed the resting and evoked Ca2+ transient in neurons from 
rats in which paclitaxel-induced hypersensitivity was no longer detectable. So that behavioral 
data could be collected in a blinded fashion, paclitaxel and vehicle treated rats were run in 
parallel. Cold sensitivity was detectable in paclitaxel-treated rats (n =6) after the first day of 
treatment (Figure 9A), with withdrawal latencies significantly (p < 0.01) shorter than those in 
vehicle treated rats (n = 6). This difference persisted through day 28 post-treatment. For the same 
group of rats, paw withdrawal probability to 4 g and 15 g von Frey filaments also increased at a 
comparable time point to the cold hypersensitivity and resolved by day 39 (Figure 9B and 9C, p 
> 0.05). While we have observed a significant decrease in the duration of the evoked Ca2+ 
transient in putative nociceptive glabrous neurons from 27 different cohorts of rats one week 
after the last paclitaxel injection (Yilmaz and Gold, 2015, 2016), by six weeks after the last 
paclitaxel injection, there was no detectable difference between neurons from paclitaxel (n = 12 
neurons from 4 rats) and vehicle (n = 12 neurons from 4 rats) treated rats with respect to the 
duration of evoked Ca2+ transients (p > 0.05, Figure 9D and 9E). Nor were there differences 
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between these groups with respect to resting [Ca2+]i, or the magnitude of the evoked Ca2+ 
transient.  
 
Figure 9. The recovery of the paclitaxel-induced decrease in the duration of the depolarization evoked Ca2+ 
transient correlates with the resolution of paclitaxel-induced hypersensitivity. Paclitaxel (black circles) 
administered at 2 mg/kg every other day for a total of 4 injections (pink column) induced mechanical allodynia (A), 
hyperalgesia (B), and cold sensitivity (C), as assessed with 4 g and 15 g Von Frey filaments, and the dry ice test, 
respectively. No changes in nociceptive behavior were observed in vehicle treated (grey circles) animals. Following 
resolution of behavioral sensitivity (at week 6), acutely dissociated DRG neurons retrogradely labeled from the 
glabrous skin of the hindpaw were studied with Ca2+ imaging. High K+ (30 mM, 4 sec) evoked transients in putative 
nociceptive neurons (IB4+, capsaicin sensitive, small diameter) from vehicle- (gray trace) and paclitaxel-treated 
(black trace) rats were comparable (D). Pooled data (E) confirmed the absence of a significant difference in the 
duration of evoked Ca2+ transients, quantified as the time to decay 50 percent of the magnitude of the evoked Ca2+ 
transient. The number of neurons in each group is in parenthesis in each bar. 
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4.3.2 Mitochondrial [Ca2+]i buffering is increased in putative nociceptive glabrous skin 
neurons from paclitaxel-treated rats. 
Evoked Ca2+ transients in putative nociceptive neurons is generally bi-phasic, with a rapidly 
decaying phase followed by a more slowly decaying phase the results in the emergence of a 
“shoulder” at 30-40% of the peak increase (Figure 10A). Mitochondrial “buffering” of Ca2+ is 
thought to contribute to this unique decay profile: The initial decay of the evoked transient is due 
to the rapid uptake of cytosolic Ca2+ by mitochondria via the mitochondrial Ca2+ uniporter 
(MCU), while the “shoulder” is due to the slow release of Ca2+ from mitochondria via the 
mitochondrial Na+/Li+-Ca2+-exchanger (NLCX) (Werth and Thayer, 1994, Rizzuto et al., 2012). 
One prediction of this model is that if mitochondrial Ca2+ uptake is increased, the rapid phase 
would make up a greater proportion of the transient and the slow-decaying phase would become 
even slower. To test this prediction, we performed a more detailed analysis of the evoked Ca2+ 
transient decay in glabrous putative nociceptive skin neurons from vehicle- and paclitaxel-treated 
rats. Results of this analysis indicate that while there was no detectable influence of paclitaxel on 
the relative contribution of rapid component of the overall decay of the evoked Ca2+ transient, 
the duration of the evoked transient was significantly shorter throughout the decay of the evoked 
transient in neurons (n = 18) from paclitaxel treated rats compared to neurons from vehicle 
treated rats (n = 18, Figure 10B).  
To more directly assess the contribution of mitochondria to the decay of the evoked Ca2+ 
transient we assessed the impact of pharmacologically blocking mitochondrial Ca2+ buffering in 
neurons from vehicle- and paclitaxel-treated rats on the evoked Ca2+ transient. Furthermore, 
based on previous data indicating that the impact of paclitaxel is significantly greater in glabrous 
skin neurons, than in neurons innervating structures such as the dorsal skin of the hindpaw of the 
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inner thigh, where there was no detectable changes in mechanical sensitivity, we also assessed 
the impact of blocking mitochondrial Ca2+ uptake in neurons innervating these structures from 
vehicle- and paclitaxel-treated rats. Mitochondrial Ca2+ uptake depends on an intact 
mitochondrial membrane potential and uncouplers such as CCCP and FCCP are widely used to 
diminish the Ca2+ uptake into these organelles (Hajnoczky et al., 2006). To block mitochondrial 
Ca2+ uptake without ATP depletion due to the membrane potential loss-induced reversal of the 
ATP synthase (Hogan et al., 2014), we applied the uncoupler CCCP together with ATP synthase 
inhibitor oligomycin (Figure 10C). Application of CCCP/oligomycin caused an increase in the 
duration of evoked Ca2+ transient duration in all putative nociceptors (Figure 10D). However the 
CCCP/Oligomycin-induced increase in the transient duration was significantly (p < 0.01, two-
way ANOVA, with the Holm-Sidak post-hoc test) larger in glabrous putative nociceptive 
neurons from paclitaxel-treated rats (n = 13) when compared to all other groups included in the 
analysis. These included unlabeled neurons from the same coverslips (n = 15), glabrous skin 
neurons from vehicle treated rats (n = 13), and dorsal skin neurons of the hindpaw (n = 10, and 
11) or inner thigh neurons (n = 12 and 8) from vehicle- and paclitaxel-treated rats (Figure 10D). 
To determine whether there were differences between groups of putative nociceptive neurons 
defined by target of innervation with respect to the CCCP/Oligomycin-induced increase in the 
duration of the evoked Ca2+ transient, data from paclitaxel treated rats were analyzed as a fold 
change from respective vehicle neurons. Pooled data were analyzed with a one-way ANOVA 
that indicated there was a significant difference between groups (p < 0.01). Post-hoc analysis 
showed that while there was no difference among unlabeled, hairy hindpaw, and thigh skin 
neurons with respect to the CCCP/Oligomycin-induced increase in T50, the increase in the 
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duration of the evoked transient in putative nociceptive glabrous skin neurons was significantly 
greater than that in other neurons (Figure 10E). 
 
 
Figure 10. Mitochondrial [Ca2+]i buffering is increased in putative nociceptive glabrous skin neurons from 
paclitaxel-treated rats. Consistent with previous results, and in marked contrast to the evoked Ca2+ transients 6 
weeks after the last paclitaxel injection, the duration of the Ca2+ transient evoked with high K+ (30 mM, 4 sec (hiK+) 
was significantly shorter in putative nociceptive neurons from paclitaxel treated rats, one week after the last 
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paclitaxel injection (A). This appeared to be true throughout the transient decay. When analyzed as the time to decay 
25 (T25), 50 (T50), 75 (T75), and 90 (T90) percent of the peak of the evoked Ca2+ transient (as indicated in A), 
pooled data confirmed that the duration was significantly reduced at each of these time points compared to neurons 
from vehicle treated rats (p < 0.01, two-way ANOVA). Data plotted were calculated as a percent change from 
neurons from vehicle treated rats (B).  (C) Representative hiK+ evoked Ca2+ transients from putative nociceptive 
glabrous skin neurons from vehicle (top) and paclitaxel (bottom) treated rats before and after application CCCP (10 
μM) and oligomycin (10 μM). (D) The increase in the duration of the evoked Ca2+ transient in the presence of 
CCCP/oligomycin, was analyzed as a percent change from baseline at T50. Analysis of pooled data from putative 
nociceptive glabrous skin (Glab), unlabeled (Unl), dorsal hindpaw skin (Dor), and inner thigh skin (Thi) neurons 
from vehicle (gray bars) and paclitaxel (black bars) treated rats revealed a significant interaction between paclitaxel 
treatment and target of innervation. (E) To determine whether the relative increase observed in glabrous skin 
neurons from paclitaxel treated rats was significant, data were analyzed as a percent change from vehicle. The 
difference between groups was significant (p < 0.01, one-way ANOVA). The number of neurons in each group is in 
parenthesis in each bar. ** is p < 0.01. 
 
4.3.3 While there are differences between putative nociceptive and non-nociceptive DRG 
neurons with respect to resting mitochondrial Ca2+ levels, paclitaxel was not associated 
with an increase in mitochondrial Ca2+ uptake in putative nociceptive glabrous skin 
neurons.  
Because our results with CCCP/Oligomycin suggested that a relative increase in the contribution 
of mitochondrial Ca2+ uptake contributed to the observed decrease in the duration of the evoked 
Ca2+ transient in putative nociceptive glabrous skin neurons, we next sought to determine 
whether this influence of mitochondria was due to an increase in the amount of Ca2+ taken up by 
mitochondria. To address this issue, mitochondrial Ca2+ levels were assessed with Rhod-2 
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(Fonteriz et al., 2010). We first confirmed that depolarization-evoked Rhod-2 transients reflected 
changes in mitochondria Ca2+ levels by demonstrating that the evoked Rhod-2 transient could be 
blocked following treatment with CCCP/Oligomycin (Figure 11A). Interestingly, in neurons 
from naïve rats, resting Rhod-2 levels were significantly (p < 0.05) higher in putative non-
nociceptive neurons (n = 6, large cell body diameter, IB4(-), capsaicin unresponsive), than in 
small diameter (n = 17) IB4(+) capsaicin(+) neurons (Figure 11B) and the magnitude of the 
depolarization evoked Rhod-2 transient was significantly smaller (p < 0.01) in putative non-
nociceptive neurons (Figure 11C and 11D), although there was no difference between these two 
groups with respect to the duration (p > 0.05) of the depolarization evoked Rhod-2 transient 
(Figure 3E). More importantly, there was no detectable influence of paclitaxel on either resting 
Rhod-2 levels, on either the magnitude or duration of the depolarization-induced increase in 
Rhod-2 levels, in putative nociceptive glabrous skin neurons (n = 14), compared to neurons from 
vehicle treated rats (n = 15, Figure 11F, 11G, and 11H).  
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Figure 11. Paclitaxel was not associated with an increase in mitochondrial Ca2+ uptake in putative nociceptive 
glabrous skin neurons. (A) To confirm that Rhod-2 fluorescence reflected changes in mitochondrial Ca2+ levels, 
high K+ (30 mM, 4 sec) was used to evoke a Ca2+ transient a naïve neuron before and after application of 
CCCP/oligomycin. Similar results were obtained in the 10 other neurons tested in this manner. (B) Distribution of 
resting Rhod-2 intensity levels in arbitrary units, in the absence of stimulation in small diameter IB4+ capsaicin 
responsive (sm IB4+ cap+, solid traces) and large diameter IB4- neurons unresponsive to capsaicin (lg IB4- cap-, 
dotted traces) from naïve rats. Solid bars indicate the mean of each group, which were significantly different (p < 
0.01). (C) Typical high K+ (30 mM, 4 sec) evoked increases in Rhod-2 fluorescence a small diameter IB4+ 
capsaicin+ neuron and a large diameter IB4- capsaicin- neuron from a naïve rat. Both the magnitude and the time-
course of decay appear to be different. Pooled data confirmed this impression for magnitude (D) but not duration (E) 
when analyzed as a T50. However, the T25 and the T90 were different between these subpopulations of neurons. (F) 
Typical high K+ (30 mM, 4 sec) evoked increases in Rhod-2 fluorescence (blue traces) recorded simultaneously 
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with Fura-2 (dotted black traces), in putative nociceptive glabrous skin neurons from vehicle (left) and paclitaxel 
(right) treated rats. Pooled resting (G), and evoked (magnitude (H) and T50 duration (I)) Rhod-2 data from glabrous 
skin neurons from vehicle and paclitaxel treated rats. Note the absence of a significant difference between groups, 
even for duration, in contrast to the significant decrease in the duration of the fura-2 signal in neurons from 
paclitaxel treated rats. The number of neurons in each group is in parenthesis in each bar. ** is p < 0.01. 
 
4.3.4 Paclitaxel is associated with an increase in mitochondria in putative nociceptive 
glabrous skin neurons. 
Our results with CCCP/Oligomycin and Rhod-2 raised the possibility that the apparent increase 
in mitochondrial Ca2+ buffering in neurons from paclitaxel treated rats was due to an increase in 
the number of mitochondria in these neurons. Three additional experiments were used to test this 
possibility. The first of these involved the use of mitotracker green, a fluorescent compound that 
binds to thiol groups on mitochondria, enabling an estimation of total mitochondria from the 
relative intensity of the mitrotracker fluorescence (Cottet-Rousselle et al., 2011). Putative 
nociceptive neurons targeting either the glabrous, dorsal hindpaw, or inner thigh skin from naïve, 
vehicle-, and paclitaxel-treated rats were studied. The neurons from each group were analyzed in 
parallel with the same confocal settings for image acquisition. The average fluorescence intensity 
per unit area was determined for each neuron, by dividing the cumulative intensity over the 
entire cell area, minus the area of the nucleus (Figure 12A). Representative images (Figure 12A) 
suggested that mitotracker levels were higher in glabrous neurons from paclitaxel treated rats 
(Figure 12A). Pooled data confirmed this impression, as the fluorescence per μm2 in glabrous 
neurons from paclitaxel treated rats (n = 50) was significantly (p < 0.01, Holm-Sidak post-hoc 
test), higher than that in glabrous neurons from vehicle or naïve rats (n = 26 (naïve) and 41 
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(vehicle)), or from dorsal hindpaw (n = 20, 30, 36) or thigh skin (n = 23, 29, 31) neurons from 
naïve, vehicle treated, or paclitaxel treated rats, respectively (Figure 12B and 12C).  
Because an increase in mitotracker fluorescence, may reflect an increase in the thiol 
groups the dye binds to rather than an increase in mitochondria number, we performed a second 
complimentary experiment using the antibody against the 20 kDa mitochondrial protein, 
translocase of outer membrane 20 (Tom20). Only small diameter IB4(+) glabrous skin neurons 
from naïve, vehicle-treated and paclitaxel-treated rats were studied. As with mitotracker, there 
appeared to be more Tom20 staining in neurons from paclitaxel treated rats, than from vehicle 
treated rats (Figure 12D). Pooled data again confirmed this impression, as the fluorescence per 
μm2, in neurons from paclitaxel treated rats (n = 19) was significantly higher than that in neurons 
from vehicle (n = 19) rats (Figure 12E, t-test, p < 0.05).  
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Figure 12. Paclitaxel is associated with an increase in the mitochondria in putative nociceptive glabrous skin 
neurons. (A) Live-cell confocal microscopy composite (top; green = mitotracker green, orange-red = DiI, blue = 
IB4) and mitotracker green (bottom) images of neurons from naïve, vehicle, and paclitaxel treated rats innervating 
the glabrous skin of the hindpaw, dorsal hindpaw, and inner thigh skin from paclitaxel treated rats. (B) Pooled 
mitotracker green intensity data from neurons from naïve (white bars), vehicle treated (gray bars), and paclitaxel 
treated (black bars) rats innervating the glabrous hindpaw, dorsal hindpaw, and inner thigh skin. There was a 
significant (p < 0.05, two-way ANOVA) interaction between paclitaxel treatment and target of innervation. (C) As 
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in Figure 3, to determine whether the change in mitotracker staining was significant between groups, data were 
analyzed as a percent change from control. In this case, because there were no detectable differences between 
neurons from naïve and vehicle treated rats, data from these two groups of neurons were pooled for each target of 
innervation. The difference between groups defined by target of innervation was significant (p < 0.01, one way 
ANOVA). Composite (top; green = Tom20, orange-red = DiI, DAPI = blue, light gray = IB4) and Tom20 (bottom) 
images (D) and pooled data (E) from glabrous skin neurons from vehicle and paclitaxel treated rats. Scale bars are 
20 µm for all neurons in (A) and 25 µm for neurons in (D). The number of neurons in each group is in parenthesis in 
each bar. ** is p < 0.01. 
 
Finally, to confirm that the increase in Tom20 staining was due to an increase in 
mitochondria, neurons from each group were analyzed with higher resolution imaging techniques 
combined with image deconvolution post-processing, to enable resolution of individual 
mitochondria in each neuron. With post-processing in which the same settings were used to 
analyze the Tom20 staining pattern, it was possible to estimate the relative volume, size, and 
number of mitochondria in each neuron. (Figure 13A). Pooled data indicate that total 
mitochondrial volume was increased in putative nociceptive glabrous skin neurons from 
paclitaxel-treated rats (19.41 ± 5.53 %, n = 9) when compared to vehicle controls (6.96 ± 2.16%, 
n = 11; Figure 13B, p < 0.05). This increase in volume was not due to increase in number of 
mitochondria in neurons from paclitaxel treated rats, which was, in fact, significantly smaller in 
neurons from paclitaxel treated rats than vehicle treated rats (Figure 13C, p < 0.05). Rather, the 
difference in mitochondrial volume appeared to be due to formation of so called 
“megamitochondria” (Wakabayashi, 2002) which presented itself as large networks of 
interconnected mitochondria and thus fewer smaller mitochondria.  
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Figure 13. Paclitaxel is associated with an increase in the mitochondrial volume in putative nociceptive 
glabrous skin neurons. (A) Confocal images of Tom20 staining (top = mid-section on the z-axis, bottom – 
mid-section on the y-axis) in neurons from vehicle (left) and paclitaxel (right) treated rats. Images were 
post-processed with 20 deconvolution iterations, to enable resolution of individual mitochondria. 
Predicted mitochondria as determined with deconvolution are outlined in red. Pooled data from 8 neurons 
in each group analyzed as in A, for percent cytoplasmic volume comprised of mitochondria (B) and 
number of distinct mitochondria units (C). * is p < 0.05 and ** is p < 0.01. 
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4.3.5 Paclitaxel does not reduce the health and functionality of mitochondria in putative 
nociceptive glabrous skin neurons. 
Studies have shown that bath application of paclitaxel to a variety of cell types is capable of 
causing damage to mitochondria (Andre et al., 2000, Goncalves et al., 2000). As noted above, 
there is also ample evidence that mitochondria in sensory neuron axons are damaged by 
paclitaxel treatment (Flatters and Bennett, 2006, Xiao et al., 2011). Therefore it is possible that 
the increase in mitochondrial volume in putative nociceptive glabrous skin neurons was a 
reflection of some of this damage, such as swelling. Two additional experiments were performed 
to address this possibility. First, we used confocal live imaging of neurons labeled with the 
mitochondrial membrane potential dependent dye TMRM.  The intensity of TMRM staining 
correlates with the mitochondrial membrane potential; higher TMRM staining intensity is 
observed in mitochondria that are relatively hyperpolarized (Gerencser et al., 2012). Similarly, 
the mitochondrial membrane potential is indicative of mitochondrial functionality since the 
membrane potential is necessary for essential functions such as ATP synthesis and Ca2+ uptake 
(Hajnoczky et al., 2006, Gerencser et al., 2012). We first confirmed that TMRM staining 
reflected the mitochondrial membrane potential by demonstrating that TMRM staining is 
completely eliminated with CCCP/Oligomycin (Figure 14A). Interestingly, consistent with our 
Rhod-2 data, TMRM staining was significantly higher in putative non-nociceptive neurons than 
putative nociceptive neurons from naïve rats (Figure 14B and 14C, p < 0.05). More interestingly, 
and in contrast to the prediction that total TMRM fluorescence would be lower in neurons from 
paclitaxel treated rats because of the presence of unhealthy mitochondria, the TMRM 
fluorescence intensity was higher (p < 0.05, one way ANOVA, Holm-Sidak post-hoc) in neurons 
 98 
from paclitaxel-treated rats (n = 25) than in naïve controls (n = 18). However, the difference 
between paclitaxel-treated and vehicle treated (n = 20) was not significant (Figure 14D).  
 
 
Figure 14. Paclitaxel does not reduce the functionality of mitochondria in putative nociceptive glabrous skin 
neurons. (A) To confirm TMRM fluorescence was associated with the mitochondrial membrane potential, TMRM 
was assessed before and after depolarizing mitochondria with CCCP/oligomycin with live cell confocal microscopy.  
Images with TMRM (left, red = TMRM) and mitotracker far red (right, blue = mitotracker far red) are from the 
same naïve neurons before (top) and 30 minutes after (bottom) the addition of CCCP/oligomycin. (B) Composite 
(top; red = TMRM, blue = mitotracker far red, green = DiO) and TMRM (bottom) live cell confocal microscopy 
images from naïve (left), vehicle treated (middle), paclitaxel treated (right) neurons. (C) Pooled TMRM intensity 
data from small diameter IB4+ and large diameter IB4- neurons from naïve rats. (D) Pooled TMRM intensity data 
from neurons from naïve (white bar), vehicle treated (gray bar) and paclitaxel treated (black bar) rats. The number of 
neurons in each group is in parenthesis in each bar. Scale bars are 20 µm for all panels, * is p < 0.05 and ** is p < 
0.01. 
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Evidence suggests that 1–2% of oxygen consumed is converted into superoxide due to 
transfer of electrons that have leaked from the electron transfer chain to oxygen molecules during 
oxidative phosphorylation (Orrenius et al., 2007). Moreover, under certain conditions, such as 
cellular stress or mitochondrial damage, there is a surge in the number of leaked electrons, 
resulting in an increase in the generation of mitochondrial superoxide (West et al., 2011). Thus, 
to further assess the presence of a subpopulation of damaged mitochondria in neurons from 
paclitaxel treated rats, we tested in sister coverslips the mitochondrial superoxide indicator, 
Mitosox Red. While Antimycin A, which was used as a positive control for driving an increase 
in mitochondrial superoxide generation (Polster et al., 2014), produced an increase in Mitosox 
Red staining in DRG neurons (Figure 15A), there was no detectable difference between putative 
nociceptive neurons innervating the glabrous skin from naïve (n = 13), vehicle- (n = 14), and 
paclitaxel-treated (n = 14) rats, with respect to the intensity of Mitosox Red staining (Figure 15B, 
15C, and 15D, p > 0.05). 
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Figure 15. Paclitaxel does not reduce the health of mitochondria in putative nociceptive glabrous skin 
neurons. (A) To confirm that it was possible to detect an increase in mitosox staining in neurons in which there was 
an increase in superoxide, neurons were studied with live confocal imaging before (top) and after (bottom) a 30 min 
application of antimycin A to induce mitochondrial superoxide production. Mitosox Red (left, red = mitosox) and 
mitotracker far red (right, blue = mitotracker far red), were monitored in the same neurons. (B) Composite (top; red 
= mitosox, blue = mitotracker far red, green = DiO) and mitosox (bottom) images from neurons from naïve (left), 
vehicle treated (middle), paclitaxel treated (right) rats. (C) Pooled data from glabrous skin neurons from the three 
groups of rats shown in B. The number of neurons in each group is in parenthesis in each bar. Scale bars are 20 µm 
for all panels. 
 
4.3.6 Paclitaxel increases ATP-dependent Ca2+ uptake into endoplasmic reticulum.  
There are two other major regulators of the duration of evoked Ca2+ transients, SERCA and 
PMCA (Lu et al., 2006, Gemes et al., 2012, Duncan et al., 2013). Interestingly, both of these 
proteins are membrane bound Ca2+ pumps that utilize the energy released from ATP hydrolysis 
to reduce the [Ca2+]i (Demaurex et al., 2009). Moreover mitochondria can act as Ca2+ relay 
centers by quickly taking up the increased [Ca2+]i and then releasing it through NLCX at specific 
domains near SERCA (Demaurex et al., 2009, Takeuchi et al., 2015). This relay process have 
been suggested to play a significant role in the refilling of intracellular Ca2+ stores, enabling Ca2+ 
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funneling to these stores even without detectable changes in [Ca2+]i (Demaurex et al., 2009). 
Therefore it is possible that mitochondria also contribute to the attenuation of the evoked 
transient in neurons from paclitaxel treated rats via indirectly facilitating Ca2+ uptake via 
SERCA. We tested this possibility indirectly with Fura-2 imaging before and after blocking 
SERCA activity with the SERCA inhibitor CPA. Inhibition of SERCA resulted in significant 
increases in the duration of the evoked Ca2+ transient in neurons from both vehicle- and 
paclitaxel-treated rats (Figure 16A), suggesting SERCA contributes to the regulation of the 
duration of the evoked transient in putative nociceptive glabrous skin neurons. However, the 
relative increase in the Ca2+ transient duration after CPA application was significantly larger in 
neurons from paclitaxel-treated rats when compared to vehicle controls (Figure 16B, n = 31 
(paclitaxel) n = 27 (vehicle) p < 0.05).  
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Figure 16. Paclitaxel increases ATP-dependent Ca2+ uptake into endoplasmic reticulum. (A) Fura-2 was used 
to assess high K+ (30 mM, 4 seconds) evoked Ca2+ transients in glabrous skin neurons from vehicle and paclitaxel 
treated rats before and after blocking SERCA with CPA (10 μM). To assess the impact of CPA on the duration of 
the evoked Ca2+ transient, data obtained in the presence of CPA were analyzed as a percent change from baseline 
T50. (B) Pooled data from neurons analyzed in this way indicated that the relative increase in putative nociceptive 
glabrous skin neurons from paclitaxel treated rats was significantly greater than that in vehicle treated rats. The 
number of neurons in each group is in parenthesis in each bar. * is p < 0.05. 
 
 
 
 
 103 
4.4 DISCUSSION 
The purpose of this study was to begin to test the hypothesis that CIPN is due to both increases 
and decreases in mitochondria function, with changes manifest in distinct subpopulations of 
afferents. We started by further testing the association between the changes in Ca2+ regulation 
and the changes in nociceptive behavior: changes in Ca2+ regulation were no longer detectable at 
a time point when paclitaxel-induced hypersensitivity had fully resolved. A detailed time course 
analysis of depolarization-evoked Ca2+ transients revealed that while the duration of the evoked 
transient was significantly shorter throughout the decay in neurons from paclitaxel-treated rats, 
the overall shape of the transient, thought to reflect mitochondrial Ca2+ uptake and release, was 
unchanged. Nevertheless, the relative impact of pharmacologically blocking mitochondrial Ca2+ 
uptake resulted in a significantly larger increase in the duration of the evoked Ca2+ transient in 
putative nociceptive glabrous skin neurons from paclitaxel treated rats than that in glabrous skin 
neurons from vehicle treated or naïve rats, or from hindpaw hairy skin or inner thigh skin 
neurons from paclitaxel treated or control rats. However, there was no detectable difference in 
relative amount of Ca2+ taken up by mitochondria in neurons from paclitaxel-treated rats. In 
contrast, staining intensities of mitochondrial markers were significantly higher in putative 
nociceptive glabrous skin neurons from paclitaxel-treated rats than in neurons from control rats 
or those innervating hairy hindpaw or thigh skin. Higher resolution analysis of mitochondria in 
sensory neurons revealed an increase in mitochondrial volume.  Furthermore, while there were 
differences between putative nociceptive and non-nociceptive neurons with respect to 
mitochondria resting membrane potential, there was no evidence of mitochondria with a low 
resting membrane potential in putative nociceptive glabrous skin neurons from paclitaxel treated 
rats. In addition, neurons from paclitaxel-treated rats had levels of mitochondrial superoxide 
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comparable to controls. Finally, in addition to an increase in a direct role for mitochondria in the 
attenuation of the evoked Ca2+ transient, we obtained evidence of an increase in an indirect role, 
with at least a significant increase in the contribution of SERCA to the regulation of the evoked 
Ca2+ transient in neurons from paclitaxel treated rats. Taken together our results support our 
initial hypothesis that CIPN is due to both increases and decreases in mitochondria function, with 
changes manifest in distinct subpopulations of afferents. 
The resolution of the paclitaxel-induced decrease in the evoked Ca2+ transient duration in 
neurons from rats in which and cold/mechanical hypersensitivity had also resolved does not 
mean that these two phenomena are causally linked. However, the persistence of the Ca2+ 
dysregulation in neurons from rats in which hypersensitivity had resolved would have suggested 
that the changes in Ca2+ regulation are not sufficient to maintain hypersensitivity. That said, 
given the importance of the tight regulation of [Ca2+]i for numerous cellular processes and that 
the observation of the paclitaxel-induced decrease in the evoked Ca2+ transient duration is 
limited to a specific subpopulation of neurons, establishing a causal link between the decrease in 
the evoked Ca2+ transient and pain associated with CIPN will not be easy.  A more detailed 
analysis of the time-course of the changes in Ca2+ regulation may help in this regard, if only to 
enable rejection of the hypothesis. The use of IB4-saporin, to eliminate the neurons in which the 
changes are manifest, as we have done previously (Scheff et al., 2014), would also help in this 
regard. It may also be possible to acutely manipulate Ca2+ levels in sensory neurons with Ca2+ 
ionophores, or Ca2+ uptake with blockers, as was done previously in a model of CIPN (Siau and 
Bennett, 2006). With respect to the specific role for mitochondrial Ca2+, it would be possible to 
target the uniporter pharmacologically, where a block of MCU would be expected to normalize 
pain behavior. While genetic strategies may also enable a more targeted approach, we suggest 
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that the first step should be to determine where in the sensory neuron, the changes in Ca2+ 
regulation are manifest, and now that we have identified a potential mechanism underlying these 
changes, such experiments should be possible. 
The time course of the paclitaxel-induced mechanical sensitivity observed in the present 
study was consistent with that previously described (Cata et al., 2008).  However, there is 
evidence that mechanical hypersensitivity may persist for considerably longer (Flatters and 
Bennett, 2006). While additional factors may contribute to the relative duration of the 
hypersensitivity, we suggest one likely factor is the route of paclitaxel administration: it was 
administered I.V. in the present study and I.P. in the study in which a more persistent 
hypersensitivity was observed. Given the impact of route of administration on pharmacokinetic 
and pharmacodynamics of the drug administered (Turner et al., 2011), combined with evidence 
that the signs and symptoms of CIPN are dose and treatment duration dependent dosage 
(Quasthoff and Hartung, 2002, Jaggi and Singh, 2012), it will be important to determine whether 
the more persistent hypersensitivity reflects the same underlying mechanisms. In this regard, it 
was interesting to note that there was a difference in the resolution of cold and mechanical 
hypersensitivity, suggesting that there are sensory neuron subpopulation specific differences in 
the response to same dose and route of administered paclitaxel. 
While we employed a variety of different analyses and approaches in this study, all were 
internally consistent and pointed to a direct role of mitochondria in the paclitaxel-induced 
decrease in the duration of the depolarization-evoked Ca2+ transient due to an increase in 
mitochondria size, and consequently buffering capacity, rather than a change in functionality. 
The CCCP/oligomycin data were consistent with an increase in the relative contribution of 
mitochondria to the control of the duration of the evoked Ca2+ transient in neurons from 
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paclitaxel treated rats. The results of the detailed analysis of the decay of the Ca2+ transient were 
consistent with an increase in the total mitochondrial buffering capacity rather than a shift in 
functionality, as changes to either uptake or release should have resulted in changes to the fast 
and/or slow components of the transient, and/or the relative proportion of the decay accounted 
for by either component. Consistent with this interpretation, the TMRM data argued against a 
change in mitochondrial resting membrane potential, where hyperpolarization could have 
contributed to faster Ca2+ uptake and/or a slower release. Conversely, the presence of even a 
subpopulation of damaged mitochondria with a low resting membrane potential should have 
resulted in a decrease in average TMRM signal. The absence of a change in mitochondrial 
resting membrane potential was confirmed with the Rhod-2 data, which indicated that there was 
no influence of paclitaxel on either the magnitude of the mitochondrial Ca2+ uptake, or the rate of 
release. These data also argue against paclitaxel-induced changes in either MCU or NCLX 
activity. Similarly, the absence of a detectable influence of paclitaxel on mitosox staining, argues 
against the presence of even a subpopulation of injured mitochondria. On the other hand, the 
increase in mitotracker and Tom20 staining both point to an increase in mitochondria, where the 
higher resolution of the Tom20 data confirmed the increase in total mitochondria volume. 
Importantly, the presence of an increase in Tom20 in cutaneous afferent somata in situ, suggests 
that the changes observed in the present study are not an artifact of cell culture. Thus, in stark 
contrast to the chemotherapeutic-induced mitotoxicity described in sensory axons, the 
chemotherapeutic-induced changes in Ca2+ regulation in the cell body, appear to be due, at least 
in part, to an increase in otherwise healthy mitochondria. 
It is known that mitochondria form a complex reticulum in many cell types (Sukhorukov et 
al., 2012, Schwarz, 2013, Glancy et al., 2015), however axonal mitochondria are separated from 
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this network and observed as individual entities of typically 1-3 μm in length (Schwarz, 2013). 
Our high resolution imaging results indicate a paclitaxel induced increase in mitochondrial 
volume that was reflected as an enlargement of the interconnected mitochondrial network and 
reduction of the number of individual smaller mitochondria. However, we cannot rule out the 
possibility that paclitaxel-induced increase in mitochondrial volume is due to an increase in the 
number of mitochondria in very close proximity that is below the resolution limit of imaging 
techniques employed. Additional higher-resolution techniques may be required to determine the 
nature of the paclitaxel-induced changes in mitochondrial volume. 
There are several mechanisms that could account for the paclitaxel-induced increase in the 
total volume of mitochondria in putative nociceptors. First, it might be a reaction to a more distal 
insult associated with paclitaxel treatment, where an increase in density of mitochondria may 
enable the neurons to respond to the increased demands associated with injury. Similarly, if 
mitochondria in the axons are damaged, the increase in mitogenesis in the soma may enable the 
neuron to compensate for the loss of energy production. Such a mechanism has been described in 
the Leprdb/db diabetic neuropathy mouse model, where mitochondria are increased in DRG 
neurons and the dorsal root (Vincent et al., 2010), which was suggested to compensate for the 
decrease in ATP production (Vincent et al., 2010, Bennett et al., 2014). Moreover, a large 
network of mitochondria that are either interconnected or in close proximity that facilitates 
fusion/fission may be a mechanism to sustain mitochondrial health as fusion/fission kinetics of 
mitochondria are closely linked to mitochondrial health and function. Fusion is thought to protect 
mitochondrial function by providing an opportunity for mitochondria to mix their contents, 
which in turn enables efficient repairing and complementation of damaged components and 
functions and sharing a bigger pool of structural/functional proteins and metabolites 
 108 
(Wakabayashi, 2002, Chen and Chan, 2009).  Moreover, mitochondria resume normal structure 
and function after the response to an insult is resolved (Takeuchi et al., 2015).  
Another mechanism that could account for the paclitaxel-induced increase in mitochondrial 
volume is a reduction in axonal transport (Gornstein and Schwarz, 2014), which may result in 
accumulation of mitochondria in the cell bodies. If paclitaxel treatment increases the volume of 
mitochondria by facilitating fusion, these organelles may also be too large or heavy to be 
transported along the axons.  
There are at least two possibilities that can account for the apparent increase in healthy 
mitochondria observed in the present study in the face of all the previous data pointing to 
chemotherapy-induced mitotoxicity. First, it is possible that the increase in healthy mitochondria 
in the cell body and mitotoxicity along the axons occur in separate subpopulations of afferents. 
As noted previously, morphological evidence of paclitaxel-induced mitotoxicity was only 
present in 25 - 40 % of the small and large-diameter fibers (Flatters and Bennett, 2006, Xiao et 
al., 2011), and we have studied an even smaller proportion of the neurons contributing axons to 
the peripheral nerve. That we failed to detect a change in Ca2+ regulation or mitochondria in 
putative non-nociceptive afferents argues against a role for the changes observed in putative 
nociceptive glabrous skin neurons in either the numbness or tingling associated with CIPN. And 
to the extent to which numbness is due to the chemotherapeutic-induced decrease in intra-
epidermal nerve fiber density and associated loss of Merkel cell innervation, the presence of 
mitotoxicity in myelinated fibers, puts this mechanism in the right population to mediate this 
effect. This begs the question, however, as to whether there is a subpopulation of nociceptive 
afferents in which mitotoxicity also accounts for the CIPN-induced pain, or whether the pain is 
due to the changes described in the present study. 
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The second possibility is that both the increase in mitochondrial volume and the mitotoxicity 
occur in the same subpopulation of neurons. The increase in mitochondrial volume may then be a 
consequence or/response to mitotoxicity in the axons as discussed above. This possibility would 
also beg the question as to which, if either of the two changes contribute to the pain associated 
with CIPN. Given the presence of Ca2+-dependent K+ channels in putative nociceptive glabrous 
skin neurons (Zhang et al., 2010), and the role for these channels in controlling the excitability of 
these neurons (Zhang et al., 2010), a paclitaxel-induced decrease in Ca2+ could contribute to an 
increase in neuronal excitability and pain secondary to the decrease in K+ current. Minimally, 
however, the presence of both an increase in healthy mitochondria in the cell body and damaged 
mitochondria in the axons would suggest that the mitochondria damage is not initiated within the 
cell body as previously suggested (Xiao et al., 2011).  
It is possible that paclitaxel influences SERCA activity via a mechanism independent of the 
changes in mitochondria. However, given that SERCA activity is ATP-dependent and that 
mitochondria and ER are structurally and functionally linked, especially in the context of Ca2+ 
regulation (Contreras et al., 2010, Rowland and Voeltz, 2012, Eisner et al., 2013, Marchi et al., 
2014), we suggest that it is most-likely that the apparent increase in SERCA activity is secondary 
to the paclitaxel-induced increase in mitochondrial volume. This may be due to an associated 
increase in resting ATP levels and/or a more tightly coupled mitochondria and ER. Such an 
increase in ATP levels could also contribute to an increase in the excitability of putative 
nociceptive neurons secondary to an increased Na+-K+-ATPase-dependent membrane 
hyperpolarization. The increase in excitability would be due to the increase in voltage-gated Na+ 
channels able to contribute to action potential generation following hyperpolarization-induced 
relief of channel inactivation. 
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Taken together, our study provides evidence that paclitaxel-induced decrease in evoked Ca2+ 
transient duration in glabrous putative nociceptors is mediated by mitochondria, whose structure 
and volume, but not health and functionality is greatly affected by this treatment. Our results 
argue against the notion that mitotoxicity is manifest throughout the sensory neuron, and raise 
the possibility that mitotoxicity is present in a subpopulation of neurons that do not contribute to 
the pain associated with CIPN. In addition, since these large mitochondrial networks are still 
functional, it may explain why clinical trials with acetyl-L-carnitine treatment that aimed to 
improve mitochondrial function resulted in worsening of the symptoms (Hershman et al., 2013). 
Moreover, our results suggest that SERCA activity also is important for paclitaxel-induced 
decrease in the evoked Ca2+ transient duration in putative nociceptors innervating the glabrous 
skin. Understanding the contribution of these changes in Ca2+ regulation as well as increased 
mitochondria volume to the pain associated with CIPN, may provide novel therapeutic strategies 
to limit the most debilitating side effects of some of the most effective cancer treatments.  
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5.0  DISCUSSION 
5.1 SUMMARY OF THE DISSERTATION 
5.1.1 The Goal of the Study 
When I came to the pain research field I was intrigued by the observation that all classes of 
chemotherapeutics with different primary mechanisms lead to the development of CIPN, a 
condition with both loss- and gain-of-function symptoms and localized predominantly in soles 
and palms of patients. Activation of inflammatory pathways, selective damage to long axons, and 
mitotoxicity were proposed to underlie CIPN. There is evidence supporting the involvement, and 
to some degree, interdependence of these mechanisms in CIPN. However, each failed to account 
for all of the clinical features of this form of neuropathy. For example, the release of 
inflammatory mediators within DRG or spinal cord cannot explain numbness and tingling 
associated with CIPN and if only a mechanism of pain, it is unclear how the somatotopic 
manifestation of the pain is established or maintained. Similarly, while mitotoxicity could 
account for both the numbness and pain, this mechanism also fails to account for the somatotopic 
manifestation of CIPN. Even though there is evidence of the tremendous heterogeneity among 
sensory neurons regarding their resting properties, as well as the response to injury, the potential 
impact of target of innervation on CIPN has been overlooked. Moreover, regulation of Ca2+ in 
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primary afferents are of significant importance, not only in the presence of injury, but also its 
role in the manifestation of both positive and negative signs of neuropathic pain. Based on these 
lines of evidence in combination with the limitations associated with the current models of 
CIPN, I hypothesized that both the positive and negative signs of CIPN are due to subpopulation 
and target-of-innervation specific changes in Ca2+ regulation. Using a paclitaxel-induced 
peripheral neuropathy model, I set forth two specific aims to tackle this hypothesis. My first aim 
was to characterize paclitaxel-induced changes in Ca2+ regulation in different subpopulations of 
sensory neurons based on target of innervation. My second aim was to characterize the 
underlying mechanisms with paclitaxel-induced change in Ca2+ regulation in sensory neurons.  
5.1.2 Summary of the Findings 
I first showed that paclitaxel treatment was associated with mechanical hypersensitivity in the 
glabrous skin of the hindpaw, but not the hairy skin of the hindpaw or mid-thigh. This 
observation argued against the axon length hypothesis, as there should have been no difference 
between the glabrous and hair skin of the hindpaw with respect to the hypersensitivity detected. 
In contrast, it provided support for my hypothesis that painful symptoms of CIPN were due to 
intrinsic properties of the neurons targeting distinct areas. Further support for this hypothesis was 
provided by the observation that there was a significant decrease in the duration of the evoked 
Ca2+ transients in putative nociceptive afferents, which was significantly larger in neurons 
innervating glabrous skin than those innervating hairy skin targets. The observation that there 
was a correlation between the peak manifestation and recovery of hypersensitivity and the 
changes in Ca2+ regulation was consistent with the possibility that the changes in Ca2+ regulation 
contribute to the manifestation of the hypersensitivity.  
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The first mechanism I tested as the potential culprit for the paclitaxel-induced decrease in 
the transient duration in putative nociceptors was the Ca2+ extrusion via NCX. I hypothesized 
that an increase in NCX activity underlies the paclitaxel-induced change in the evoked transient 
because NCX is a major Ca2+ extrusion mechanism, is active solely in putative nociceptive DRG 
neurons, and contributes to the regulation of the duration but not the magnitude of the evoked 
Ca2+ transient. However, the paclitaxel-induced decrease in the duration of the evoked Ca2+ 
transient was not due to an increase in NCX activity. Nevertheless, both vehicle and paclitaxel 
treatments were associated with NCX sensitization and there was evidence of a compensatory 
Ca2+ regulatory mechanism in putative nociceptors innervating target areas where there was no 
detectable paclitaxel-induced mechanical hypersensitivity.  
After ruling out NCX as the source of paclitaxel-induced decrease in the evoked Ca2+ 
transient duration, I determined whether mitochondria are directly and/or indirectly responsible 
for this change in the transient despite the evidence in the field suggesting paclitaxel treatment 
should lead to defective mitochondria. Our data argued against the notion that paclitaxel 
treatment is associated with defective mitochondria in all sensory neurons. Rather, the paclitaxel-
induced decrease in the evoked Ca2+ transient duration appears to be due to an increase in both 
the direct and indirect involvement of mitochondrial in Ca2+ regulation.  
Taken together, I have been able to implicate a novel mechanism of CIPN. I have also 
been able to uncover additional layers of sensory neuron heterogeneity based on both phenotypic 
characteristics and target of innervation.  
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5.2 COMPLEXITY OF CA2+ REGULATION 
There were several recurring themes that emerged at all stages of this work. One such theme was 
the complexity of Ca2+ regulation. The Ca2+ regulatory toolkit contains many components, all of 
which contribute to the Ca2+ maintenance and/or signaling. Moreover, some of these players 
have similar and overlapping functions and some of their activities are interrelated or even 
dependent upon the functions of the others. For example, NCX, PMCA, SERCA, and 
mitochondria are all working together to reduce the Ca2+ load following the Ca2+ influx through 
the VGCCs. Among these, mitochondria can also indirectly influence the activity/function of 
PMCA and SERCA by both providing ATP and by directing or diverting Ca2+ towards or away 
from these pumps. This complexity of Ca2+ regulation was reflected most prominently in 
subpopulation differences in Ca2+  transients in neurons from paclitaxel-treated rats; 
compensatory mechanisms for the vehicle-treated glabrous skin neurons as well as the paclitaxel-
treated thigh skin neurons that had increased NCX activity with no detectable influence of 
paclitaxel on the duration of the depolarization-evoked Ca2+ transient in these neurons; 
paclitaxel-induced increase in direct Ca2+ uptake in mitochondria as well as indirect 
mitochondrial Ca2+ regulation via SERCA. 
One problem with the complexity of Ca 2+ regulation is the difficulty to identify 
differences due to potential compensatory actions of distinct regulatory components. In this 
regard, the main concern is that in the presence of a robust compensation, there is increased 
likelihood for false negatives or incorrect interpretations. For example, the virtual lack of effect 
of paclitaxel on Ca2+ transient in thigh neurons was not because there was no change in Ca2+ 
regulation but because the NCX-mediated change in Ca2+ regulation was compensated by 
 115 
another mechanism. We could have missed this change and come to a very different conclusion 
about thigh neurons, if we did not include this group of neurons as a control group 
Another problem with the complexity in Ca2+ regulation is due to difficulties to interpret 
results that are obtained with relatively non-specific approaches employed to study components 
of the Ca2+ regulatory toolkit. For example, Li+ not only blocks all NCX isoforms that may be 
affected differently by the treatment, but there is also evidence that it can affect other Ca2+ 
regulatory components (Mo et al., 2012) or mechanisms (Mo et al., 2012) that may contribute to 
Ca2+ regulation. Similarly, the NCX3 preferring blocker KB-R7943 also has some affinity for 
MCU thus may affect mitochondrial Ca2+ uptake. Moreover, the mitochondrial uncoupler CCCP 
can also embed itself on the plasma membrane and cause membrane depolarization which may 
influence the regulation of intracellular Ca2+. Therefore, using multiple approaches, such as 
following up CCCP/oligomycin experiments with Rhod-2 imaging, is one way to reduce the 
likelihood of data misinterpretation, since confirmation of the results with one approach can 
strengthen the interpretation of data or the lack thereof may imply an unspecific effect.  
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5.3 HETEROGENEITY OF NEURONS BASED ON PHENOTYPE AND TARGET 
OF INNERVATION 
As discussed in the introduction, the heterogeneity of primary afferent neurons is well 
documented. For example our laboratory and others have described electrophysiological and 
biochemical differences among sensory neurons based on target of innervation (Yoshimura et al., 
2003, Beyak et al., 2004, Gold and Traub, 2004, Harriott et al., 2006, Harriott and Gold, 2009, 
Vaughn and Gold, 2010, Malin et al., 2011).  The results presented in this thesis work add to 
these observations by providing further evidence of differences in Ca2+ regulation. For example, 
both putative nociceptive and non-nociceptive neurons from naïve rats innervating the thigh skin 
exhibited a lower resting [Ca2+]i compared to neurons innervating the glabrous or the dorsal skin 
of the hindpaw. In addition, putative non-nociceptive thigh skin neurons from naïve rats had a 
smaller magnitude of depolarization-evoked Ca2+ transient compared to those innervating other 
targets. Moreover there was evidence of different expression of NCX isoforms based on target of 
innervation. Previously, our group identified NCX3 to be the only active isoform in glabrous 
putative nociceptors, however we observed NCX1 activity in thigh putative nociceptors in this 
current study. 
Another example of heterogeneity among subpopulations was the differences in 
mitochondria. There was no evidence of heterogeneity in mitotracker staining among 
subpopulations in naïve neurons. However, there was heterogeneity among neurons with respect 
to the staining intensity of TMRM, which was relatively higher in putative non-nociceptors when 
compared to putative nociceptors, independent of target of innervation. Similarly, Rhod2 staining 
was also consistently higher in putative non-nociceptors. These observations are likely linked 
since resting mitochondrial Ca2+ concentration is determined by the mitochondrial membrane 
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potential. In addition, ATP synthesis is directly linked to mitochondrial membrane 
hyperpolarization (Dimroth et al., 2000). It is possible that large diameter putative non-
nociceptive neurons have higher energy needs due to relatively high levels of neural activity, as 
well as to keep up with maintenance of a larger cell. Therefore an increase in mitochondrial 
membrane potential may assure relatively high levels of ATP generation to meet the energy 
needs of these neurons  
There is also documented heterogeneity among subpopulations defined by target of 
innervation with respect to the response to injury, inflammatory mediators (Gold and Traub, 
2004, Vaughn and Gold, 2010) and persistent inflammation (Harriott et al., 2006, Zhang et al., 
2012b). I have provided further evidence of heterogeneity in response to injury given the 
differences between glabrous and thigh skin putative nociceptive neurons with respect to the 
response to paclitaxel. These differences were specific to putative nociceptive neurons as they 
were not observed in putative non-nociceptors. 
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5.4 EXPERIMENTAL LIMITATIONS 
5.4.1 Isolated Cell Body  
Because the isolated sensory neuron cell body has many advantages for the study of Ca2+ 
regulatory pathways it was utilized throughout this project. These include: 1) the presence of 
many of the same molecular mechanisms that are expressed in free nerve endings both at the 
peripheral and central terminals (Baccaglini and Hogan, 1983, Malin et al., 2007). 2) The 
isolated cell body allows precise control of the extracellular environment, which is highly 
advantageous for studying physiological, pharmacological, and electrical properties of sensory 
neurons. 3) Isolated neurons are easy to prepare. 4) Isolated cell bodies can be readily 
characterized using a multi-criterion approach. 5) Isolated neuron facilitates identification of 
intrinsic changes in neurons that are not dependent on the influence of other cell types/mediators 
and 6) it allows studying distinct subpopulations of neurons innervating only the area of interest, 
which is a great benefit in a highly heterogeneous population of neurons.  
Despite the many advantages of the isolated sensory neurons cell body for the study of 
Ca2+ regulation, it is important to be aware of the limitations of this model system. One major 
disadvantage is that the dissociation of neurons requires axotomy of both central and peripheral 
processes, thus introduces an injury and associated cellular cascades to every neuron. Even if the 
same molecules and proteins are present in the soma and the axons and terminals, the spatial 
distribution and local concentration of these molecules may differ based on location. Therefore, 
it will always be necessary to confirm that the interactions observed in the cell body are present 
in the neuronal compartment (axons and terminals) of interest.  Moreover, there is always the 
possibility that the behavior of a cell in culture may be different than in an intact system. For 
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some treatment-induced changes, signals from neighboring cells or the extracellular environment 
may be key for their responses, which would be taken away in isolated preparations.  
5.4.2 Generalizability of Paclitaxel Model to CIPN 
All major classes of chemotherapeutics produce CIPN with the same general phenotype, 
suggesting that CIPN produced by one class of drugs potentially involves the same main players 
as CIPN produced by other chemotherapeutics. In fact, this was the case for studies 
characterizing chemotherapy-induced mitotoxicity along the sensory neurons axons: Initial 
observations with the paclitaxel model were later confirmed with oxaliplatin and bortezomib 
models showing that systemic chemotherapy treatment with any of these antineoplastic drugs 
resulted in mitotoxicity along sensory axons (Flatters and Bennett, 2006, Xiao et al., 2011, 
Zheng et al., 2011, 2012), supporting the notion of generalizability of findings with paclitaxel 
model to other CIPN models. 
The behavioral phenotype we observed with the paclitaxel rat model is comparable to the 
clinical observations. The mechanical hypersensitivity in the rat was limited to the glabrous skin, 
which is analogous to the area where patients suffer from painful symptoms. Moreover, the 
hypersensitivity observed with the rat was also reversible after cessation of therapy, again 
resembling the clinical observations. An open question, however, is what underlies the negative 
symptoms of CIPN, such as numbness and tingling. Although my initial hypothesis was that both 
the positive and negative signs of CIPN are due to changes in Ca2+ regulation. Besides putative 
nociceptors, I also predicted that paclitaxel would induce changes in Ca2+ regulation in large 
diameter putative non-nociceptors. The lack of a change in Ca2+ regulation in large diameter 
neurons suggest another mechanism accounts for the impact of chemotherapy on this 
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subpopulation. Another interpretation would be that other chemotherapy-induced changes, such 
as mitotoxicity or inflammatory mediators cause numbness and tingling in the absence of Ca2+ 
dysregulation, whereas presence of the Ca2+ dysregulation causes pain. It would be difficult to 
test these possibilities due to lack of models to test some of the CIPN symptoms, such as 
tingling. 
Patients often receive paclitaxel in combinations of two or more antineoplastic drugs. 
Since all classes of chemotherapeutics result in comparable CIPN phenotypes and based on 
studies showing comparable changes with different CIPN models, I would argue that using 
paclitaxel alone is not a major concern/limitation with the model employed. However we are 
aware that certain combinations of chemotherapy drugs may have additive or synergistic effects 
on underlying mechanisms. Our group recently started establishing a novel paclitaxel-carboplatin 
combination chemotherapy model.  
Another concern regarding the rat model is the dosing and timing schedule of paclitaxel 
delivery. In this work, we used a single dosing and timing schedule, consisting of four paclitaxel 
injections every other day for a cumulative dose of eight mg/kg. This schedule is assumed to 
mimic a dosing/timing of human treatments that would result in CIPN. However, in the clinic 
there are multiple dosing and timing schedules of paclitaxel chemotherapy based on the patients’ 
needs. This becomes important with evidence that there is a positive correlation between 
cumulative dose and severity of CIPN symptoms. Therefore, it is possible that there are 
additional paclitaxel-induced changes that occur with larger cumulative doses that we did not 
detect with the model we used. 
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A third concern is that all rats in this study were healthy young adult animals within a 
very specific age and weight range, whereas in the clinic cancer patients with a much wider 
variability for age and weight measures are treated with chemotherapy.  
It is possible that physiological impact of age, weight, or cancer influences mechanisms 
responsible for the manifestation of CIPN. For example there is a positive correlation between 
age and production of proinflammatory cytokines and markers (Cevenini et al., 2010).  Similarly, 
there is a correlation with body weight and inflammatory state as well as risk for cancer 
(Hursting, 2014), and studies draw a link between  the inflammatory markers such as IL-6 and 
TNFα in the circulatory system and cancer susceptibility (Il'yasova et al., 2005, Song et al., 
2013). If the inflammatory milieu impacts the manifestation and mechanisms of CIPN, it is 
therefore possible that the changes observed in the rat may not translate well to the patient care. 
Yet another concern is that almost all the data in this work was collected at a single timepoint, 
two weeks after the start of the paclitaxel treatment, which was the time of peak mechanical 
hypersensitivity. The only other timepoint that I assessed the paclitaxel-induced decrease in the 
depolarization-evoked Ca2+ transients was after the resolution of the paclitaxel-induced 
hypersensitivity, where the paclitaxel-induced change in Ca2+ transient duration was comparable 
to vehicle controls. However, I did not characterize any changes during the onset of CIPN. 
Therefore, it is not clear when paclitaxel-induced changes are initiated.  Similarly, I did not 
characterize any changes during recovery, such as four weeks after the start of the treatment 
when the hypersensitivity started to dissolve, thus it is uncertain how long the changes in Ca2+ 
regulation are present.  
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5.4.3 Species Differences 
We observed changes in a specific subpopulation of sensory neurons in the rat that responds to 
capsaicin and binds IB4. However, the subpopulations defined by IB4 and capsaicin sensitivity 
are very different in the rat and the mouse (Woodbury et al., 2004). Thus it is not clear whether 
and which subpopulation of mouse neurons express any subpopulation-specific changes that I 
observed with the rat model.  
More importantly, while the behavioral phenotype observed in the rat model of CIPN is 
comparable to that observed in patients, there are important species differences between rats and 
humans to consider. As noted above, these include dosing, which are generally determined by 
surface area, which is dramatically different in the rat. However, human DRG neurons do not 
bind IB4 (Davidson et al., 2014), thus, similar to mice, it is not clear whether and which 
subpopulation of human neurons express the changes I observed with the rat putative 
nociceptors. Furthermore, evidence also exists for pharmacological or mechanistic species 
differences regarding primary afferent function between rats and humans (McIntyre et al., 2001, 
Serrano et al., 2012), likely accounting at least partially for the relatively high failure rates of 
translational studies. Therefore, attempts to test the validity of results presented in this 
dissertation in post-mortem human primary afferent neurons taken from control subjects and 
donors who underwent chemotherapy may provide answers about the presence, and if so, neuron 
subpopulation specificity, of comparable chemotherapy-induced changes.  
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5.4.4 Sex Differences 
We used only male rats were in this dissertation. To date, the majority of CIPN animal model 
data in literature have been obtained using males. One reason behind using only males is to avoid 
potential complicating influences of the estrous cycle. Another reason is to reduce the number of 
animals for initial characterizations with the assumption that most biological processes will be 
conserved among the two sexes. This approach may be problematic, given the evidence of sex-
differences in prevalence and mechanisms in certain pain conditions, such as inflammatory pain 
(Mogil and Bailey, 2010, Scheff and Gold, 2011, Mogil, 2012, McIlvried et al., 2015, McIlvried 
et al., 2016). Moreover, paclitaxel is most commonly used to treat breast, ovarian, and non-small 
cell lung cancers, therefore majority of patients receiving paclitaxel treatment are women. 
Consequently, it will be essential to characterize paclitaxel-induced changes using female rats. 
5.5 FUTURE DIRECTIONS 
5.5.1 Paclitaxel-Induced Changes in Ca2+ Regulation and Pain-Related Behavior 
So far, I have only been able to establish the presence of a correlation between the changes in 
Ca2+ and mechanical/cold hypersensitivity induced by paclitaxel. In future studies, it will be 
necessary to determine whether there is a causal link between the two. Towards this goal, the 
first step would be to characterize the paclitaxel-induced mitochondrial changes in the axons and 
terminals of putative nociceptors innervating the glabrous skin. Based on the literature, 
mitochondria are defective in many axons. However, these axons were not defined by target of 
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innervation. Thus, it is possible that paclitaxel has an ill effect on mitochondria in axons of other 
sensory neurons, sparing the ones innervating the glabrous skin of the hindpaw. This may be 
assessed by examination of mitochondria in glabrous and control skin nerve terminals, as well as 
mitochondria along the retrogradely labeled axons using electron microscopy. If the paclitaxel-
induced changes in the somata are also observed in the axons and terminals of the neurons 
innervating the glabrous skin, targeting mitochondrial Ca2+ buffering may provide answers as to 
whether a mitochondrial change in the entirety of these afferents is mediating pain-related 
symptoms of paclitaxel treatment. One way to test this would be blocking the protein responsible 
for mitochondrial Ca2+ intake, the mitochondrial Ca2+ uniporter (MCU). This can be 
accomplished by injecting the MCU inhibitor Ru360 directly into the glabrous hindpaw skin of 
paclitaxel-treated rats and test for the behavioral endpoints.  
5.5.2 Compensatory Mechanisms 
The presence of a compensatory mechanism opposing the increased NCX activity in putative 
nociceptors innervating the thigh skin raised the question as to whether the painful symptoms are 
due to the absence of this compensatory change in putative nociceptors innervating the glabrous 
skin. It was beyond the focus of this work to characterize such compensatory mechanisms in 
thigh neurons, especially without a clear causal link between changes in Ca2+ regulation and 
pain-related behavior induced by paclitaxel.  However, if a compensatory change in Ca2+ 
regulation is protective for the neurons projecting to the thigh skin, then activating this 
mechanism in neurons innervating the glabrous skin may provide a new avenue for pain 
treatment in CIPN patients. Thus, characterization of such mechanisms with future studies may 
be useful for new clinical approaches.  
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Based on what we know about Ca2+ regulatory toolkit in primary afferents, 
characterization of this compensatory mechanism would start with the regulators that affect the 
duration of the depolarization-evoked Ca2+ transients, such as SERCA and PMCA, testing the 
hypothesis that the decrease in the activity of one or more of these regulators may oppose the 
decrease in the duration that is caused by increased NCX activity in neurons innervating the 
thigh skin. We have evidence that mitochondria and SERCA do not mediate this compensatory 
change in putative nociceptors innervating the thigh skin. However it is possible that NCX 
activity is increased in these neurons as a response to dysfunctional mitochondria. Therefore if 
PMCA and any other potential pathway is eliminated, the electron microscopy studies suggested 
previously may also clarify aspects of our observation in thigh neurons regarding the paclitaxel-
induced increase in NCX activity. 
5.5.3 Clinical Implications 
Currently there is no effective treatment for CIPN. Steroids, topical creams, anti-seizure 
medications, antidepressants, and even opioids have limited efficacy to alleviate painful 
symptoms of CIPN. Many adjuvant therapies involving Ca2+, Mg2+, vitamin B, glutathione, 
acetyl-L-carnitine, selenium, and vitamin E supplementation were shown to be ineffective in 
preventing or treating CIPN (Wolf et al., 2008, Hershman et al., 2014, Pachman et al., 2014, 
Schneider et al., 2015). Among these, glutathione, acetyl-L-carnitine, selenium and vitamin E are 
used with the expectations that their antioxidant properties will help prevent or treat neuronal 
damage exerted by antineoplastic drugs due to oxidative stress. Our results may explain why 
these treatments are not effective; paclitaxel-induced mitochondrial Ca2+ regulation changes we 
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have observed are localized in a specific subpopulation of neurons and these neurons do not 
appear to exhibit signs of increased oxidative stress.  
Despite the success of interventions designed in increase mitochondrial function in 
alleviating chemotherapy-induced mechanical hypersensitivity in preclinical studies (Ghirardi et 
al., 2005a, Ghirardi et al., 2005b), differences in preclinical and clinical endpoints may also 
account for the failure of these interventions to translate. Whereas research in preclinical studies, 
including the experiments in this dissertation, have been focused mainly on chemotherapy-
induced mechanical or cold hypersensitivity, the main complaint in the clinic is ongoing rather 
than evoked pain. This raises the possibility that mitochondrial dysfunction is the underlying 
mechanism for evoked pain. And while a stretch, it would also then be possible that the 
mitochondrial gain-of-function described here, is important for ongoing painful symptoms of 
CIPN. However, this possibility needs to be tested. Critical first steps here would involve an 
assessment of the dependence of spontaneous activity in isolated neurons on intact mitochondria. 
It may also be possible to disrupt mitochondrial Ca2+ signaling in the glabrous skin or DRG in a 
behavioral assay of ongoing pain such as the conditioned place preference test.  
As mentioned earlier, a sign of CIPN that is observed both in the clinic and preclinical 
studies is the loss of IENF. It is generally assumed that the loss of IENF accounts for the 
numbness observed in CIPN. This would suggest that the fibers lost are low threshold 
mechanoreceptors. Given the relatively selective manifestation of changes in Ca2+ regulation in 
putative nociceptive afferents, the increase in mitochondrial volume described in this thesis is 
unlikely to be associated with a decrease in the epidermal density of this fiber type. However, the 
nature of the fibers lost has yet to be unequivocally determined. It is therefore possible that at 
least some of the fibers lost are nociceptive. Furthermore, with evidence that patients suffering 
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from CIPN tend to have cold hands and feet (Boyette-Davis et al., 2011b), combined with 
evidence that one of the efferent functions of peptidergic nociceptive afferents is to maintain 
vasal tone, it is reasonable to speculate that there is at least some loss of nociceptive afferent 
terminals. It is therefore possible that the changes in mitochondria observed in putative 
nociceptive afferents is associated with a decrease in nociceptive IENF density. One way to 
assess such an association would be by to determine the impact of disrupting mitochondrial Ca2+ 
regulation in skin on a paclitaxel-induced decrease in IENF density. Potential outcomes of such 
an experiment include enhancement, reduction of, or no effect on the IENF density, all of which 
would have important implications. A reduction of IENF loss would imply that mitochondrial 
changes that we observed in soma are also taking place in the distal ends of the neurons. An 
enhancement of the IENF loss would imply that in contrast to the cell body, there is a decrease in 
mitochondrial function and/or mitotoxicity taking place at the distal terminals. A negative result 
should be followed up with control experiments and interpreted carefully, however it may 
indicate that the mitochondrial changes we have characterized and the IENF loss occur in 
different neurons. When coupled with experiments specifically targeting the mitochondrial Ca2+ 
regulation in the cell bodies of these neurons, the results of such experiments should provide 
information critical to our understanding of the implications of mitochondrial changes due to 
paclitaxel treatment. 
While I have implicated a mitochondria-dependent mechanism for CIPN in this thesis 
work, it would be extremely difficult to target mitochondria, ER, or any other organelle 
specifically in one subpopulation without affecting any other cells. Therefore other avenues need 
to be taken to target the paclitaxel-induced changes to organelle functions in specific 
subpopulations. For example, NCX3 activity is in putative nociceptive afferents innervating the 
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glabrous skin does not differ in paclitaxel and vehicle conditions and there is evidence that other 
NCX isoforms are activated in neurons innervating other regions. Therefore, treatments aiming 
to reduce only NCX3 activity instead of using a general NCX inhibitor may provide relief that 
also has some degree of specificity for the putative nociceptors innervating the glabrous skin.  
Based on our findings, inhibition of SERCA is another treatment option. However, SERCA is 
expressed at high levels in muscle tissue, therefore treatments targeting SERCA has to be local 
or neuron-specific. Currently there are multiple SERCA inhibitors, most of which have a higher 
affinity to SERCA1 over other isoforms although they inhibit all three isoforms (Michelangeli 
and East, 2011). SERCA1 is most common in muscle tissue but non-muscle tissues including 
neurons express either SERCA2b alone or in combination with SERCA3 (Michelangeli and East, 
2011). Unfortunately, there are no isoform-specific inhibitors for SERCA2 splice variants or 
SERCA3 (Michelangeli and East, 2011) Therefore if selective inhibitors are characterized, the 
first step would be to determine which SERCA isoform(s) and/or splice variants are expressed in 
these specific subpopulation of sensory neurons to be able to block SERCA activity specifically 
in these neurons without affecting muscle functioning. Otherwise, neuron-specific virus-
mediated gene therapy targeting SERCA or perineural injection of SERCA inhibitors may be 
effective to provide relief without muscle dysfunction.  
There is also preclinical evidence about the effectiveness of Li+ treatment to prevent or 
attenuate CIPN (Mo et al., 2012, Pourmohammadi et al., 2012). It is suggested that Li+ treatment 
alters Ca2+ regulation via multiple pathways (Meltzer, 1986, Mo et al., 2012), therefore it is 
possible that in these studies Li+ provided relief by ameliorating Ca2+ dysregulation. For 
example, in the study from Mo et al., paclitaxel treatment was associated with decreases in 
intracellular Ca2+ signaling, and lithium treatment inhibited the development of paclitaxel-
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induced hypersensitivity by via neuronal calcium sensor 1 (NCS-1), and the inositol 1,4,5-
trisphosphate receptor (IP3R) pathways (Mo et al., 2012).  
In summary, I aimed to characterize a novel mechanism of CIPN in this study. While the 
data I presented in this document contributes to the literature of CIPN mechanisms, additional 
studies are needed to translate findings of this thesis work into effective treatment options.  
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